<?xml version='1.0' encoding='UTF-8'?>
<chapter id="ch0144">
    <title>123 Aspergillus, Talaromyces, and Penicillium</title>
    <sect1 id="ch0144s0001">
      <title>123 Aspergillus, Talaromyces, and Penicillium</title>
      <anchor id="ch0144s0001a0001"/>
      <anchor id="ch0144s0001a0002"/>
      <para id="ch0144s0001p0001" role="chapterAuthor">SHARON C.-A. CHEN, WIELAND MEYER, TANIA C. SORRELL, AND CATRIONA L. HALLIDAY</para>
      <sect2 id="ch0144s0001s0001">
        <title>ASPERGILLUS SPECIES</title>
        <anchor id="ch0144s0001s0001a0001"/>
        <anchor id="ch0144s0001s0001a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0144s0002">
      <title>Taxonomy</title>
      <anchor id="ch0144s0002a0001"/>
      <anchor id="ch0144s0002a0002"/>
      <para id="ch0144s0002p0001">The genus<emphasis>Aspergillus</emphasis> is classified in the family Trichocomaceae of the Ascomycota. Taxonomic assignment of members of this genus has evolved substantially, with over 350 species now described (<link linkend="ch0144s0025s0001li0001">1</link>, <link linkend="ch0144s0025s0001li0002">2</link>) (<ulink url="http://www.aspergilluspenicillium.org">http://www.aspergilluspenicillium.org</ulink>). The majority (64%) of species show no sexual reproduction (<link linkend="ch0144s0025s0001li0003">3</link>), with the anamorphic (asexual) genus <emphasis>Aspergillus sensu stricto</emphasis> being phylogenetically related to the anamorphic genera <emphasis>Penicillium sensu stricto</emphasis> and <emphasis>Paecilomyces</emphasis> (<link linkend="ch0144s0025s0001li0004">4</link>).</para>
      <para id="ch0144s0002p0002">Raper and Fennell in 1965 first classified 132<emphasis>Aspergillus</emphasis> species into 18 subgroups (<emphasis>Aspergillus candidus, A. clavatus, A. cervinus, A. cremeus, A. flavipes, A. flavus, A. fumigatus, A. glaucus, A. nidulans, A. niger, A. ochraceus, A. ornatus, A. restrictus, A. sparsus, A. terreus, A. ustus, A. versicolor</emphasis>, and <emphasis>A. wentii</emphasis>) and 18 varieties based on their morphological characters (<link linkend="ch0144s0025s0001li0005">5</link>). With advancements in molecular phylogeny, however, taxonomic changes in species classification have been made, resulting in new subdivisions, subgenera, and sections (<link linkend="ch0144s0025s0001li0001">1</link>, <link linkend="ch0144s0025s0001li0002">2</link>). Using multigene phylogeny based on four genetic loci—(i) β-tubulin, (ii) calmodulin, (iii) the internal transcribed spacer (ITS) and large subunit of the ribosomal DNA (rDNA) gene cluster, and (iv) RNA polymerase II subunit RPB2—Peterson established five subgenera, <emphasis>Aspergillus, Circumdati, Fumigati, Nidulantes</emphasis>, and <emphasis>Ornati.</emphasis> These subgenera were further subdivided into 16 sections (<emphasis>Aspergillus, Candidi, Cervini, Clavati, Circumdati, Cremei, Falvi, Flavipedes, Fumigati, Nidulantes, Nigri, Restricti, Sparsi, Terrei, Usti</emphasis>, and <emphasis>Versicolores</emphasis>), either retaining formerly recognized sections or reclassifying them (<link linkend="ch0144s0025s0001li0006">6</link>). This restructuring resulted in a number of important changes within the genus, including the fact that specific groups of aspergilli now contain uniseriate and biseriate species as well as species characterized by different colony colors. This was not the case previously, when phenotypic characteristics such as colony color were used as key features to separate different groups of aspergilli. The application of this polyphasic phylogenetic species concept has led to the discovery and description of new cryptic or sibling species within the most frequent pathogens, e.g., <emphasis>A. lentulus</emphasis> (<link linkend="ch0144s0025s0001li0007">7</link>) and <emphasis>A. alabamensis</emphasis> (<link linkend="ch0144s0025s0001li0008">8</link>). In the latest taxonomic revisions, Samson et al. (<link linkend="ch0144s0025s0001li0001">1</link>), Chen et al. (<link linkend="ch0144s0025s0001li0002">2</link>), and Kocsube et al. (<link linkend="ch0144s0025s0001li0009">9</link>) extended the work of Peterson (<link linkend="ch0144s0025s0001li0006">6</link>) and grouped more than 350 species into eight subgenera (<emphasis>Aspergillus, Fumigati, Circumdati, Candidi, Terrei, Nidulantes, Warcupi</emphasis>, and <emphasis>Ornati</emphasis>), which are subdivided into sections or species complexes.</para>
      <para id="ch0144s0002p0003">Molecular work established sequence-based associations between the anamorph (asexual) and teleomorph (sexual) stages for aspergilli (where relevant) independent of whether mating occurs. At the time of writing, the anamorphic species of the genus<emphasis>Aspergillus</emphasis> are associated with 10 teleomorphic genera (<emphasis>Cristaspora, Hemisartorya, Emericella, Eurotium, Fennellia, Neocarpenteles, Neopetromyces, Neosartorya, Petromyces</emphasis>, and <emphasis>Saitoa</emphasis>) within the taxon Trichocomaceae (<link linkend="ch0144s0025s0001li0009">9</link>). Peterson had suggested splitting the genus <emphasis>Aspergillus</emphasis> based on the teleomorph states associated with particular monophyletic lineages (<link linkend="ch0144s0025s0001li0006">6</link>); however, this would have deemphasized the most common morphological features associated with the genus <emphasis>Aspergillus.</emphasis> With the establishment of the “one fungus, one name” principle in 2011 at the International Botanic Congress in Melbourne, Australia, a new International Code of Nomenclature for Algae, Fungi, and Plants (<link linkend="ch0144s0025s0001li0010">10</link>), and the abolition of the priority of the teleomorph designation for fungi (<link linkend="ch0144s0025s0001li0011">11</link>), the naming of <emphasis>Aspergillus</emphasis> species is still strongly debated. The <emphasis>Aspergillus</emphasis> Working Group of the International Society for Human and Animal Mycology (ISHAM) in 2012 agreed to retain the name <emphasis>Aspergillus</emphasis> and not adopt the teleomorph nomenclature (<emphasis>sensu</emphasis> Raper and Fennell [5]) by adopting a “wide <emphasis>Aspergillus</emphasis>” concept. This decision has significant consequences, as it results in the loss of the well-known teleomorph genera <emphasis>Emericella, Eurotium</emphasis>, and <emphasis>Neosartorya.</emphasis> The argument for maintaining <emphasis>Aspergillus</emphasis> for the whole genus is ensuring stability for nomenclature of most medically important <emphasis>Aspergillus</emphasis> species and their clinical interpretation. Pitt and Taylor (<link linkend="ch0144s0025s0001li0012">12</link>), on the other hand—following Peterson’s (<link linkend="ch0144s0025s0001li0006">6</link>) original suggestion to adopt a teleomorph-based nomenclature (i.e., the “narrow <emphasis>Aspergillus</emphasis>” concept), which will preserve this genus for a small group of related species and takes into account that those species are morphologically discordant—provide a more consistent taxonomy. This approach results in the assignment of more taxonomically consistent genera that are monophyletic and convey precise morphological and physiological characteristics (<link linkend="ch0144s0025s0001li0013">13</link>). Discussions are ongoing whether to use the anamorph name for the whole genus (“side <emphasis>Aspergillus</emphasis>” concept) or to split the genus according to teleomorph form (“narrow <emphasis>Aspergillus</emphasis>” concept). In this chapter, however, we follow the current official view on nomenclature advocated by the International Commission of <emphasis>Penicillium</emphasis> and <emphasis>Aspergillus</emphasis> by using the anamorphic name followed by its teleomorph stage in parentheses (<ulink url="http://www.aspergilluspenicillium.org">http://www.aspergilluspenicillium.org</ulink>).</para>
      <anchor id="ch0144s0002a0003"/>
      <beginpage pagenum="2379"/>
      <para id="ch0144s0002p0004">The majority of human infections due to known<emphasis>Aspergillus</emphasis> species are caused by <emphasis>A. fumigatus</emphasis> (teleomorph synonym: <emphasis>Neosartorya fumigata</emphasis>), followed by <emphasis>A. flavus</emphasis> (teleomorph synonym: <emphasis>Petromyces flavus</emphasis>), <emphasis>A. terreus</emphasis>, and <emphasis>A. niger</emphasis>, with recognition that these designations represent complexes of closely related species. In addition, at least another 48 <emphasis>Aspergillus</emphasis> species have been implicated in disease (<link linkend="ch0144s0025s0001li0014">14</link>). These uncommon but important pathogens are shown in <anchor id="ch0144s0002a0004"/><link linkend="ch0144s0004a0003">Table 1</link>. The phylogenetic relationships, based on ITS1 and ITS2 rDNA sequence analysis, of most of these species are shown in <anchor id="ch0144s0002a0005"/><link linkend="ch0144s0004a0004">Fig. 1</link>.</para>
    </sect1>
    <sect1 id="ch0144s0003">
      <title>Description of the Agent</title>
      <anchor id="ch0144s0003a0001"/>
      <anchor id="ch0144s0003a0002"/>
      <para id="ch0144s0003p0001"><emphasis>Aspergillus</emphasis> species are ubiquitous. They grow rapidly and form powdery colonies on mycological media. Colony color varies with species and is influenced by growth conditions and factors such as whether vegetative hyphae, conidial heads, and/or sexual structures are present. The color of the aerial part of the colony may also be different from that exhibited by the portion in the growth medium. The growth rates of <emphasis>Aspergillus</emphasis> species and their colony diameters in media at a certain age are important features to aid species identification, as well as the appearance of the colony at its margins. The margins can be sharply delineated or thin and diffuse, smooth over their entirety or irregularly lobed, and submerged or aerial. The texture of the colony surface, which ranges from velvety to floccose to granular and which may show a zonation, is also used to assist with species designation (<link linkend="ch0144s0025s0001li0014">14</link>) (see “Identification”).</para>
      <para id="ch0144s0003p0002"><emphasis>Aspergillus</emphasis> spp. form nonseptate stipes or conidiophores (walls), which commonly terminate in a vesicle (distinct inflated part) from which phialides are produced synchronously. They reproduce via conidia, which are formed in dry chains on the end of the phialides. The phialides can be formed directly from the vesicle (uniseriate) or, alternatively, they can form metulae (intermediate series of cells) (biseriate) (<link linkend="ch0144s0025s0001li0014">14</link>). <anchor id="ch0144s0003a0003"/><link linkend="ch0144s0004a0006">Figure 2</link> provides a schematic of the important structural features of aspergilli. Morphological characteristics of clinically relevant sections and species are listed in <anchor id="ch0144s0003a0004"/><link linkend="ch0144s0004a0007">Table 2</link>.</para>
    </sect1>
    <sect1 id="ch0144s0004">
      <title>Epidemiology and Transmission</title>
      <anchor id="ch0144s0004a0001"/>
      <anchor id="ch0144s0004a0002"/>
      <para id="ch0144s0004p0001"><emphasis>Aspergillus</emphasis> species are environmental saprophytes that thrive in decaying vegetation and are readily cultured from soil, water, certain foods, and air. Although conidia are inhaled from the environment, they are eliminated from healthy hosts via mucociliary clearance or following phagocytosis by alveolar macrophages (<link linkend="ch0144s0025s0001li0015">15</link>). In hosts with altered lung function, e.g., in those with cystic fibrosis, they may colonize the respiratory tract or cause allergic or invasive pulmonary disease. Severely immunocompromised individuals are at particular risk of invasive pulmonary aspergillosis, which may spread to contiguous sites or disseminate to other body sites via the bloodstream (<link linkend="ch0144s0025s0001li0016">16</link>, <link linkend="ch0144s0025s0001li0017">17</link>).</para>
      <table id="ch0144s0004t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0144s0004a0003"/><link linkend="ch0144s0002a0004">TABLE 1</link></phrase></emphasis> Known uncommon pathogenic <emphasis>Aspergillus</emphasis> species

</title>
        
        <tgroup cols="2">
          <tbody>
            <row>
              <entry><phrase role="center">Anamorph</phrase>
              </entry>
              <entry><phrase role="center">Teleomorph (synonym)</phrase>
              </entry>
            </row>
            <row>
              <entry><emphasis>Aspergillus acidus</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. aculeatus</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. alabamensis</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. alliaceus</emphasis>
              </entry>
              <entry><emphasis>Petromyces alliaceus</emphasis>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. avenaceus</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. brasiliensis</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. caesiellus</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. calidoustus</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. candidus</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. carneus</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. chevalieri</emphasis>
              </entry>
              <entry><emphasis>Eurotium chevalieri</emphasis>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. clavato-nanicus</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. clavatus</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. conicus</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. deflectus</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. fischeri</emphasis> (formerly <emphasis>A. fischerianus</emphasis>)</entry>
              <entry><emphasis>Neosartorya fischeri</emphasis>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. flavipes</emphasis>
              </entry>
              <entry><emphasis>Fennellia flavipes</emphasis>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. fumigatiaffinis</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. fumisynnematus</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. glaucus</emphasis>
              </entry>
              <entry><emphasis>Eurotium herbariorum</emphasis>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. granulosus</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. montevidensis</emphasis> (formerly <emphasis>A. hollandicus</emphasis>)</entry>
              <entry><emphasis>Eurotium amstelodami</emphasis>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. janus</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. japonicus</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. lentulus</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. nidulans</emphasis>
              </entry>
              <entry><emphasis>Emericella nidulans</emphasis>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. niveus</emphasis>
              </entry>
              <entry><emphasis>Fennellia nivea</emphasis>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. nomius</emphasis>
              </entry>
              <entry><emphasis>Petromyces nomius</emphasis>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. ochraceopetaliformis</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. ochraceus</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. oryzae</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. persii</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. pseudoglaucus</emphasis> (formerly <emphasis>A. reptans</emphasis>)</entry>
              <entry><emphasis>Eurotium repens</emphasis>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. restrictus</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. rugulosus</emphasis> (formerly <emphasis>A. rubrobrunneus</emphasis>)</entry>
              <entry><emphasis>Emericella rugulosa</emphasis>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. sclerotiorum</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. sydowii</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. tamari</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. quadrilineatus</emphasis> (formerly <emphasis>A. tetrazonus</emphasis>)</entry>
              <entry><emphasis>Emericella quadrilineata</emphasis>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. spinosus</emphasis>
              </entry>
              <entry><emphasis>Neosartorya spinosa</emphasis>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. thermomutatus</emphasis>
              </entry>
              <entry><emphasis>Neosartorya pseudofischeri</emphasis>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. tritici</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. tubingensis</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. udagawae</emphasis>
              </entry>
              <entry><emphasis>Neosartorya udagawae</emphasis>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. unguis</emphasis>
              </entry>
              <entry><emphasis>Emericella unguis</emphasis>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. ustus</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. versicolor</emphasis>
              </entry>
              <entry/>
            </row>
            <row>
              <entry><emphasis>A. viridinutans</emphasis>
              </entry>
              <entry/>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para id="ch0144s0004p0002">Cases of invasive aspergillosis are rising as at-risk populations continue to expand. This is due to many factors including advancements in modern medicine and widening access to therapeutic interventions that impact the immune system, such as chemotherapy for cancer, as well as the ever-increasing number of critically ill patients undergoing invasive medical procedures and receiving antibiotics. New host groups are constantly being identified and now include patients with chronic obstructive pulmonary disease (COPD), liver or kidney disease, severe viral respiratory tract infections such as influenza, and those with prior nontuberculous mycobacterial infections. More recently, COVID-19-associated pulmonary aspergillosis (or CAPA) has been increasingly described in patients with SARS-CoV-2 infection, where the use of dexamethasone in these patients increases the risk of aspergillosis, which in turn may result in increased mortality (<link linkend="ch0144s0025s0001li0018">18</link>, <link linkend="ch0144s0025s0001li0019">19</link>).</para>
      <figure id="ch0144s0004f0001"><title><phrase role="figureLabel"><anchor id="ch0144s0004a0004"/><link linkend="ch0144s0002a0005"><emphasis role="strong">FIGURE 1</emphasis></link></phrase> Maximum-likelihood tree of pathogenic <emphasis>Aspergillus</emphasis> species as listed in the <emphasis>Atlas of Clinical Fungi</emphasis>, 4th ed. (<ulink url="http://www.clinicalfungi.org">http://www.clinicalfungi.org</ulink>), based on ITS1 and ITS2 sequences of the rDNA gene obtained from GenBank using the program MEGA, version 7.0. Teleomorph names are given in parentheses.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0144f06.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0144s0004p0003">In health care facilities,<emphasis>Aspergillus</emphasis> has been cultured from unfiltered air, ventilation systems, dust, food, hospital water supplies, and related wet environments, including shower outlets (<link linkend="ch0144s0025s0001li0020">20</link>, <link linkend="ch0144s0025s0001li0021">21</link>). Outbreaks of hospital-acquired invasive infection have been described, mostly following inhalation of airborne spores originating from construction or demolition activities (<link linkend="ch0144s0025s0001li0022">22</link>). Aerosolization of water from contaminated sources or surfaces may also occur (<link linkend="ch0144s0025s0001li0021">21</link>, <link linkend="ch0144s0025s0001li0023">23</link>). Warris and Verweij have proposed control measures for the prevention of waterborne infection in hospitals, though the importance of water as a source of hospital outbreaks remains uncertain (<link linkend="ch0144s0025s0001li0023">23</link>). Most outbreaks are associated with pulmonary disease, but clusters of surgical wound and skin infections have also been described (<link linkend="ch0144s0025s0001li0024">24</link>). In some studies, identification of a common source was supported by molecular genotyping (<link linkend="ch0144s0025s0001li0020">20</link>, <link linkend="ch0144s0025s0001li0022">22</link>), though in addition to clonally related genotypes and microvariants, multiple genotypes have typically been found in clinical and environmental samples (<link linkend="ch0144s0025s0001li0025">25</link>). Not all researchers have detected genetic relatedness between environmental and clinical isolates (<link linkend="ch0144s0025s0001li0023">23</link>). Concentrations of airborne fungi in patient care areas during outbreak investigations have ranged from 0 to &gt;100 spores/m<superscript>3.</superscript> Though higher concentrations of airborne spores have been associated with outbreaks (<link linkend="ch0144s0025s0001li0025">25</link>), a threshold below which patients are considered safe has not been determined. Determining this threshold is problematic due to use of variable sampling methods, rapid temporal variation in spore counts, delayed sampling as a result of delays in clinical presentation after exposure, and differences in host susceptibility to infection (<link linkend="ch0144s0025s0001li0020">20</link>). In a 10-year air sample analysis of <emphasis>Aspergillus</emphasis> prevalence, Falvey and Streifel concluded that routine air sampling was not an effective means of predicting hospital-acquired infections, although a transient spike may indicate a potential in-house source of contamination (<link linkend="ch0144s0025s0001li0026">26</link>). The Centers for Disease Control and Prevention and the Healthcare Infection Control Practices Advisory Committee have published guidelines on prevention of aspergillosis in health care facilities (<link linkend="ch0144s0025s0001li0027">27</link>).</para>
      <anchor id="ch0144s0004a0005"/>
      <beginpage pagenum="2380"/>
      <figure id="ch0144s0004f0002"><title><phrase role="figureLabel"><anchor id="ch0144s0004a0006"/><link linkend="ch0144s0003a0003"><emphasis role="strong">FIGURE 2</emphasis></link></phrase> Key to representative species of <emphasis>Aspergillus</emphasis>.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0144f07.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <table id="ch0144s0004t0002"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0144s0004a0007"/><link linkend="ch0144s0003a0004">TABLE 2</link></phrase></emphasis> Characteristics of some medically important <emphasis>Aspergillus</emphasis> species<superscript><emphasis><anchor id="ch0144s0004a0008"/><link linkend="ch0144s0004a0013">a</link></emphasis></superscript> grown on identification media

</title>
        
        <tgroup cols="6">
          <tbody>
            <row>
              <entry><phrase role="center">Section and species</phrase>
              </entry>
              <entry><phrase role="center">Seriation</phrase>
              </entry>
              <entry><phrase role="center">Colony color</phrase>
              </entry>
              <entry><phrase role="center">Microscopic features<superscript><emphasis><anchor id="ch0144s0004a0009"/><link linkend="ch0144s0004a0014">b</link></emphasis></superscript></phrase>
              </entry>
              <entry><phrase role="center">Comments<superscript><emphasis><anchor id="ch0144s0004a0010"/><link linkend="ch0144s0004a0015">c</link></emphasis></superscript></phrase>
              </entry>
            </row>
            <row>
              <entry><phrase role="center">Uniseriate</phrase>
              </entry>
              <entry><phrase role="center">Biseriate</phrase>
              </entry>
            </row>
            <row>
              <entry><para id="ch0144s0004p0004"><emphasis role="strong">
                    <emphasis>Fumigati</emphasis>
                  </emphasis>
                </para>
              </entry>
            </row>
            <row>
              <entry><emphasis>Aspergillus fumigatus sensu stricto</emphasis> (teleomorph: <emphasis>Neosartorya fumigata</emphasis>)</entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry/>
              <entry>Dark blue-green to gray-turquoise; slate gray with age; reverse variable (<anchor id="ch0144s0004a0011"/><link linkend="ch0144s0008a0003">Fig. 3B</link>)</entry>
              <entry><para id="ch0144s0004p0005">Conidiophore: up to 300 μm long and 5–8 μm wide, smooth, noncolored or greenish</para>
                <para id="ch0144s0004p0006">Vesicle: dome-shaped, 20–30 μm diameter, phialides on upper half only</para>
                <para id="ch0144s0004p0007">Head: strongly columnar</para>
              </entry>
              <entry><para id="ch0144s0004p0008">Characteristic blue-green colonies, growth at 50°C (growth temperature range, 15–50°C)</para>
                <para id="ch0144s0004p0009">Columnar heads with single layer of phialides</para>
                <para id="ch0144s0004p0010">Sterile, white, fast-growing or glabrous cerebriform slow-growing variants confirmed by thermotolerance and DNA sequencing</para>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. felis</emphasis>
              </entry>
              <entry><phrase role="center">+/−<superscript><emphasis><anchor id="ch0144s0004a0012"/><link linkend="ch0144s0004a0016">d</link></emphasis></superscript></phrase>
              </entry>
              <entry/>
              <entry>Floccose, usually white with poor sporulation</entry>
              <entry><para id="ch0144s0004p0011">Conidia: subglobose to globose, smooth to echinulate, 2–3.5 μm diameter (<link linkend="ch0144s0008a0003">Fig. 3C</link>)</para>
                <para id="ch0144s0004p0012">Morphology similar to<emphasis>A. fumigatus sensu stricto</emphasis></para>
              </entry>
              <entry><para id="ch0144s0004p0013">Cryptic, relatively new species within<emphasis>A. fumigatus</emphasis> species complex</para>
                <para id="ch0144s0004p0014">Distinguished from<emphasis>A. fumigatus sensu stricto</emphasis> by inability to grow at 50°C</para>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. lentulus</emphasis>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry/>
              <entry>Suede-like to floccose, usually white, interspersed with gray-green colonies; reverse yellow, no diffusible pigment (<link linkend="ch0144s0008a0003">Fig. 3D</link>)</entry>
              <entry><para id="ch0144s0004p0015">Stipes: 250–300 μm long, 2–7 μm wide, smooth, sometimes sinuous and often constricted at the neck, colorless</para>
                <para id="ch0144s0004p0016">Vesicle: diminutive, 8–10 μm wide, hyaline, subclavate or subglobose, fertile over only half of the area, few short flask-shaped phialides</para>
                <para id="ch0144s0004p0017">Head: short columnar</para>
                <para id="ch0144s0004p0018">Conidia: fewer than 6 or 7 per chain, globose to ellipsoidal, rough with ornamentation, 2.5–3 μm diameter, bluish to olive green (<link linkend="ch0144s0008a0003">Fig. 3E</link>)</para>
              </entry>
              <entry><para id="ch0144s0004p0019">Cryptic relatively new species within<emphasis>A. fumigatus</emphasis> species complex. Slow-sporulating, white</para>
                <para id="ch0144s0004p0020">Does not grow at 50°C (growth temperature range, 10–45°C)</para>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. thermomutatus</emphasis> (teleomorph: <emphasis>N. pseudofischeri</emphasis>)</entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry/>
              <entry>Suede-like to floccose, usually white to pale yellow with slow to poor conidiation</entry>
              <entry>Morphologically similar to<emphasis>A. fumigatus sensu stricto</emphasis></entry>
              <entry>Cryptic, relatively new species within<emphasis>A. fumigatus</emphasis> species complex; slow-sporulating, white</entry>
            </row>
            <row>
              <entry><emphasis>A. udagawae</emphasis> (teleomorph: <emphasis>N. udagawae</emphasis>)</entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry/>
              <entry>Suede-like to floccose, usually white to pale yellow with slow to poor conidiation</entry>
              <entry>Morphologically similar to<emphasis>A. fumigatus sensu stricto</emphasis></entry>
              <entry>Cryptic, relatively new species within<emphasis>A. fumigatus</emphasis> species complex; slow-sporulating, white</entry>
            </row>
            <row>
              <entry><para id="ch0144s0004p0021"><emphasis role="strong">
                    <emphasis>Flavi</emphasis>
                  </emphasis>
                </para>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. flavus</emphasis> (teleomorph: <emphasis>Petromyces flavus</emphasis>)</entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry>Yellow to dark yellowish green (<link linkend="ch0144s0008a0003">Fig. 3F</link>)</entry>
              <entry><para id="ch0144s0004p0022">Conidiophore: 400–850 μm long, 20 μm wide, roughened, uncolored</para>
                <para id="ch0144s0004p0023">Vesicle: subglobose/globose, 25–45 μm diameter</para>
                <para id="ch0144s0004p0024">Head: loosely radiate or splitting into columns with age (<link linkend="ch0144s0008a0003">Fig. 3G</link>)</para>
                <para id="ch0144s0004p0025">Conidia: globose or ellipsoidal, roughened, 3–6 μm diameter</para>
              </entry>
              <entry><para id="ch0144s0004p0026">Heads vary in size and seriation, growth usually enhanced at 37°C, brown to black sclerotia may be present, colony color influenced by culture medium additions such as yeast extract</para>
                <para id="ch0144s0004p0027">Toxigenic</para>
              </entry>
            </row>
            <row>
              <entry><para id="ch0144s0004p0028"><emphasis role="strong">
                    <emphasis>Flavipedes</emphasis>
                  </emphasis>
                </para>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. flavipes</emphasis> (teleomorph: <emphasis>Fennellia flavipes</emphasis>)</entry>
              <entry/>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry>White with patches of yellow or pale grayish buff; reverse yellow to golden brown</entry>
              <entry>Conidiophore: 150–400 μm long, 4–8 μm wide, smooth to rough, uncolored to pale brown</entry>
              <entry>Distinguished from<emphasis>A. terreus</emphasis> by slower-growing colonies, metulae usually formed over</entry>
            </row>
            <row>
              <entry/>
              <entry/>
              <entry/>
              <entry/>
              <entry><para id="ch0144s0004p0029">Vesicle: subglobose, 10–290 μm diameter</para>
                <para id="ch0144s0004p0030">Head: radiate to loose columnar</para>
                <para id="ch0144s0004p0031">Conidia: globose, smooth, 2–3 μm diameter</para>
                <para id="ch0144s0004p0032">Cleistothecia and Hülle cells rare</para>
              </entry>
              <entry><para role="TB ParaOverride-9">entire vesicle with radiate to loosely columnar heads</para>
              </entry>
            </row>
            <row>
              <entry><para id="ch0144s0004p0033"><emphasis role="strong">
                    <emphasis>Nidulantes</emphasis>
                  </emphasis>
                </para>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. nidulans</emphasis> (teleomorph: <emphasis>Emericella nidulans</emphasis>)</entry>
              <entry/>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry>Dark green if mainly conidial; buff to purple brown if cleistothecial; reverse: deep red to purple</entry>
              <entry><para id="ch0144s0004p0034">Conidiophore: 70–150 μm long, 3–6 μm wide, smooth, brown</para>
                <para id="ch0144s0004p0035">Vesicle: hemispherical, 8–12 μm diameter</para>
                <para id="ch0144s0004p0036">Head: phialides on upper part, columnar</para>
                <para id="ch0144s0004p0037">Conidia: globose, rough, 3–4 μm diameter</para>
                <para id="ch0144s0004p0038">Cleistothecia: reddish brown, globose, 100–250 μm (<link linkend="ch0144s0008a0003">Fig. 3H</link>)</para>
                <para id="ch0144s0004p0039">Hülle cells: globose</para>
                <para id="ch0144s0004p0040">Ascospores: lenticular with 2 longitudinal crests ca. 5 μm long, red purple</para>
                <para id="ch0144s0004p0041">Conidial heads, ascocarps and Hülle cells similar to those of<emphasis>E. nidulans</emphasis></para>
                <para id="ch0144s0004p0042">Ascospores also similar but have 2 major and 2 minor equatorial crests</para>
              </entry>
              <entry><para id="ch0144s0004p0043">Distinguished by red-brown cleistothecia, abundant Hülle cells, red-purple ascospores with 2 crests, short conidiophores, and short metulae</para>
                <para id="ch0144s0004p0044">Toxigenic</para>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. quadrilineatus</emphasis> (teleomorph: <emphasis>Emericella quadrilineata</emphasis>)</entry>
              <entry/>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry>Olive green to grayish purple; reverse purple</entry>
              <entry/>
              <entry>Distinguished from<emphasis>E. nidulans</emphasis> by 4 crests on ascospores</entry>
            </row>
            <row>
              <entry><para id="ch0144s0004p0045"><emphasis role="strong">
                    <emphasis>Nigri</emphasis>
                  </emphasis>
                </para>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. niger</emphasis>
              </entry>
              <entry/>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry>Black with white margin, yellow surface mycelium; reverse uncolored or pale yellow</entry>
              <entry><para id="ch0144s0004p0046">Conidiophore: 400–3,000 μm long, 15–20 μm wide, smooth, uncolored to brownish near tip</para>
                <para id="ch0144s0004p0047">Vesicle: globose, 30–75 μm diameter</para>
                <para id="ch0144s0004p0048">Head: radiate, then splitting into columns with age</para>
                <para id="ch0144s0004p0049">Conidia: globose with thick walls, brownish black, rough, 4–5 μm diameter</para>
              </entry>
              <entry>Frequent cause of otomycosis, sometimes associated with intracavitary colonization, especially in diabetes mellitus</entry>
            </row>
            <row>
              <entry><emphasis>A. tubingensis</emphasis>
              </entry>
              <entry/>
              <entry><phrase role="center">+/–</phrase>
              </entry>
              <entry>Conidial heads in gray black-brown shades, borne on long conidiophores; reverse white</entry>
              <entry><para id="ch0144s0004p0050">Conidiophore: 2–3 mm long, smooth and coarse, diameter 15–20 μm.</para>
                <para id="ch0144s0004p0051">Conidial heads: spherical to radiate, mostly 200–300 μm</para>
                <para id="ch0144s0004p0052">Conidia: spherical, 3.0–3.5 μm in diam, becoming progressively darker and rougher</para>
                <para id="ch0144s0004p0053">Sclerotia produced in some strains, spherical to subspherical, cream colored, becoming pinkish buff, sometimes darkening to almost black with age, usually 500–800 μm in diameter</para>
              </entry>
              <entry><para id="ch0144s0004p0054">Slow-sporulating, white</para>
                <para id="ch0144s0004p0055">Commonly involved in pulmonary disorders and otomycosis</para>
                <para id="ch0144s0004p0056">Distinguishable from other members of section<emphasis>Nigri</emphasis> by <emphasis>benA</emphasis> or <emphasis>CaM</emphasis> gene sequencing</para>
              </entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <table id="ch0144s0004t0003"><title>Table 3 (continued)</title>
        
        <tgroup cols="6">
          <tbody>
            <row>
              <entry><para id="ch0144s0004p0057"><emphasis role="strong">
                    <emphasis>Terrei</emphasis>
                  </emphasis>
                </para>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. terreus</emphasis>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry>Tan to cinnamon brown</entry>
              <entry><para id="ch0144s0004p0058">Conidiophore: 100–150 μm long, 4.5–6 μm wide, smooth, uncolored</para>
                <para id="ch0144s0004p0059">Vesicle: dome shaped, 10–16 μm diameter, phialides on upper half</para>
                <para id="ch0144s0004p0060">Head: columnar</para>
                <para id="ch0144s0004p0061">Conidia: globose/subglobose, smooth, 2 μm diameter, solitary single-celled conidia (chlamydoconidia), commonly sessile on submerged hyphae</para>
              </entry>
              <entry><para id="ch0144s0004p0062">Distinctive features: cinnamon-colored colonies, columnar heads and solitary accessory conidia; conida are also produced<emphasis>in vivo</emphasis></para>
                <para id="ch0144s0004p0063">Often resistant to amphotericin B</para>
              </entry>
            </row>
            <row>
              <entry><para id="ch0144s0004p0064"><emphasis role="strong">
                    <emphasis>Usti</emphasis>
                  </emphasis>
                </para>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. ustus</emphasis>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry>Brown-gray or olive gray; reverse yellow, dull red or purplish</entry>
              <entry><para id="ch0144s0004p0065">Conidiophore: 75–400 μm long, 4–7 μm wide, smooth, becoming brown</para>
                <para id="ch0144s0004p0066">Vesicle: globose/subglobose, 7–16 μm diameter, fertile over upper two-thirds</para>
                <para id="ch0144s0004p0067">Head: radiate to loosely columnar</para>
                <para id="ch0144s0004p0068">Conidia: globose, rough, 3–4.5 μm diameter</para>
                <para id="ch0144s0004p0069">Irregular Hülle cells often present (<link linkend="ch0144s0008a0003">Fig. 3I</link>)</para>
              </entry>
              <entry>Hülle cells are distinguishing feature when present. Brown conidiophores</entry>
            </row>
            <row>
              <entry><emphasis>A. deflectus</emphasis>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry>Slow growing, mouse gray with pinkish margins or patches of yellow</entry>
              <entry><para id="ch0144s0004p0070">Conidiophore: 40–125 μm long, 2.5–3.5 μm wide, smooth, red-brown</para>
                <para id="ch0144s0004p0071">Vesicle: hemispherical, 5–7 μm in diameter, bent at right angle to stipe</para>
                <para id="ch0144s0004p0072">Head: phialides on upper surface, columnar</para>
                <para id="ch0144s0004p0073">Conidia; globose, 3–3.5 μm diameter, smooth to rough</para>
                <para id="ch0144s0004p0074">Hülle cells sometimes present</para>
              </entry>
              <entry>Vesicle bent almost at right angle to stipe is distinguishing feature. Rare human pathogen</entry>
            </row>
            <row>
              <entry><para id="ch0144s0004p0075"><emphasis role="strong">
                    <emphasis>Versicolores</emphasis>
                  </emphasis>
                </para>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. versicolor</emphasis>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry>Green/gray-green or tan with patches of pink or yellow; reverse variable, often deep red</entry>
              <entry><para id="ch0144s0004p0076">Vesicle: ovate to elliptical (spoon-shaped), 9–16 μm diameter</para>
                <para id="ch0144s0004p0077">Head: radiate to loosely columnar</para>
                <para id="ch0144s0004p0078">Conidia: globose, echinulate, 2.5–3 μm diameter</para>
                <para id="ch0144s0004p0079">Hülle cells globose</para>
              </entry>
              <entry><para id="ch0144s0004p0080">Distinguished by slow growing, green-tan or variably colored colonies and small biseriate vesicles</para>
                <para id="ch0144s0004p0081">Often there are reduced “penicillate-type” heads in addition to spoon-shaped vesicles</para>
              </entry>
            </row>
            <row>
              <entry><para id="ch0144s0004p0082"><emphasis role="strong">Less common pathogens</emphasis>
                </para>
              </entry>
            </row>
            <row>
              <entry><para id="ch0144s0004p0083"><emphasis role="strong">
                    <emphasis>Aspergillus</emphasis>
                  </emphasis>
                </para>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. glaucus</emphasis> (teleomorph: <emphasis>Eurotium herbariorum</emphasis> and other spp.)</entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry>Deep green mixed with bright yellow; reverse uncolored or pale yellow</entry>
              <entry><para id="ch0144s0004p0084">Conidiophore: 200–300 μm long, 7–12 μm wide, smooth, uncolored to pale brown</para>
                <para id="ch0144s0004p0085">Vesicle: globose, 15–30 μm diameter</para>
                <para id="ch0144s0004p0086">Head: large radiate</para>
                <para id="ch0144s0004p0087">Conidia; subglobose, echinulate, 5 μm diameter</para>
                <para id="ch0144s0004p0088">Cleistothecia: thin walled, yellow, globose, 75–150 μm, ascospores smooth or rough, with furrow and rounded or frilled crests</para>
              </entry>
              <entry><para id="ch0144s0004p0089">Formerly called glaucus group</para>
                <para id="ch0144s0004p0090">Osmophilic</para>
                <para id="ch0144s0004p0091">Reproduction enhanced on high-sugar media</para>
                <para id="ch0144s0004p0092">Growth poor at 37°C</para>
                <para id="ch0144s0004p0093">Readily identified by ascospore morphology rather than by conidial head features</para>
                <para id="ch0144s0004p0094">Members include<emphasis>E. umbrosus, E. ruber, E. repens</emphasis></para>
                <para id="ch0144s0004p0095"><emphasis>E. umbrosus</emphasis> is reported as cause of farmer’s lung (anamorph: <emphasis>A. glaucus</emphasis>)</para>
              </entry>
            </row>
            <row>
              <entry><para id="ch0144s0004p0096"><emphasis role="strong">
                    <emphasis>Restricti</emphasis>
                  </emphasis>
                </para>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. restrictus</emphasis>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry>Dull olive green to brownish green, very slow growing</entry>
              <entry><para id="ch0144s0004p0097">Conidiophore: 80–200 μm long, 4–8 μm wide, smooth or rough, uncolored</para>
                <para id="ch0144s0004p0098">Vesicle: hemispherical, 8–20 μm diameter</para>
                <para id="ch0144s0004p0099">Head: phialides on upper third, columnar</para>
                <para id="ch0144s0004p0100">Conidia: cylindrical to ellipsoidal, rough, 4–7 μm long, 3–4 μm wide</para>
              </entry>
              <entry>Very slow growth on standard media distinguishes this from<emphasis>A. fumigatus</emphasis>; slightly enhanced growth on high-sugar media, no growth at 37°C, cylindrical conidia developing to long, adherent columns</entry>
            </row>
            <row>
              <entry><para id="ch0144s0004p0101"><emphasis role="strong">
                    <emphasis>Candidi</emphasis>
                  </emphasis>
                </para>
              </entry>
            </row>
            <row>
              <entry><emphasis>A. candidus</emphasis>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry><phrase role="center">+</phrase>
              </entry>
              <entry>White to cream</entry>
              <entry><para id="ch0144s0004p0102">Conidiophore: mostly 200–500 μm long, 7–10 μm wide, smooth to rough, uncolored</para>
                <para id="ch0144s0004p0103">Vesicle: globose/subglobose, 17–35 μm diameter</para>
                <para id="ch0144s0004p0104">Head: fertile over entire surface, radiate</para>
                <para id="ch0144s0004p0105">Conidia: globose, smooth, 3–4 μm diameter</para>
                <para id="ch0144s0004p0106">Sclerotia: sometimes, present, reddish purple</para>
              </entry>
              <entry>Distinguished from all colored aspergilli by white, slow-growing colonies; however, be cautious about white, slow-growing forms of poor sporulators of<emphasis>A. fumigatus</emphasis> species complex</entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0144s0004a0013"/><link linkend="ch0144s0004a0008">a</link></emphasis></superscript>Modern concepts have replaced group names with subgenera and sections.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0144s0004a0014"/><link linkend="ch0144s0004a0009">b</link></emphasis></superscript>Refer to “Taxonomy” above for descriptions of terms.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0144s0004a0015"/><link linkend="ch0144s0004a0010">c</link></emphasis></superscript>Only species producing potent toxins are noted as toxigenic, but other species may produce toxins of lesser significance.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0144s0004a0016"/><link linkend="ch0144s0004a0012">d</link></emphasis></superscript>Implies may be present or absent.</para>
      <para id="ch0144s0004p0107"><emphasis>A. fumigatus</emphasis> is the most common cause of invasive aspergillosis, accounting for at least 65% of cases, especially in the highest-risk group, patients with hematological malignancies (<link linkend="ch0144s0025s0001li0028">28</link>–<link linkend="ch0144s0025s0001li0031">31</link>). Other pathogenic species include members of the <emphasis>A. flavus, A. terreus</emphasis>, and <emphasis>A. niger</emphasis> species complexes and, infrequently, <emphasis>A. nidulans</emphasis> and <emphasis>A. ustus</emphasis> (<link linkend="ch0144s0025s0001li0032">32</link>–<link linkend="ch0144s0025s0001li0034">34</link>). <emphasis>A. flavus</emphasis> infections are more common in developing countries and in arid climates, where they comprise the majority of cases of allergic aspergillosis, trauma-associated endophthalmitis, and sino-orbital-cerebral disease (<link linkend="ch0144s0025s0001li0029">29</link>, <link linkend="ch0144s0025s0001li0035">35</link>, <link linkend="ch0144s0025s0001li0036">36</link>), while in other regions, <emphasis>A. terreus</emphasis> may be the most frequent species (<link linkend="ch0144s0025s0001li0037">37</link>). Health care-related outbreaks of aspergillosis are most common in patients with hematological cancers and are almost always caused by <emphasis>A. fumigatus</emphasis> or <emphasis>A. flavus</emphasis> (<link linkend="ch0144s0025s0001li0021">21</link>, <link linkend="ch0144s0025s0001li0022">22</link>). In the U.S.-based Transplant-Associated Infection Surveillance Network (TRANSNET) study conducted from 2001 to 2006, 67% of isolates were identified as <emphasis>A. fumigatus</emphasis>; cryptic species of <emphasis>A. fumigatus</emphasis> comprised 6% of this complex (<link linkend="ch0144s0025s0001li0031">31</link>). CAPA has been overwhelmingly due to <emphasis>A. fumigatus</emphasis> (<link linkend="ch0144s0025s0001li0018">18</link>, <link linkend="ch0144s0025s0001li0019">19</link>, <link linkend="ch0144s0025s0001li0038">38</link>).</para>
      <anchor id="ch0144s0004a0017"/>
      <beginpage pagenum="2381"/>
      <anchor id="ch0144s0004a0018"/>
      <beginpage pagenum="2382"/>
      <anchor id="ch0144s0004a0019"/>
      <beginpage pagenum="2383"/>
      <anchor id="ch0144s0004a0020"/>
      <beginpage pagenum="2384"/>
      <anchor id="ch0144s0004a0021"/>
      <beginpage pagenum="2385"/>
      <para id="ch0144s0004p0108">While<emphasis>A. fumigatus sensu stricto</emphasis> represents by far the leading human pathogen, laboratories should remain vigilant to the isolation and detection of other species of section <emphasis>Fumigati</emphasis> (<link linkend="ch0144s0025s0001li0039">39</link>).</para>
    </sect1>
    <sect1 id="ch0144s0005">
      <title>Clinical Significance</title>
      <anchor id="ch0144s0005a0001"/>
      <anchor id="ch0144s0005a0002"/>
      <para id="ch0144s0005p0001">Aspergilli can cause disease as a result of ingestion of mycotoxins or other metabolites (see<ulink url="ch0151#ch0151s0001">chapter 130</ulink> of this <emphasis>Manual</emphasis>); direct inoculation into traumatized skin, eyes, or other sites; and inhalation of spores causing hypersensitivity or invasive disease. Infection may also affect the ears, causing otomycosis, and more rarely traumatized nails, casuing onychomycosis. Aspergillosis most commonly involves the lungs, but almost every organ can be involved as a result of primary infection, contiguous spread, or hematogenous dissemination (<link linkend="ch0144s0025s0001li0040">40</link>). Lung infection presents as a spectrum of disease, depending on the extent of immunosuppression, genetic factors, and structural abnormalities within the respiratory system. Certain species are associated with specific forms of disease (<anchor id="ch0144s0005a0003"/><link linkend="ch0144s0005a0004">Table 3</link>). Invasive aspergillosis, the second most common hospital-acquired fungal infection after invasive candidiasis, is associated with high morbidity and mortality, especially in patients with hematological malignancies or allogeneic stem cell or lung transplants (<link linkend="ch0144s0025s0001li0041">41</link>, <link linkend="ch0144s0025s0001li0042">42</link>). Other groups at increased risk and with poor outcomes include patients who have had heart, liver, and, less commonly, renal transplants; patients receiving immunomodulators such as infliximab or tumor necrosis factor alpha inhibitors; patients with advanced HIV infection, malnutrition, or other underlying qualitative and quantitative immune cell defects; and patients requiring hemodialysis. Critically ill patients in intensive care units and patients with chronic respiratory tract disease such as cystic fibrosis are also at risk of invasive pulmonary aspergillosis (<link linkend="ch0144s0025s0001li0017">17</link>, <link linkend="ch0144s0025s0001li0028">28</link>–<link linkend="ch0144s0025s0001li0031">31</link>, <link linkend="ch0144s0025s0001li0043">43</link>, <link linkend="ch0144s0025s0001li0044">44</link>). Specifically, influenza-associated aspergillosis and, most recently, the recognition of CAPA as a disease entity have added to the challenges not only of diagnosis, but of managing patients with viral-fungal coinfections (<link linkend="ch0144s0025s0001li0018">18</link>, <link linkend="ch0144s0025s0001li0019">19</link>, <link linkend="ch0144s0025s0001li0038">38</link>).</para>
      <table id="ch0144s0005t0001"><title><emphasis role="strong"><phrase role="figureLabel"><anchor id="ch0144s0005a0004"/><link linkend="ch0144s0005a0003">TABLE 3</link></phrase></emphasis> Clinical categorization of <emphasis>Aspergillus</emphasis> infection and major causative species<superscript><emphasis><anchor id="ch0144s0005a0005"/><link linkend="ch0144s0005a0010">a</link></emphasis></superscript>

</title>
        
        <tgroup cols="3">
          <tbody>
            <row>
              <entry><phrase role="center">Clinical presentation</phrase>
              </entry>
              <entry><phrase role="center">Syndromes</phrase>
              </entry>
              <entry><phrase role="center">Associations</phrase>
              </entry>
            </row>
            <row>
              <entry>Allergic (hypersensitivity)</entry>
              <entry>ABPA; SAFS<superscript><emphasis><anchor id="ch0144s0005a0006"/><link linkend="ch0144s0005a0011">b</link></emphasis></superscript></entry>
              <entry><emphasis>Aspergillus fumigatus</emphasis> (<emphasis>A. terreus</emphasis>); <emphasis>Aspergillus</emphasis> spp.; asthma</entry>
            </row>
            <row>
              <entry>Saprophytic</entry>
              <entry><para id="ch0144s0005p0002">Aspergilloma</para>
                <para id="ch0144s0005p0003">Otomycosis</para>
                <para id="ch0144s0005p0004">Onychomycosis</para>
              </entry>
              <entry><para id="ch0144s0005p0005"><emphasis>A. fumigatus</emphasis>; preexisting cavities, tuberculosis</para>
                <para id="ch0144s0005p0006"><emphasis>A. niger</emphasis> and <emphasis>A. terreus</emphasis> are common causes</para>
                <para id="ch0144s0005p0007"><emphasis>A. versicolor</emphasis> complex and <emphasis>A. sydowii</emphasis> are common causes</para>
              </entry>
            </row>
            <row>
              <entry>Semi-invasive<superscript><emphasis><anchor id="ch0144s0005a0007"/><link linkend="ch0144s0005a0012">c</link></emphasis></superscript> (hyphal invasion of tissue)</entry>
              <entry><para id="ch0144s0005p0008">Chronic necrotizing pulmonary aspergillosis</para>
                <para id="ch0144s0005p0009">Keratitis</para>
              </entry>
              <entry><para id="ch0144s0005p0010"><emphasis>A. fumigatus</emphasis>; structural lung disease</para>
                <para id="ch0144s0005p0011"><emphasis>A. fumigatus, A. flavus</emphasis>, and other species</para>
              </entry>
            </row>
            <row>
              <entry>Invasive<superscript><emphasis><anchor id="ch0144s0005a0008"/><link linkend="ch0144s0005a0013">d</link></emphasis></superscript></entry>
              <entry>Rhinosinusitis (rhino-orbital/cerebral disease) (acute invasive, chronic invasive, chronic granulomatous forms; aspergilloma)</entry>
              <entry><para id="ch0144s0005p0012"><emphasis>A. fumigatus, A. flavus</emphasis>
                </para>
                <para id="ch0144s0005p0013"><emphasis>A. flavus</emphasis> is the commonest cause in arid countries. Granulomatous sinusitis (Sudan, India, Pakistan, Saudi Arabia)</para>
                <para id="ch0144s0005p0014"><emphasis>A. flavus</emphasis> (90%), <emphasis>A. fumigatus, A. niger</emphasis></para>
                <para id="ch0144s0005p0015"><emphasis>A. fumigatus, A. flavus, A. nidulans, A. terreus</emphasis>
                </para>
              </entry>
            </row>
            <row>
              <entry>Invasive bronchial aspergillosis (superficial, pseudomembranous or ulcerative tracheobronchitis)</entry>
              <entry>Lung transplantation, AIDS</entry>
            </row>
            <row>
              <entry>Invasive pulmonary aspergillosis<superscript><emphasis><anchor id="ch0144s0005a0009"/><link linkend="ch0144s0005a0014">e</link></emphasis></superscript></entry>
              <entry><emphasis>A. fumigatus, A. terreus, A. flavus</emphasis>
              </entry>
            </row>
            <row>
              <entry>Hyphal invasion (pyogranulomatous inflammation/necrosis)</entry>
              <entry><para id="ch0144s0005p0016">Immunosuppression, no neutropenia: GVHD, SOT, CGD, HIV/AIDS, corticosteroids</para>
                <para id="ch0144s0005p0017">Prolonged, severe neutropenia</para>
              </entry>
            </row>
            <row>
              <entry>Angioinvasion (coagulative necrosis, hemorrhagic infarction)</entry>
            </row>
          </tbody>
        </tgroup>
      </table>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0144s0005a0010"/><link linkend="ch0144s0005a0005">a</link></emphasis></superscript>See reference <link linkend="ch0144s0025s0001li0037">37</link>. Abbreviations: CGD, chronic granulomatous disease; IPA, invasive pulmonary aspergillosis; GVHD, graft-versus-host disease; SAFS, severe asthma with fungal sensitization; SOT, solid-organ transplant.</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0144s0005a0011"/><link linkend="ch0144s0005a0006">b</link></emphasis></superscript>SAFS can be caused by fungi other than <emphasis>Aspergillus</emphasis>; it does not meet serological criteria for ABPA (<link linkend="ch0144s0025s0001li0040">40</link>).</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0144s0005a0012"/><link linkend="ch0144s0005a0007">c</link></emphasis></superscript>As defined by Chakrabarti et al. (<link linkend="ch0144s0025s0001li0029">29</link>) and Thompson (<link linkend="ch0144s0025s0001li0016">16</link>).</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0144s0005a0013"/><link linkend="ch0144s0005a0008">d</link></emphasis></superscript>Classified by Hope et al. (<link linkend="ch0144s0025s0001li0040">40</link>) on the basis of tissue invasion by hyphae (with or without angioinvasion).</para>
      <para role="table-footnote"><superscript><emphasis><anchor id="ch0144s0005a0014"/><link linkend="ch0144s0005a0009">e</link></emphasis></superscript>Includes COVID-19-associated pulmonary aspergillosis (<link linkend="ch0144s0025s0001li0018">18</link>, <link linkend="ch0144s0025s0001li0019">19</link>, <link linkend="ch0144s0025s0001li0038">38</link>).</para>
      <para id="ch0144s0005p0018">In diagnosing aspergillosis, positive cultures (or antigen- or nucleic acid-based tests) for<emphasis>Aspergillus</emphasis> from clinical specimens may not in themselves indicate a pathological process. Similarly, small nodules have been described in the lungs without evidence of progressive disease. The distinction between colonization of the respiratory tract and invasive disease is particularly difficult in highly immunosuppressed patients, in patients with chronic airway disease (<link linkend="ch0144s0025s0001li0045">45</link>, <link linkend="ch0144s0025s0001li0046">46</link>), or in patients in receipt of inhaled corticosteroid therapy, but the probability of requiring treatment increases with increasing immunosuppression. To enable standardization in assisting diagnosis, and for the purpose of clinical trials in patients with hematological malignancies, updated consensus definitions of proven and probable aspergillosis are published by the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium (EORTC/MSGERC). These incorporate host immune status, lung imaging (computerized tomography) findings, antigen-based biomarker tests, and histology and culture findings, and now, <emphasis>Aspergillus</emphasis> nucleic acid detection tests as well as rRNA-based panfungal PCR assays (<link linkend="ch0144s0025s0001li0047">47</link>) (see below). Criteria have also been developed for diagnosis of invasive aspergillosis in patients with chronic obstructive lung disease and for the entity of chronic pulmonary aspergillosis (<link linkend="ch0144s0025s0001li0048">48</link>–<link linkend="ch0144s0025s0001li0050">50</link>). Demonstration of hyphae in tissue or other clinical samples, and culture of a heavy growth of <emphasis>Aspergillus</emphasis> from a single specimen or the same species from multiple specimens, point to invasive disease in the appropriate clinical context. Antigen- and nucleic acid-based diagnostics are discussed below.</para>
      <anchor id="ch0144s0005a0015"/>
      <beginpage pagenum="2386"/>
    </sect1>
    <sect1 id="ch0144s0006">
      <title>Collection, Transport, and Storage of Specimens</title>
      <anchor id="ch0144s0006a0001"/>
      <anchor id="ch0144s0006a0002"/>
      <para id="ch0144s0006p0001">Methods to collect appropriate clinical specimens (see<ulink url="ch0139#ch0139s0001">chapter 118</ulink> of this <emphasis>Manual</emphasis>) are especially important for diagnosis of invasive pulmonary aspergillosis due to uncertainty in differentiation of <emphasis>Aspergillus</emphasis> colonization (or even contamination) from <emphasis>Aspergillus</emphasis> disease. Diagnosis can be difficult (<link linkend="ch0144s0025s0001li0050">50</link>) and appears to be most problematic in nonneutropenic hosts and in patients with compromised airways (e.g., lung transplant recipients). The most convincing evidence of aspergillosis is provided by recovery of the fungus from lung tissue and other sterile sites and/or by histopathologic demonstration of hyphae in tissue. However, nonsterile specimens such as sputum and bronchoalveolar lavage (BAL) fluid are frequent specimens submitted for culture in which recovery of aspergilli may reflect colonization (<link linkend="ch0144s0025s0001li0051">51</link>). Culture results should be interpreted in combination with an assessment of clinical, radiographic, and other diagnostic tests.</para>
      <para id="ch0144s0006p0002">Other than the respiratory tract,<emphasis>Aspergillus</emphasis> can be recovered from culture of any body site, including sinus, cerebrospinal fluid (CSF), skin, other tissue, the eye, and heart valves. In <emphasis>Aspergillus</emphasis> endocarditis, as with other invasive infections, blood cultures are typically negative. Conversely, positive blood cultures for <emphasis>Aspergillus</emphasis> are often indicative of contamination even in populations at high risk for invasive aspergillosis (<link linkend="ch0144s0025s0001li0052">52</link>), although they uncommonly are helpful in disseminated infection, and cases of fungemia, especially <emphasis>A. terreus</emphasis> fungemia, have been described, possibly due to the production of chlamydoconidia <emphasis>in vivo</emphasis> which act as easily disseminated viable propagules (<link linkend="ch0144s0025s0001li0053">53</link>). All specimens should be transported to the laboratory as soon as practicable for culture and other diagnostic testing. For detection of <emphasis>Aspergillus</emphasis> DNA in archived samples, such as paraffin-embedded (PE) tissue, tissue should be sent in thin (approximately 10- by 10-μm) sections in a sterile receptacle (<link linkend="ch0144s0025s0001li0054">54</link>). It is advisable to discard the first section due to possible contamination with fungal spores.</para>
      <anchor id="ch0144s0006a0003"/>
      <beginpage pagenum="2387"/>
    </sect1>
    <sect1 id="ch0144s0007">
      <title>Direct Examination</title>
      <anchor id="ch0144s0007a0001"/>
      <anchor id="ch0144s0007a0002"/>
      <sect2 id="ch0144s0007s0001">
        <title>Microscopy</title>
        <anchor id="ch0144s0007s0001a0001"/>
        <anchor id="ch0144s0007s0001a0002"/>
        <para id="ch0144s0007s0001p0001">Microscopic examination of fresh and/or stained specimens of tissue, BAL fluid, sputum, tissue aspirates, and other specimens may reveal fungal structures, but this method is insensitive, and specimens are often positive only in advanced disease. Hyphal elements can be observed using routine potassium hydroxide preparations or enhanced with a fluorescent stain such as calcofluor white or Blankophor. In tissue biopsy sections, hyphae may be seen if specific fungal stains are used, including either the Gomori methenamine silver stain or Grocott’s modification of such, and periodic acid-Schiff. In hematoxylin and eosin (H&amp;E)-stained tissue, hyphae can also be visualized, although care must be taken to minimize undue trauma to tissue prior to paraffin embedding. Viable hyphae are typically basophilic to amphophilic, while damaged or necrotic hyphae are more often eosinophilic (<link linkend="ch0144s0025s0001li0055">55</link>).</para>
        <para id="ch0144s0007s0001p0002">Although species identification of<emphasis>Aspergillus</emphasis> is not possible, microscopy provides relevant preliminary diagnostic information; some assessment of fungal morphology and demonstration of fungal hyphae in tissue are requirements of the EORTC/MSGERC classification for a “proven” fungal infection (<link linkend="ch0144s0025s0001li0047">47</link>). <emphasis>Aspergillus</emphasis> hyphae are typically hyaline, septate, and 6 μm in diameter and branch dichotomously at acute (~45°) angles, although not all the above features may be evident (see <link linkend="ch0144s0008a0003">Fig. 3A</link> for an H&amp;E-stained section of lung showing <emphasis>Aspergillus</emphasis> with smooth hyaline hyphae). Hyphae have smooth parallel walls with no or slight constrictions at the septa (<link linkend="ch0144s0025s0001li0014">14</link>, <link linkend="ch0144s0025s0001li0055">55</link>). Where invasion has occurred, hyphae may extend throughout the tissue and form parallel or radial arrays. Aspergilli in chronic lung cavities grow as tangled masses of hyphae and may exhibit atypical hyphal features, such as swellings measuring up to 12 μm in diameter or the absence of conspicuous septa. Unusual features, such as swelling of the terminal portion of the hyphae, may also be seen in patients who have received antifungal therapy, especially with the echinocandin class.</para>
        <para id="ch0144s0007s0001p0003">Adventitial forms (conidia, ascomata, and other asexual structures [<link linkend="ch0144s0004a0006">Fig. 2</link>]) of <emphasis>Aspergillus</emphasis> may be recognized in histopathologic sections to allow presumptive identification of the fungus. Of note, adventitial forms are not always evident, but rather are visualized mostly in situations where the fungal growth communicates with an airway, for example, in fungal sinus balls. Where the fruiting head is intact, microscopic features may be sufficient to identify the pathogen, although it is advisable to confirm the identity by other diagnostic methods as well. In tissue, <emphasis>A. terreus</emphasis> displays distinctive aleurioconidia along the lateral hyphal walls (<link linkend="ch0144s0025s0001li0056">56</link>). Calcium oxalate crystals have been associated with <emphasis>A. niger</emphasis> infection (<link linkend="ch0144s0025s0001li0057">57</link>). However, culture, immunohistochemical staining, or nucleic acid amplification is required to identify the pathogen. The specificity of microscopic methods is low for distinguishing non-<emphasis>Aspergillus</emphasis> hyaline moulds from <emphasis>Aspergillus</emphasis> (<link linkend="ch0144s0025s0001li0058">58</link>); for example, <emphasis>Fusarium</emphasis> spp. and <emphasis>Scedosporium</emphasis> spp. can look identical to <emphasis>Aspergillus. In situ</emphasis> hybridization techniques using a specific fluorescent antibody that binds to fungal elements in tissue may aid diagnosis; in one study, <emphasis>Fusarium</emphasis> was distinguished from <emphasis>Aspergillus</emphasis> elements in tissue with a 100% positive predictive value (PPV) (<link linkend="ch0144s0025s0001li0059">59</link>), although the use of immunohistochemistry has not been validated for this purpose.</para>
      </sect2>
      <sect2 id="ch0144s0007s0002">
        <title>Antigen Detection</title>
        <anchor id="ch0144s0007s0002a0001"/>
        <anchor id="ch0144s0007s0002a0002"/>
        <para id="ch0144s0007s0002p0001">Galactomannan (GM) is a major polysaccharide constituent of the cell walls of<emphasis>Aspergillus</emphasis>, most <emphasis>Penicillium</emphasis> (<emphasis>Talaromyces</emphasis>) species, and certain other moulds and is released <emphasis>in vivo</emphasis> from growing hyphae. Commercial assays for GM are standardized and are well validated. The Platelia <emphasis>Aspergillus</emphasis> enzyme-linked immunosorbent assay (ELISA) (Bio-Rad Laboratories, Hercules, CA) is a double sandwich enzyme immunoassay that has been cleared by the U.S. Food and Drug Administration (FDA) for diagnostic use and that utilizes the rat monoclonal antibody (MAb) EBA-2, directed against the galactofuranoside side chain of the GM antigen (reviewed in reference <link linkend="ch0144s0025s0001li0060">60</link>). It is data from this test that resulted in inclusion of GM in the updated EORTC/MSGERC consensus definitions of invasive aspergillosis in immunosuppressed patients and in both hematology and solid-organ transplant patients (<link linkend="ch0144s0025s0001li0047">47</link>, <link linkend="ch0144s0025s0001li0060">60</link>–<link linkend="ch0144s0025s0001li0067">67</link>). These definitions were developed for use in clinical and epidemiological research; in clinical practice, they must be taken in context with clinical-pathologic descriptions and classifications (see “Clinical Significance” below). Although the EORTC/MSGERC definitions include GM detection in plasma, serum, BAL fluid, or CSF, extensive clinical validations have only been performed for serum and BAL fluid, following release of a newer format of the above assay from Bio-Rad (for reviews, meta-analyses, and systematic analyses, see references <link linkend="ch0144s0025s0001li0061">61</link> through <link linkend="ch0144s0025s0001li0065">65</link> and <link linkend="ch0144s0025s0001li0067">67</link>). Of note, the updated definitions have adopted different optical density index (ODI) thresholds for different specimens, which differ from those recommended by the manufacturer. A cutoff ODI of ≥1.0 was selected for serum, plasma, BAL fluid, and CSF, or a single serum/plasma cutoff of ≥0.7 and BAL fluid of ≥0.8 (<link linkend="ch0144s0025s0001li0047">47</link>). These cutoffs were chosen as the best compromise between diagnostic likelihood and patient eligibility for inclusion into epidemiologic, diagnostic, and therapeutic research (<link linkend="ch0144s0025s0001li0067">67</link>). These cutoffs are <emphasis>not</emphasis> for use in routine clinical care.</para>
        <para id="ch0144s0007s0002p0002">Meta-analyses of the performance of GM in serum or plasma, using an ODI cutoff of 1.0 for the diagnosis of invasive aspergillosis, had pooled sensitivity and specificity of 0.65 to 0.71 and 0.90 to 0.94, respectively, with a positive likelihood ratio (PLR) of 6.5 to 11.83 and negative likelihood ratio (NLR) of 0.24 to 0.26 (<link linkend="ch0144s0025s0001li0061">61</link>, <link linkend="ch0144s0025s0001li0062">62</link>), suggesting that GM is more suitable as a screening to exclude aspergillosis than as a diagnostic test. The sensitivity and specificity of serum GM testing vary substantially in different studies, mainly due to differences in study design and study populations. It is much more sensitive when used for samples from neutropenic and hematopoietic stem cell transplant recipients than for patients with solid-organ transplants or critically ill patients with chronic obstructive pulmonary disease, i.e., populations that are not neutropenic (<link linkend="ch0144s0025s0001li0068">68</link>–<link linkend="ch0144s0025s0001li0072">72</link>). As a diagnostic test in patients with hematological malignancies, the specificity and PPV of serum GM testing increased to 98.6% when two separate and consecutive samples were positive at an ODI of at least 0.5, with only slight loss of sensitivity (<link linkend="ch0144s0025s0001li0068">68</link>). This ODI is used because the goals are to minimize the risk of invasive aspergillosis by “screening out” patients unlikely to have disease. Maertens et al. have further recommended that a single positive GM index of ≥0.7 should prompt a diagnostic workup (<link linkend="ch0144s0025s0001li0073">73</link>). As the use of mould-active antifungal agents reduces the sensitivity of the serum GM test (<link linkend="ch0144s0025s0001li0074">74</link>), serial screening is not recommended in patients receiving mould-active prophylaxis (<link linkend="ch0144s0025s0001li0075">75</link>).</para>
        <anchor id="ch0144s0007s0002a0003"/>
        <beginpage pagenum="2388"/>
        <para id="ch0144s0007s0002p0003">False positives have occurred in patients receiving piperacillin-tazobactam (although the frequency of false-positive results appears to be reduced with newer formulations of this antimicrobial agent), in those receiving amoxicillin-clavulanate in association with bifidobacteria in the gut of neonates, and in those who have ingested foods containing GM (<link linkend="ch0144s0025s0001li0070">70</link>). Some non-<emphasis>Aspergillus</emphasis> moulds may yield positive GM results (<emphasis>Talaromyces marneffei, Histoplasma capsulatum, Fusarium oxysporum, Paecilomyces</emphasis> species, and <emphasis>Alternaria</emphasis> species) (<link linkend="ch0144s0025s0001li0064">64</link>).</para>
        <para id="ch0144s0007s0002p0004">Data in children are fewer, but performance of serum GM appears to be similar to that in adults (<link linkend="ch0144s0025s0001li0072">72</link>). One systematic review of 19 studies that employed serum GM testing concluded that, in children, the sensitivity, specificity, and PPV were highly variable when this test was used both as a screening tool and as a diagnostic test in patients with symptoms; the negative predictive values (NPVs) were 85 to 100% for screening and 70 to 100% in the diagnostic setting (<link linkend="ch0144s0025s0001li0075">75</link>). In CAPA, serum GM is commonly negative, with studies reporting positivity rates of only 11 to 28% for probable CAPA (<link linkend="ch0144s0025s0001li0076">76</link>–<link linkend="ch0144s0025s0001li0078">78</link>).</para>
        <para id="ch0144s0007s0002p0005">Three systematic reviews and meta-analyses of the utility of GM in BAL fluid in patients with hematological malignancies or mixed comorbidities were published (<link linkend="ch0144s0025s0001li0063">63</link>–<link linkend="ch0144s0025s0001li0065">65</link>). All of them acknowledged limitations of the studies analyzed, but concluded that the BAL GM assay was more sensitive than the serum GM assay, though the overall recommendations for a cutoff ODI for BAL fluid positive samples differed: 1.0 was recommended by Zou et al. (<link linkend="ch0144s0025s0001li0063">63</link>), and 1.5 was recommended by Heng et al. (<link linkend="ch0144s0025s0001li0064">64</link>), but Guo et al. arrived at no consensus (<link linkend="ch0144s0025s0001li0065">65</link>). Using a higher cutoff of ≥1.0 for a positive test improves specificity with only a small decrease in sensitivity (78% versus 88%; <emphasis>P</emphasis> = 0.36) (<link linkend="ch0144s0025s0001li0079">79</link>). Data regarding the effect of mould-active agents on level of BAL GM are conflicting, and standardization across studies is needed to resolve these differences (<link linkend="ch0144s0025s0001li0064">64</link>). Nonetheless, the positivity threshold is recommended to be at least 1.0 in BAL fluid for assessment of diagnosis (<ulink url="http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM420248.pdf">http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM420248.pdf</ulink>). There is also evidence that BAL GM is more sensitive and specific than serum GM in critically ill patients with chronic obstructive pulmonary disease, though the proposed cutoff of 0.8 for the ODI requires confirmation (<link linkend="ch0144s0025s0001li0080">80</link>).</para>
        <para id="ch0144s0007s0002p0006">Obtaining BAL specimens from patients with COVID-19 represents a significant infection control risk, and nondirected BAL specimens have been increasingly relied on for GM testing to provide mycological evidence of CAPA (<link linkend="ch0144s0025s0001li0081">81</link>). Recently defined European Confederation of Medical Mycology and International Society for Human and Animal Mycology (ECMM/ISHAM) consensus criteria for CAPA recommend a BAL GM index of ≥1.0 for a probable diagnosis of CAPA (<link linkend="ch0144s0025s0001li0019">19</link>). Using this criterion, studies have reported GM positivity rates from BAL fluid of 62 to 78% in CAPA patients (<link linkend="ch0144s0025s0001li0077">77</link>, <link linkend="ch0144s0025s0001li0078">78</link>).</para>
        <sect3 id="ch0144s0007s0002s0001">
          <title>Aspergillus Antigen Detection Using Lateral Flow Technology</title>
          <anchor id="ch0144s0007s0002s0001a0001"/>
          <anchor id="ch0144s0007s0002s0001a0002"/>
          <para id="ch0144s0007s0002s0001p0001">Two types of lateral flow tests are now comercialized to facilitate more rapid diagnosis of invasive aspergillosis, e.g., in settings where the Platelia<emphasis>Aspergillus</emphasis> ELISA (Biorad) is not readily available or to improve turnaround times. These are: (i) the IMMY sona <emphasis>Aspergillus</emphasis> galactomannan lateral flow assay (IMMY LFA) (IMMY, Norman, OK) that detects GM; and (ii) the <emphasis>Aspergillus</emphasis> lateral flow device (AspLFD) (OLM Diagnostics, Newcastle upon Tyne, United Kingdom), which detects an extracellular mannoprotein antigen secreted exclusively during active growth of <emphasis>Aspergillus</emphasis> spcies via the JF5 monoclonal antibody (<link linkend="ch0144s0025s0001li0082">82</link>–<link linkend="ch0144s0025s0001li0084">84</link>). Both assays allow for single-sample testing of serum and BAL fluid samples with results available in less than 1 hour. Notably, the AspLFD requires no pretreatment steps if BAL fluid samples are nonbloody or nonviscous, whereas the IMMY LFA requires pretreatment of all BAL fluid specimens, making the turnaround time 45 min (versus 15 to 25 min) (<link linkend="ch0144s0025s0001li0082">82</link>). Neither test has been incorporated as a microbiologic criterion into the updated EORTC/MSGERC definitions, as their performance and corresponding cutoff values have not been fully assessed (<link linkend="ch0144s0025s0001li0084">84</link>).</para>
          <para id="ch0144s0007s0002s0001p0002">Both LFA tests have shown promise in diagnosing aspergillosis using serum samples, particularly relevant in patients with COVID-19 infection in whom bronchoscopy may not be performed. Testing of serum samples from patients with hematological malignancies suggests that the AspLFD is as specific as, but may be more sensitive than, the GM assay (<link linkend="ch0144s0025s0001li0085">85</link>–<link linkend="ch0144s0025s0001li0087">87</link>) and that both sensitivity and specificity may be improved by using it in combination with PCR-based assays (<link linkend="ch0144s0025s0001li0087">87</link>). A meta-analysis reported a pooled sensitivity of 68% (95% confidence interval [CI], 52 to 81%), specificity of 87% (95% CI, 80 to 92%), and diagnostic odds ratio (DOR) of 11.9 (95% CI, 3.54 to 39.96) for distinguishing proven or probable aspergillosis from absence of disease (<link linkend="ch0144s0025s0001li0085">85</link>). In a recent single-center retrospective case-control study of 179 serum samples from 136 patients with invasive fungal disease, using a positive threshold of ≥0.5, the IMMY LFA had a sensitivity and specificity of 96.9% (31/32) and 98% (98/100), respectively. The agreement between this LFA and GM ELISA was 89%, with most discordance arising from false-negative GM ELISA samples that were positive by LFA (<link linkend="ch0144s0025s0001li0083">83</link>). Another single-center study evaluating the performance of both point-of-care tests in serum of hematology patients (<emphasis>n</emphasis> = 239) found the IMMY LFA had a sensitivity of 49% (95% CI, 33 to 65%), specificity of 95% (95% CI, 91 to 98%), and NPV of 90% (95% CI, 86 to 92%), performing similarly to the GM ELISA. By comparison, the performance of the AspLFD had a sensitivity of only 24% (95% CI, 12 to 40%), specificity of 89% (94% CI, 84 to 93%), and NPV of 84% (95% CI, 82 to 87%) (<link linkend="ch0144s0025s0001li0084">84</link>). The potential of both assays to diagnose aspergillosis using serum in nonhematologic patients is uncertain.</para>
          <para id="ch0144s0007s0002s0001p0003">Comparative studies of both lateral flow devices in BAL fluid from patients with underlying hematological malignancy found that both tests were highly sensitive and specific (<link linkend="ch0144s0025s0001li0088">88</link>, <link linkend="ch0144s0025s0001li0089">89</link>); however, the multicenter study showed higher sensitivity (0.83 versus 0.69, <emphasis>P</emphasis> = 0.008) and a better NPV (0.89 versus 0.82, <emphasis>P</emphasis> = 0.009) for the IMMY LFA in cases of proven and probable IPA, with performance further improved by using a digital reader (<link linkend="ch0144s0025s0001li0082">82</link>). Studies evaluating the performance of these tests on BAL fluid from patients at risk for IPA in other settings demonstrated that the IMMY LFA had a sensitivity and specificity of 80 to 88% and 75 to 81%, respectively, in intensive care unit patients, using an ODI cutoff of 1.0 (<link linkend="ch0144s0025s0001li0088">88</link>, <link linkend="ch0144s0025s0001li0090">90</link>). In solid-organ transplant recipients, however, while the sensitivity was 100%, the specificity was only 42% (<link linkend="ch0144s0025s0001li0090">90</link>). The performance of both tests improves if combined with GM ELISA, and sensitivity is lower in patients receiving antifungal therapy compared with those who are antifungal naive (<link linkend="ch0144s0025s0001li0082">82</link>). While these tests are helpful for point-of-care diagnosis of IPA in nonneutropenic patients, they are likely to be more useful for targeted testing in patients with clinical suspicion of disease rather than for general screening of all patients (<link linkend="ch0144s0025s0001li0089">89</link>).</para>
          <anchor id="ch0144s0007s0002s0001a0003"/>
          <beginpage pagenum="2389"/>
        </sect3>
        <sect3 id="ch0144s0007s0002s0002">
          <title>(1,3)-β-D-Glucan</title>
          <anchor id="ch0144s0007s0002s0002a0001"/>
          <anchor id="ch0144s0007s0002s0002a0002"/>
          <para id="ch0144s0007s0002s0002p0001">Besides tests to detect<emphasis>Aspergillus</emphasis> GM and novel <emphasis>Aspergillus-</emphasis>specific antigens, colorimetric detection of (1,3)-β-<emphasis role="smallcaps">D</emphasis>-glucan in the serum of patients represents another strategy for diagnosis of invasive aspergillosis. As with <emphasis>Aspergillus</emphasis> GM, detection of (1,3)-β-<emphasis role="smallcaps">D</emphasis>-glucan is included as a diagnostic criterion in the EORTC/MSGERC assessment for probability of invasive aspergillosis (<link linkend="ch0144s0025s0001li0047">47</link>). This antigen is a major component of the fungal cell wall, and circulating (1,3)-β-<emphasis role="smallcaps">D</emphasis>-glucan can be quantified in the serum of patients with invasive aspergillosis (<link linkend="ch0144s0025s0001li0091">91</link>–<link linkend="ch0144s0025s0001li0094">94</link>). Concentrations approaching 1 pg of antigen/ml can be detected, with a level of ≥80 ng/ml (Fungitell Assay; Associates of Cape Cod, Inc., Falmouth, MA) being considered indicative of fungal infection. Other assays (e.g., Fungitec-G, Seikagaku Corporation, Tokyo, Japan) have been commercialized in Asia, but only the Fungitell assay (Associates of Cape Cod, Inc.) is approved and cleared by the FDA for diagnostic use. (1,3)-β-<emphasis role="smallcaps">D</emphasis>-Glucan assays are validated and approved for use in serum only.</para>
          <para id="ch0144s0007s0002s0002p0002">However, the inability of the test to discriminate between<emphasis>Aspergillus-</emphasis>related infections and those caused by other fungi—i.e., its low PPV (approximately 50% at best)—is a key limitation of the assay for diagnosing aspergillosis. The sensitivity, specificity, and NPV of the assay for any systemic fungal infection are described to be approximately 93, 77, and 98%, respectively (<link linkend="ch0144s0025s0001li0092">92</link>). In meta-analyses encompassing a variety of fungal infections in hematology and other patient populations, the pooled sensitivity was 60 to 83%, with a specificity of 79 to 90% (<link linkend="ch0144s0025s0001li0091">91</link>–<link linkend="ch0144s0025s0001li0097">97</link>); in one analysis, the positive likelihood ratio was 5.2 and the negative likelihood ratio was 0.29 (<link linkend="ch0144s0025s0001li0095">95</link>). One meta-analysis restricted to five cohort studies of hematology-oncology patients reported sensitivity of 61% and specificity of 91%, with specificity increasing to 99% with the requirement of two consecutive positive tests (<link linkend="ch0144s0025s0001li0091">91</link>). The estimated positive and negative predictive values for any invasive fungal disease with a prevalence of 10% were 83.5% and 94.6%, respectively (<link linkend="ch0144s0025s0001li0091">91</link>). Different (1,3)-β-<emphasis role="smallcaps">D</emphasis>-glucan assays were noted to have similar accuracy for the diagnosis of fungal infection.</para>
          <para id="ch0144s0007s0002s0002p0003">Data indicate that the sensitivity for invasive aspergillosis ranges widely, from 60 to 100%. Despite these limitations, the serum (1,3)-β-<emphasis role="smallcaps">D</emphasis>-glucan test may be useful as a negative predictor of aspergillosis if combined with more specific tests; exposure to mould-active antifungal agents reduces the sensitivity of the test (<link linkend="ch0144s0025s0001li0093">93</link>–<link linkend="ch0144s0025s0001li0095">95</link>). Conversely, false-positive results are common under conditions of hemodialysis (cellulose membranes), treatment with immunoglobulin products, and exposure to glucan-containing material (<link linkend="ch0144s0025s0001li0095">95</link>). Cross-reactivity with amoxicillin-clavulanic acid and cell wall components of Gram-positive organisms has occurred. Test results should be interpreted within the clinical context, and further validation is required to determine its usefulness for monitoring therapeutic response. The updated EORTC/MSGERC criteria specify that while BDG can be used for the detection of invasive aspergillosis, because of its limited sensitivity, it should <emphasis>not</emphasis> be used to rule out invasive fungal disease in oncological patients (<link linkend="ch0144s0025s0001li0047">47</link>, <link linkend="ch0144s0025s0001li0098">98</link>).</para>
          <para id="ch0144s0007s0002s0002p0004">(1,3)-β-<emphasis role="smallcaps">D</emphasis>-Glucan testing in BAL fluid has been less extensively investigated but unsurprisingly appears to have poor specificity for aspergillosis, as it likely to produce positive results due to commensal yeasts often found in respiratory samples. A single-center study performed on patients with pulmonary infiltrates reported modest sensitivities and specificities of 56.5% and 83.2%, respectively, but poor PPV of 34.2% (<link linkend="ch0144s0025s0001li0099">99</link>). In children there is a recommendation by ESCMID-ECMM against the use of BDG for screening or for the evaluation of suspected invasive aspergillosis in immunocompromised children at high risk to develop invasive aspergillosis (<link linkend="ch0144s0025s0001li0100">100</link>).</para>
        </sect3>
      </sect2>
      <sect2 id="ch0144s0007s0003">
        <title>Nucleic Acid Detection</title>
        <anchor id="ch0144s0007s0003a0001"/>
        <anchor id="ch0144s0007s0003a0002"/>
        <para id="ch0144s0007s0003p0001"><emphasis>Aspergillus</emphasis> DNA can be detected in clinical specimens either by nucleic acid amplification methods specifically targeting <emphasis>Aspergillus</emphasis> or by panfungal PCR assays followed by DNA sequencing for species identification. The former has the better sensitivity and faster turnaround time (no need for DNA sequencing), but panfungal assays have broader diagnostic potential. Both strategies may identify <emphasis>Aspergillus</emphasis> spp. directly in tissue, blood, CSF, and respiratory samples (<link linkend="ch0144s0025s0001li0054">54</link>, <link linkend="ch0144s0025s0001li0101">101</link>–<link linkend="ch0144s0025s0001li0103">103</link>) with good overall sensitivity and specificity, although with wide interstudy variability in performance (40 to 100% for sensitivity; 60 to 100% for specificity) (reviewed in reference <link linkend="ch0144s0025s0001li0104">104</link>). Technical advances in amplicon detection methods have enabled real-time detection and quantification of <emphasis>Aspergillus</emphasis> DNA (quantitative PCR) using TaqMan, LightCycler, high-resolution melting curve analysis, or nucleic acid sequence-based amplification; these methods are detailed elsewhere (<link linkend="ch0144s0025s0001li0060">60</link>, <link linkend="ch0144s0025s0001li0105">105</link>, <link linkend="ch0144s0025s0001li0106">106</link>). Multiple in-house PCR assays targeting various genetic sequences (18S rDNA, ITS region, and mitochondrial DNA) have been developed for detection of <emphasis>Aspergillus</emphasis> spp. in clinical specimens, but substantial variation in results was observed across studies due to lack of standardization of PCR methods, including the procedure of DNA extraction.</para>
        <para id="ch0144s0007s0003p0002">Prior to initiatives by the European<emphasis>Aspergillus</emphasis> PCR Initiative (EAPCRI) working group of the ISHAM to address the above limitations of <emphasis>Aspergillus</emphasis> PCR assays (see below), Mengoli et al. undertook a systematic review to assess assays for their (i) diagnostic value (specifically, DORs) or (ii) role in screening for invasive aspergillosis (<link linkend="ch0144s0025s0001li0107">107</link>), which was updated in 2019 (<link linkend="ch0144s0025s0001li0108">108</link>). In the update, 29 studies that employed PCR on blood, serum, or plasma samples (&gt;28,000 samples from 4,718 patients, mean invasive aspergillosis prevalence of 16.3%) were included. The meta-analysis showed that a single PCR-negative result was sufficient to exclude a diagnosis of proven or probable aspergillosis if PCR was used as a screening tool from the start of the at-risk period. Two positive PCR results are required to maximize specificity. The calculated pooled sensitivity was 79.2% (95% CI, 71.0 to 85.5) and specificity was 79.6% (95% CI, 68.9 to 86.6) for a single positive test and 59.6% (95% CI, 40.7 to 76.0) and 95.1% (95% CI, 87.0 to 98.2) for two consecutive positive test results (<link linkend="ch0144s0025s0001li0108">108</link>). The diagnostic accuracy is moderate when used as a screening test for invasive aspergillosis in high-risk patient groups; however, the high NPV (95.1% for a single positive test criterion and 92.4% for two positive test criteria) means that a negative test allows exclusion of invasive aspergillosis. Antimould prophylaxis significantly reduces the pretest probability of invasive aspergillosis, which is associated with a lower specificity of <emphasis>Aspergillus</emphasis> PCR testing of blood (from 79 to 64%) with no significant increase of sensitivity (75% to 82%). There was heterogeneity in the patient population studied, PCR method, nature of samples (e.g., whole blood versus serum), and volume of sample tested (<link linkend="ch0144s0025s0001li0108">108</link>); 1-ml serum volumes have yielded superior sensitivity (100% versus 76.5%) compared with standard 100-μl volumes (<link linkend="ch0144s0025s0001li0109">109</link>).</para>
        <para id="ch0144s0007s0003p0003">PCR performed on BAL fluid samples has good potential to assist diagnosis of invasive pulmonary aspergillosis; however, while a negative result is useful to exclude disease, a positive result cannot distinguish colonization from infection (<link linkend="ch0144s0025s0001li0064">64</link>, <link linkend="ch0144s0025s0001li0081">81</link>, <link linkend="ch0144s0025s0001li0110">110</link>). Receipt of antimould prophylaxis does not adversely effect PCR positivity on BAL fluid (<link linkend="ch0144s0025s0001li0081">81</link>). A recent evaluation of a real-time pan-<emphasis>Aspergillus</emphasis> PCR in lung transplant patients showed a sensitivity and specificity of 100% and 88%, respectively, with similar performance characteristics noted for an <emphasis>A. fumigatus</emphasis>-specific PCR (<link linkend="ch0144s0025s0001li0110">110</link>). Despite assay differences, studies have demonstrated a high NPV and good sensitivity, with variable PPVs reflecting differences in diagnostic certainty.</para>
        <anchor id="ch0144s0007s0003a0003"/>
        <beginpage pagenum="2390"/>
        <para id="ch0144s0007s0003p0004">The derivation of standardized protocols for each PCR step, especially for DNA extraction, by the EAPCRI with international collaboration (<link linkend="ch0144s0025s0001li0111">111</link>, <link linkend="ch0144s0025s0001li0112">112</link>) has allowed multicenter clinical validation of PCR assays. Notably, the following factors are critical in influencing the quality and success of <emphasis>Aspergillus</emphasis> PCR assays: the type of specimen, the volume of specimen, the DNA fungal extraction method, and the potential for automation of the PCR process itself (to increase sensitivity). There was no significant difference in sensitivity between the use of whole blood and the use of serum for PCR-based diagnosis of aspergillosis, although in some studies there was a trend for whole blood to be more sensitive (85 to 91% versus 79%) and specific (96%) and to show earlier positive results (36 days versus 15 days) compared with serum (<link linkend="ch0144s0025s0001li0113">113</link>, <link linkend="ch0144s0025s0001li0114">114</link>). Against this finding is the reduced false-positivity rate using serum, which is also easier to process. The optimum sample type should be determined by the local requirement. Another meta-analysis demonstrated higher diagnostic accuracy for studies that were compliant with the EAPCRI recommendations (<link linkend="ch0144s0025s0001li0115">115</link>). Standardization of methodologies, the availability of commercial assays and external quality control programs, and additional clinical validation resulted in the inclusion of <emphasis>Aspergillus</emphasis> PCR testing of blood (two or more consecutive PCR tests positive, or a single positive in combination with a positive BAL fluid) and respiratory samples (two or more duplicate PCR tests positive) from adults or children to the updated EORTC/MSGERC definitions (<link linkend="ch0144s0025s0001li0047">47</link>). For both sample types, a combination with other biomarkers increases likelihood of invasive aspergillosis (<link linkend="ch0144s0025s0001li0115">115</link>–<link linkend="ch0144s0025s0001li0117">117</link>). Most cases included in these studies stemmed from hematology patients; the performance of PCR testing in serum from patients with other types of immunosuppression is uncertain, but the need is growing with the increased frequency of invasive aspergillosis occurring in the intensive care setting and in CAPA patients (<link linkend="ch0144s0025s0001li0081">81</link>). In nonneutropenic patients, the utility of <emphasis>Aspergillus</emphasis> PCR is currently restricted to respiratory specimens for diagnostic confirmation, rather than high-frequency screening (<link linkend="ch0144s0025s0001li0116">116</link>).</para>
        <para id="ch0144s0007s0003p0005">A further advance is the availability of several commercial multiplex real-time PCR assays, such as AsperGenius (PathoNostics, Maastricht, the Netherlands), Fungiplex<emphasis>Aspergillus</emphasis> IVD real-time PCR kit (Bruker Daltonik GmbH, Bremen, Germany) and the MycoGENIE Real-time PCR kit (Ademtech-Bioparc BioGalien, Pessac, France) (<link linkend="ch0144s0025s0001li0118">118</link>–<link linkend="ch0144s0025s0001li0121">121</link>). These assays provide quality assurance and technical consistency which allow laboratories outside specialty mycology reference laboratories to perform testing (<link linkend="ch0144s0025s0001li0118">118</link>, <link linkend="ch0144s0025s0001li0119">119</link>). However, some of these kits are not cleared by the FDA for diagnostic use, although the MycoGENIE assay is CE <emphasis>in vitro</emphasis> diagnostic use compliant (<link linkend="ch0144s0025s0001li0119">119</link>); it has the advantage of also detecting the TR34/L98H mutation in <emphasis>A. fumigatus</emphasis> (see <ulink url="ch0156#ch0156s0001">chapter 134</ulink>), a mutation well known to be associated with azole resistance. Another, the MycAssay <emphasis>Aspergillus</emphasis> assay (Myconostica, Manchester, United Kingdom), is a platform that allows standardized detection using quality-controlled reagents. In high-risk hematology patients, the kit had a sensitivity of 65% and specificity of 95% with serum and BAL fluid (<link linkend="ch0144s0025s0001li0122">122</link>). In nonhematology patients with invasive lung aspergillosis, the sensitivity, specificity, PPV, and NPV for lower respiratory tract samples were 86.7%, 87.6%, 34.1%, and 92.2%, respectively; sensitivity increased when multiple samples were analyzed (<link linkend="ch0144s0025s0001li0123">123</link>). The median time to detection of <emphasis>Aspergillus</emphasis> was 4 hours. The AsperGenius (PathoNostics) kit allows the specific detection of <emphasis>A. fumigatus</emphasis> complex, <emphasis>A. terreus</emphasis>, and other <emphasis>Aspergillus</emphasis> species by targeting the 28S rRNA gene. It is able also to detect the most prevalent <emphasis>CYP51</emphasis> gene mutations in <emphasis>A. fumigatus</emphasis>—namely, the TR34, L98H, Y121F, and T289A mutations, which are known to confer resistance (<link linkend="ch0144s0025s0001li0118">118</link>) (see “<emphasis>In Vitro</emphasis> Antifungal Susceptibility Testing” below).</para>
        <sect3 id="ch0144s0007s0003s0001">
          <title>Clinical Utility of Combined Antigen Detection and Nucleic Acid Amplification Test</title>
          <anchor id="ch0144s0007s0003s0001a0001"/>
          <anchor id="ch0144s0007s0003s0001a0002"/>
          <para id="ch0144s0007s0003s0001p0001">The above descriptions of GM and (1,3)-β-<emphasis role="smallcaps">D</emphasis>-glucan antigen and <emphasis>Aspergillus</emphasis> PCR testing for the diagnosis of invasive aspergillosis have highlighted a number of limitations of these tests. Test performance can vary considerably, and the (1,3)-β-<emphasis role="smallcaps">D</emphasis>-glucan test is not specific for <emphasis>Aspergillus</emphasis> spp. However, substantive progress has been made in standardizing <emphasis>Aspergillus</emphasis> PCR procedures to enable its wider deployment.</para>
          <para id="ch0144s0007s0003s0001p0002">It is clear from numerous publications that it is the use of these tests in combination that assists in the earlier diagnosis of invasive aspergillosis, including in children with hematologic cancers (<link linkend="ch0144s0025s0001li0047">47</link>, <link linkend="ch0144s0025s0001li0075">75</link>). In a recent randomized trial of the <emphasis>Aspergillus</emphasis> GM and <emphasis>Aspergillus</emphasis> PCR versus culture and histology methods in high-risk hematology patients, the use of GM and PCR to direct therapy reduced the use of empiric antifungals, enabled more diagnosis of probable aspergillosis a median of 4 days earlier, and was most effective in patients receiving fluconazole, itraconazole, or no antifungal prophylaxis (<link linkend="ch0144s0025s0001li0124">124</link>). Rogers et al. demonstrated that addition of PCR to GM monitoring in the setting of hematological malignancy provided greater diagnostic accuracy for invasive aspergillosis (<link linkend="ch0144s0025s0001li0125">125</link>). Others have reported that GM or PCR can diagnose invasive aspergillosis a median of 2 to 9 days earlier than culture and high-resolution computerized tomography scans in up to 88.8% of patients (<link linkend="ch0144s0025s0001li0113">113</link>, <link linkend="ch0144s0025s0001li0126">126</link>) and that both serum GM and PCR testing led to greater sensitivity in diagnosing invasive aspergillosis in hematology patients (<link linkend="ch0144s0025s0001li0126">126</link>, <link linkend="ch0144s0025s0001li0127">127</link>), with a meta-analysis showing the association of both GM and PCR to be highly suggestive of active infection (PPV, 88%). The combined use of the <emphasis>Aspergillus</emphasis> lateral flow test (OLM Diagnostics) with <emphasis>Aspergillus</emphasis> PCR yielded a 100% sensitivity and 100% specificity for proven or probable aspergillosis in an early retrospective clinical study (<link linkend="ch0144s0025s0001li0087">87</link>).</para>
        </sect3>
      </sect2>
    </sect1>
    <sect1 id="ch0144s0008">
      <title>Isolation Procedures</title>
      <anchor id="ch0144s0008a0001"/>
      <anchor id="ch0144s0008a0002"/>
      <para id="ch0144s0008p0001"><emphasis>Aspergillus</emphasis> species are not fastidious in their growth requirements. They are usually easily recovered on standard mycological media and will also grow on bacteriological media such as blood agar. On occasions where respiratory tract specimens may be inoculated on media selective for certain non-<emphasis>Aspergillus</emphasis> moulds (e.g., dichloran rose bengal agar for selective isolation of <emphasis>Scedosporium</emphasis> species [128]), and where the presence of <emphasis>Aspergillus</emphasis> organisms may be clinically relevant, it should be noted that growth of aspergilli is inhibited on these media.</para>
      <figure id="ch0144s0008f0001"><title><phrase role="figureLabel"><anchor id="ch0144s0008a0003"/><link linkend="ch0144s0004a0011"><emphasis role="strong">FIGURE 3</emphasis></link></phrase> (A) H&amp;E-stained section of lung showing <emphasis>Aspergillus</emphasis> hyphae with smooth hyaline which are septate and branch dichotomously at acute angles. (B) Colonies of <emphasis>Aspergillus fumigatus</emphasis> on potato dextrose agar showing typical blue-green surface pigmentation with a suede-like surface consisting of a dense felt of conidiophores. (C) Conidiophores of <emphasis>Aspergillus fumigatus</emphasis> are columnar (up to 400 by 50 μm long) but may be shorter and are uniseriate. The vesicle is conical and has a singe row of phialides on the upper two-thirds. Conidia are produced in basipetal succession with long chains and are globose to subglobose. (D) Culture of <emphasis>Aspergillus lentulus.</emphasis> Colonies are suede-like to floccose, white, and interspersed with gray-green patches of conidia (conidiation is slow to poor). (E) Conidiophores of <emphasis>Aspergillus lentulus</emphasis> are short, columnar, and uniseriate. Stipes are narrower than those of <emphasis>Aspergillus fumigatus.</emphasis> Vesicles are subglobose and are smaller (6 to 25 μm in diameter) than those of <emphasis>A. fumigatus</emphasis> (10 to 26 μm). (F) Culture of <emphasis>Aspergillus flavus.</emphasis> Colonies are granular, flat, often with radial grooves, and yellow at first but quickly becoming bright to dark yellow-green with age. (G) Biseriate head of <emphasis>Aspergillus flavus.</emphasis> (H) <emphasis>Aspergillus nidulans</emphasis> (<emphasis>Emericella nidulans</emphasis>) showing cleistothecia. (I) <emphasis>Aspergillus ustus</emphasis> showing biseriate head, brown stipe, and Hülle cells.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0144f08.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0144s0008p0002">Most identification schemes utilize specific media and incubation conditions for the description of characteristics such as colony color and size (diameter) (<link linkend="ch0144s0008a0003">Fig. 3</link>). <emphasis>Aspergillus</emphasis> species usually grow without difficulty at 25°C, but also at higher temperatures. Although isolation procedures do not require specific biohazard precautions, it is good laboratory practice to handle all culture material in a class II biosafety cabinet to avoid cross-contamination and dispersal of spores through the environment. The culture process usually requires several days.</para>
      <anchor id="ch0144s0008a0004"/>
      <beginpage pagenum="2391"/>
    </sect1>
    <sect1 id="ch0144s0009">
      <title>Identification</title>
      <anchor id="ch0144s0009a0001"/>
      <anchor id="ch0144s0009a0002"/>
      <para id="ch0144s0009p0001">Culture-based identification of aspergilli remains important despite increasing use of molecular and proteomic tools. Diagnostic features of the more common pathogenic species and species complex are summarized in<link linkend="ch0144s0004a0007">Table 2</link>. For keys to taxa and additional information, see also the work of de Hoog et al. (<link linkend="ch0144s0025s0001li0014">14</link>). <link linkend="ch0144s0004a0006">Figure 2</link> presents a diagrammatic key to several species. Some species commonly produce sexual structures (i.e., cleistothecia and ascospores), which aid identification. The respective teleomorph synonyms of common <emphasis>Aspergillu</emphasis>s species are given in parentheses (e.g., <emphasis>Emericella</emphasis> and <emphasis>Neosartorya</emphasis> [<link linkend="ch0144s0004a0007">Table 2</link>]).</para>
      <para id="ch0144s0009p0002">Phenotypic identification of<emphasis>Aspergillus</emphasis> requires the assessment of both macroscopic and microscopic morphological characteristics. Inoculation media and incubation conditions affect the morphological characteristics of <emphasis>Aspergillus</emphasis> species. Czapek yeast autolysate agar and/or 2% malt extract agar (Oxoid), with or without 20% sucrose, is recommended for identification and characterization (<link linkend="ch0144s0025s0001li0001">1</link>). Isolates are usually inoculated at three points and incubated at 25°C (<link linkend="ch0144s0025s0001li0001">1</link>, <link linkend="ch0144s0025s0001li0014">14</link>). Most species sporulate within 7 days, but the teleomorph form takes longer to develop. Descriptions are primarily based on colony pigmentation and morphology of the conidial head with reference to those in expert monographs (<link linkend="ch0144s0025s0001li0004">4</link>, <link linkend="ch0144s0025s0001li0008">8</link>).</para>
      <sect2 id="ch0144s0009s0001">
        <title>Macroscopic Features</title>
        <anchor id="ch0144s0009s0001a0001"/>
        <anchor id="ch0144s0009s0001a0002"/>
        <para id="ch0144s0009s0001p0001">Important colony characteristics, recorded after 7 days, include growth rate, texture, degree of sporulation, surface and reverse colony color, the presence of exudate droplets and diffusible pigments, and the production of sclerotia, Hülle cells, and cleistothecia or ascospores (<link linkend="ch0144s0008a0003">Fig. 3B</link> to I) (<link linkend="ch0144s0025s0001li0001">1</link>, <link linkend="ch0144s0025s0001li0014">14</link>, <link linkend="ch0144s0025s0001li0129">129</link>). Isolates that are not identifiable should be retained longer for possible development of ascomata or other structures that may aid identification.</para>
      </sect2>
      <sect2 id="ch0144s0009s0002">
        <title>Microscopic Features</title>
        <anchor id="ch0144s0009s0002a0001"/>
        <anchor id="ch0144s0009s0002a0002"/>
        <para id="ch0144s0009s0002p0001">Microscopic mounts are best made from conidiophores produced on malt extract agar after 7 to 10 days, using sticky tape flag or slide culture preparations in lactic acid (<link linkend="ch0144s0025s0001li0001">1</link>, <link linkend="ch0144s0025s0001li0129">129</link>). Lactophenol is no longer recommended for mounting because it is corrosive due to the phenol content, but lactofuchsin is still widely used (<link linkend="ch0144s0025s0001li0001">1</link>). <emphasis>Aspergillus</emphasis> conidia are hydrophobic, and a drop of 70% alcohol is usually required to remove air bubbles and excess conidia. Key features are hyaline hyphae showing distinctive conidial heads with flask-shaped phialides arranged in whorls on a vesicle (<link linkend="ch0144s0004a0006">Fig. 2</link>). Specifically, important features are differences in size, shape, color, and wall ornamentation of various structures, including the stipe, shape and size of vesicles, and arrangement of phialides. A stipe or conidiophore arises either directly from the vegetative hyphae or from a specialized hyphal cell called a foot cell; it is typically nonseptate and varies in color, length, and wall ornamentation according to species. The stipe ends in a variably shaped (globose, subglobose, hemispherical, pear-shaped, or clavate [club-shaped]), swollen vesicle (<link linkend="ch0144s0004a0006">Fig. 2</link>); either the entire vesicle or its upper portion is covered with phialides, which give rise to the conidia. Conidial head morphology in <emphasis>Aspergillus</emphasis> is either uniseriate, where the phialides arise directly from the vesicle, or biseriate, where they arise from an intermediate series of cells, the metulae, or a combination of both, as occurs in <emphasis>A. flavus</emphasis> (<link linkend="ch0144s0004a0006">Fig. 2</link>; <link linkend="ch0144s0004a0007">Table 2</link>).</para>
        <anchor id="ch0144s0009s0002a0003"/>
        <beginpage pagenum="2392"/>
        <para id="ch0144s0009s0002p0002">The conidia themselves may be borne in a single column (columnar), or columns may be split, with some arising at right angles to the stipe (radiate). A dissecting microscope is required to make this distinction. Conidia are usually ellipsoidal or globose, may be echinulate, and vary in size, color, and wall markings depending on the species. Differential interference contrast microscopy is recommended for best observation of conidiophore characteristics (<link linkend="ch0144s0025s0001li0001">1</link>, <link linkend="ch0144s0025s0001li0129">129</link>).</para>
        <para id="ch0144s0009s0002p0003">Sclerotia are firm, fruiting-body-like structures comprising swollen hyphal cells but without internal spores. Hülle cells are variably globose with very thick refractile walls (<link linkend="ch0144s0008a0003">Fig. 3I</link>). They commonly occur within the growing mycelium near the colony center, where their presence is indicated by droplets of exudate. They are often associated with cleistothecial ascomata (<link linkend="ch0144s0004a0007">Table 2</link>). The interiors of cleistothecia are filled with asci and ascospores. Shape, color, size, and wall features of these structures are important in distinguishing the different teleomorph forms.</para>
      </sect2>
      <sect2 id="ch0144s0009s0003">
        <title>Poorly Sporulating Species or Variants</title>
        <anchor id="ch0144s0009s0003a0001"/>
        <anchor id="ch0144s0009s0003a0002"/>
        <para id="ch0144s0009s0003p0001">Where sporulation is poor, morphological identification may be problematic, although incubation at 25°C in light and allowing the cultures to experience the normal diurnal cycles of light and dark may help to induce sporulation (<link linkend="ch0144s0025s0001li0130">130</link>, <link linkend="ch0144s0025s0001li0131">131</link>). Poorly sporulating isolates are not uncommonly recovered from clinical specimens (<link linkend="ch0144s0025s0001li0130">130</link>), including those from patients with aspergilloma and with cystic fibrosis. When this occurs, <emphasis>A. fumigatus</emphasis> species complex could be considered if an atypical, sometimes waxy or cerebriform mould was grown at 45°C (all members of section <emphasis>Fumigati</emphasis> grow at this elevated temperature [<link linkend="ch0144s0004a0007">Table 2</link>]); it is now well established that various cryptic species such as <emphasis>A. lentulus</emphasis> and <emphasis>A. thermomutatus</emphasis> and other closely related sibling species of <emphasis>A. fumigatus</emphasis> demonstrate a poorly sporulating phenotype (<link linkend="ch0144s0025s0001li0007">7</link>, <link linkend="ch0144s0025s0001li0130">130</link>). <emphasis>A. lentulus</emphasis> does exhibit smaller vesicles (<link linkend="ch0144s0004a0007">Table 2</link>; <link linkend="ch0144s0008a0003">Fig. 3E</link>) and, unlike <emphasis>A. fumigatus</emphasis>, cannot grow at 48 or 50°C, but in practice it cannot be distinguished from <emphasis>A. fumigatus</emphasis> by morphological methods alone without scanning electron microscopy or other sophisticated microscopy. As <emphasis>A. lentulus</emphasis> has low <emphasis>in vitro</emphasis> susceptibilities to the azoles, amphotericin B, and caspofungin (<link linkend="ch0144s0025s0001li0007">7</link>), it is important to accurately identify all clinically significant isolates. Since the discovery of <emphasis>A. lentulus</emphasis> as a new species, subsequent screening studies of “<emphasis>A. fumigatus</emphasis>” isolates have uncovered pathogens misidentified as <emphasis>A. fumigatus</emphasis>, including <emphasis>A. viridinutans, A. felis</emphasis>, and <emphasis>A. udagawae</emphasis> (<link linkend="ch0144s0025s0001li0031">31</link>, <link linkend="ch0144s0025s0001li0111">111</link>, <link linkend="ch0144s0025s0001li0130">130</link>); these isolates also demonstrate variable susceptibility to antifungal drugs <emphasis>in vitro</emphasis> and are associated with high mortality rates (see “Antimicrobial Susceptibilities” below) (<link linkend="ch0144s0025s0001li0132">132</link>, <link linkend="ch0144s0025s0001li0133">133</link>). As for <emphasis>A. lentulus</emphasis> isolates, phenotypic identification methods alone will not differentiate them from <emphasis>A. fumigatus</emphasis>.</para>
      </sect2>
      <sect2 id="ch0144s0009s0004">
        <title>Molecular Identification</title>
        <anchor id="ch0144s0009s0004a0001"/>
        <anchor id="ch0144s0009s0004a0002"/>
        <para id="ch0144s0009s0004p0001">Where conventional phenotypic methods cannot identify<emphasis>Aspergillus</emphasis> isolates or identification is uncertain (e.g., with nonsporulating isolates) due to overlapping morphological features, DNA sequencing is often helpful. Comparative multilocus sequence analysis is the gold standard for molecular identification, as no single gene can be relied on (<link linkend="ch0144s0025s0001li0001">1</link>). The ITS region, including the 5.8S rRNA gene regions, is generally more discriminatory than the D1-D2 domain of the 28S subunit for the identification of aspergilli (<link linkend="ch0144s0025s0001li0131">131</link>, <link linkend="ch0144s0025s0001li0134">134</link>, <link linkend="ch0144s0025s0001li0135">135</link>), with the ITS1-5.8S-ITS2 region being the universal DNA barcode marker for fungi (<link linkend="ch0144s0025s0001li0136">136</link>). However, the ITS region does not contain enough variation for distinguishing species within some <emphasis>Aspergillus</emphasis> clades, and hence, the use of other gene targets for species identification, including the β-tubulin, rodlet A, and mitochondrial cytochrome <emphasis>b</emphasis> genes, may be necessary (<link linkend="ch0144s0025s0001li0001">1</link>, <link linkend="ch0144s0025s0001li0130">130</link>, <link linkend="ch0144s0025s0001li0132">132</link>, <link linkend="ch0144s0025s0001li0133">133</link>, <link linkend="ch0144s0025s0001li0137">137</link>). The ISHAM <emphasis>Aspergillus</emphasis> Working Group recommends the use of a comparative sequencing-based identification method that uses the ITS regions for species complex-level identification and of a protein-coding locus (β-tubulin region) for identification of species within each <emphasis>Aspergillus</emphasis> species complex (<link linkend="ch0144s0025s0001li0001">1</link>). This approach successfully identified 218 <emphasis>Aspergillus</emphasis> isolates collected for TRANSNET (<link linkend="ch0144s0025s0001li0031">31</link>) and 278 (86.3%) isolates in the FILPOP study in Spain (<link linkend="ch0144s0025s0001li0034">34</link>). However, the <emphasis>benA</emphasis> primers preferentially amplify the <emphasis>tubC</emphasis> paralogue for some species in the <emphasis>Nigri</emphasis> section (<link linkend="ch0144s0025s0001li0138">138</link>), although this locus may be too variable to be used for phylogenetic reconstruction (<link linkend="ch0144s0025s0001li0014">14</link>). The calmodulin gene, <emphasis>CaM</emphasis>, has recently been suggested as a candidate secondary identification marker in <emphasis>Aspergillus</emphasis>, as it is easy to amplify and distinguishes all species when used in combination with ITS sequencing (<link linkend="ch0144s0025s0001li0001">1</link>). To improve species identification based on ITS sequencing, sequences may be searched against the RefSeq database (<ulink url="https://www.ncbi.nlm.nih.gov/refseq/">https://www.ncbi.nlm.nih.gov/refseq/</ulink>), which contains only verified ITS sequences (<link linkend="ch0144s0025s0001li0139">139</link>).</para>
        <para id="ch0144s0009s0004p0002">Non-sequence-based identification methods include real-time PCR and<emphasis>Aspergillus</emphasis> species-specific microsphere-based assays using Luminex xMAP technology (Luminex Corp., Austin, TX). In addition, the three major species within section <emphasis>Fumigati</emphasis> (<emphasis>A. fumigatus, A. lentulus</emphasis>, and <emphasis>A. udagawae</emphasis>) can be accurately distinguished by PCR-restriction fragment length polymorphism (RFLP) analysis of the <emphasis>benA</emphasis> gene (<link linkend="ch0144s0025s0001li0140">140</link>). Alonso et al. developed a real-time PCR followed by combined probe hybridization and high-resolution melting analysis to identify section <emphasis>Fumigati</emphasis> and non-<emphasis>Fumigati Aspergillus</emphasis> isolates; the detection limit was 10<superscript>2</superscript> conidia/ml (<link linkend="ch0144s0025s0001li0105">105</link>). Microsphere-based Luminex (Luminex Corp.) assays have also enabled species complex-level identification as well as differentiation of species within the <emphasis>A. fumigatus</emphasis> complex (<link linkend="ch0144s0025s0001li0141">141</link>).</para>
        <para id="ch0144s0009s0004p0003">The preciseness of reporting of an identification of<emphasis>Aspergillus</emphasis> depends on (i) the clinical need to accurately identify the fungus species (e.g., recovery from a tissue biopsy compared with recovery from sputum) and (ii) access to molecular identification methods. In smaller laboratories, the use of the term “species complex” aids correct identification, since isolates are relatively reliably identified to the section level by morphological methods. For example, a laboratory can identify a fungus as “<emphasis>A. fumigatus</emphasis> species complex” by phenotypic methods and indicate that molecular identification is required to identify the isolate as a species within the complex.</para>
      </sect2>
      <sect2 id="ch0144s0009s0005">
        <title>MALDI-TOF Methods</title>
        <anchor id="ch0144s0009s0005a0001"/>
        <anchor id="ch0144s0009s0005a0002"/>
        <para id="ch0144s0009s0005p0001">Identification of mould cultures using matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) is increasingly undergoing evaluation to reduce the turnaround time for identification of<emphasis>Aspergillus</emphasis> cultures in clinical laboratories. Despite initial technical difficulties in analyte preparation posed by the complicated morphology and the <emphasis>Aspergillus</emphasis> cell wall, the technology has utility not only for identifying isolates to the species complex level but also for identifying species including “cryptic” <emphasis>Aspergillus</emphasis> species and, in some cases, delineating strain variation (<link linkend="ch0144s0025s0001li0142">142</link>–<link linkend="ch0144s0025s0001li0148">148</link>). There are now several well-described standardized preanalytical sample preparation methods described for filamentous fungi (<link linkend="ch0144s0025s0001li0142">142</link>, <link linkend="ch0144s0025s0001li0143">143</link>). For <emphasis>Aspergillus</emphasis> species, mechanical disruption by bead beating of cells and conidia prior to on-target lysis is recommended to ensure highly discriminatory spectra (<link linkend="ch0144s0025s0001li0144">144</link>, <link linkend="ch0144s0025s0001li0145">145</link>). A liquid cultivation method is recommended by Bruker Daltonics GmbH, but this approach is labor-intensive and time-consuming. Recently, Salah et al. reported that cultivation of isolates on top of a membrane filter was useful not only for in-house database contruction but also for identification of several <emphasis>Aspergillus</emphasis> species (<link linkend="ch0144s0025s0001li0149">149</link>). The importance of a robust and extensive database of reference spectra for accurate species identification cannot be overemphasized (<link linkend="ch0144s0025s0001li0146">146</link>–<link linkend="ch0144s0025s0001li0148">148</link>). Many commercial databases have few species and intraspecies strain representations and need to be supplemented with an in-house library incorporating well-validated spectra from adequate numbers of species and from sufficient numbers of strains representing each species for accurate identification (<link linkend="ch0144s0025s0001li0142">142</link>, <link linkend="ch0144s0025s0001li0146">146</link>–<link linkend="ch0144s0025s0001li0148">148</link>, <link linkend="ch0144s0025s0001li0150">150</link>).</para>
        <anchor id="ch0144s0009s0005a0003"/>
        <beginpage pagenum="2393"/>
        <para id="ch0144s0009s0005p0002">Bille et al. reported an overall identification rate for<emphasis>Aspergillus</emphasis> spp. of 98.4% (63/64 isolates) using the Andromas system (Andromas SA, Paris, France), and Alanio et al. reported an identification rate of 98.6% (138/140 isolates) (<link linkend="ch0144s0025s0001li0151">151</link>). Becker et al. correctly identified 99.6% of <emphasis>Aspergillus</emphasis> isolates (<emphasis>n</emphasis> = 256) to species level, compared with conventional methods, which correctly identified only 87.9% (<link linkend="ch0144s0025s0001li0146">146</link>). The only isolate unable to be identified by MALDI-TOF MS was not available in the database. Hettick et al. used MALDI-TOF MS to derive spectra for 12 <emphasis>Aspergillus</emphasis> species and five different strains of <emphasis>A. flavus</emphasis>; classification of each species and strain of <emphasis>Aspergillus</emphasis> tested was achieved with 100% accuracy (<link linkend="ch0144s0025s0001li0152">152</link>) when invasive <emphasis>Aspergillus</emphasis> isolates were analyzed. In a study from Belgium, 20 <emphasis>Aspergillus</emphasis> isolates comprising nine species recovered from the environment were successfully identified by MALDI-TOF MS using an in-house reference database (<link linkend="ch0144s0025s0001li0150">150</link>).</para>
        <para id="ch0144s0009s0005p0003">All studies have stressed the need for adequate sample preparation for MALDI-TOF MS and the construction of libraries of robust spectra from known strains, independent of the MALDI-TOF MS system. Use of MALDI-TOF MS has not been approved for the identification of<emphasis>Aspergillus</emphasis> or other moulds by the FDA, and it is unlikely that industry will invest in strengthening filamentous fungi identification capacity. Plans are under way to develop a curated, publicly accessible MALDI-TOF MS database via the Internet (<link linkend="ch0144s0025s0001li0146">146</link>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0144s0010">
      <title>Typing Systems</title>
      <anchor id="ch0144s0010a0001"/>
      <anchor id="ch0144s0010a0002"/>
      <para id="ch0144s0010p0001">Genotyping of<emphasis>Aspergillus</emphasis> is central to the understanding of epidemiological relationships between clinical and environmental isolates and to identifying the origin and tracking the spread of health care-related infections (see “Epidemiology and Transmission” above), especially in responding to public health situations (<link linkend="ch0144s0025s0001li0153">153</link>). Genotyping also assists in determining if a patient is colonized or infected with the same strain over long periods or becomes recolonized or reinfected by different strains. Many methods are described for the typing of <emphasis>Aspergillus</emphasis>; these include random amplified polymorphic DNA (RAPD) analysis, RFLP analysis, DNA fingerprinting, amplified fragment length polymorphism (AFLP) analysis, multilocus microsatellite typing (MLMT), multilocus sequence typing (MLST), and a simple single-locus sequence typing involving the gene coding for cell surface protein (CSP). Most data are based on the typing of <emphasis>A. fumigatus</emphasis>, with the reference typing method being analysis of short tandem repeats (STR) based on microsatellite analysis (see below) (<link linkend="ch0144s0025s0001li0154">154</link>).</para>
      <para id="ch0144s0010p0002">RAPD analysis has been used to differentiate between isolates of<emphasis>A. fumigatus</emphasis> (<link linkend="ch0144s0025s0001li0155">155</link>) and other species, including <emphasis>A. flavus</emphasis> (<link linkend="ch0144s0025s0001li0156">156</link>) and <emphasis>A. terreus</emphasis> (<link linkend="ch0144s0025s0001li0157">157</link>). RFLP analysis was likewise first applied to the genotyping of <emphasis>A. fumigatus</emphasis> using XhoI and SalI enzymes and then to species identification among a heterogeneous <emphasis>Aspergillus</emphasis> group, where it correctly identified <emphasis>A. flavus</emphasis> isolates (<link linkend="ch0144s0025s0001li0158">158</link>). DNA fingerprinting has utility in genotyping using probes such as those containing retrotransposon-like elements, namely, Afut1, Afut2, and Afut4 (<link linkend="ch0144s0025s0001li0159">159</link>–<link linkend="ch0144s0025s0001li0161">161</link>), while clinical and environmental <emphasis>A. flavus</emphasis> isolates from a neonatal intensive care unit have been successfully typed with the species-specific probe pAF28 (<link linkend="ch0144s0025s0001li0162">162</link>). AFLP analysis is another approach that has determined genetic diversity within <emphasis>A. fumigatus</emphasis> (<link linkend="ch0144s0025s0001li0163">163</link>) and within the sections <emphasis>Flavi</emphasis> (<link linkend="ch0144s0025s0001li0164">164</link>) and <emphasis>Nigri</emphasis> (<link linkend="ch0144s0025s0001li0165">165</link>). Widespread application of these methods, in particular RAPD and AFLP, has been hampered by a low degree of interlaboratory reproducibility due to their reliance on pattern-based typing techniques.</para>
      <para id="ch0144s0010p0003">MLMT analysis using four, and later nine, different microsatellite markers was developed to form the STRAf scheme for genotyping<emphasis>A. fumigatus</emphasis> (<link linkend="ch0144s0025s0001li0154">154</link>); this approach has been extended to include other species, including <emphasis>A. flavus</emphasis> (six or seven markers) (<link linkend="ch0144s0025s0001li0166">166</link>, <link linkend="ch0144s0025s0001li0167">167</link>), <emphasis>A. niger</emphasis> (six markers), and <emphasis>A. nidulans</emphasis> (seven markers) (<link linkend="ch0144s0025s0001li0168">168</link>, <link linkend="ch0144s0025s0001li0169">169</link>). More recent studies confirmed the high-resolution genotyping results for <emphasis>A. flavus</emphasis> (<link linkend="ch0144s0025s0001li0167">167</link>, <link linkend="ch0144s0025s0001li0170">170</link>). Hadrich et al., using six STR markers, found that among 63 clinical isolates, the marker AFLA1 had the highest discriminatory power (14 distinct alleles; discriminatory or <emphasis>D</emphasis>value, 0.903) (<link linkend="ch0144s0025s0001li0167">167</link>). STR typing has also been developed for <emphasis>A. terreus.</emphasis> By using a test set of 244 <emphasis>A. terreus</emphasis> isolates and a panel of eight STR markers, 79 genotypes of this species complex were identified with high discriminatory value; of 63 Austrian clinical isolates, 68.2% comprised three genotypes (<link linkend="ch0144s0025s0001li0037">37</link>). Further, nine STR markers were able to identify 75 genotypes among 101 Indian <emphasis>A. terreus</emphasis> complex strains (<link linkend="ch0144s0025s0001li0171">171</link>).</para>
      <para id="ch0144s0010p0004">MLST analysis with a panel of seven genetic loci has also been applied for strain typing of<emphasis>A. fumigatus</emphasis> (<link linkend="ch0144s0025s0001li0172">172</link>). CSP typing (<link linkend="ch0144s0025s0001li0022">22</link>) is a useful molecular tool but has lower discriminatory power than MLMT. Strain variation is a result of both repeat number variation and nucleotide sequence variation. In one study, CSP typing was compared with PCR fingerprinting using minisatellite (core sequence of the bacteriophage M13)-specific and microsatellite [(GTG)<subscript>5</subscript> and (GACA)<subscript>4</subscript>]-specific single primers and MLMT analysis to differentiate between <emphasis>A. fumigatus</emphasis> strains; only MLMT separated all clinical and environmental isolates implicated in a case cluster (<link linkend="ch0144s0025s0001li0022">22</link>).</para>
      <para id="ch0144s0010p0005">MLMT, MLST, and CSP typing are all highly reproducible and yield unambiguous and portable data. Microsatellite-based approaches and MLST analysis are species specific. Recently, a new genotyping method based on hypervariable tandem repeats with exons of surface protein coding genes has been reported to offer high-level discrimination of<emphasis>A. fumigatus</emphasis>, where 96 genotypes were distinguished among 126 unrelated isolates with a <emphasis>D</emphasis>value of 0.994 (<link linkend="ch0144s0025s0001li0173">173</link>). Finally, the utility of whole-genome sequencing technologies to provide state-of-the-art means of comparative analysis of genomes of pathogenic species of <emphasis>Aspergillus</emphasis>, including tracking of azole-resistant isolates, and to study <emphasis>Aspergillus</emphasis> genetic relatioships and virulence is increasingly realized (<link linkend="ch0144s0025s0001li0174">174</link>–<link linkend="ch0144s0025s0001li0177">177</link>).</para>
    </sect1>
    <sect1 id="ch0144s0011">
      <title>Serologic Tests</title>
      <anchor id="ch0144s0011a0001"/>
      <anchor id="ch0144s0011a0002"/>
      <anchor id="ch0144s0011a0003"/>
      <para id="ch0144s0011p0001">The detection of<emphasis>Aspergillus</emphasis> GM and <emphasis>Aspergillus</emphasis>-specific recombinant proteins in serum and other body fluids is discussed in “Antigen Detection” above. Methods to detect other <emphasis>Aspergillus</emphasis> antigens or anti-<emphasis>Aspergillus</emphasis> antibodies against these antigens, including determining reactivity in skin tests, have also been developed, but their clinical utility is less well defined (<link linkend="ch0144s0025s0001li0178">178</link>). The main reasons for this are related to the nature and purity of the antigen. Although antigen preparations may be available commercially, their quality is variable, and they demonstrate cross-reactivity with non-<emphasis>Aspergillus</emphasis> antigens. However, hybridoma technology and monoclonal antibody-based detection systems have changed the state of immunodiagnosis of aspergillosis. In particular, measurement of <emphasis>Aspergillus</emphasis>-specific antibodies is important in the diagnostic pathway for the more chronic forms of aspergillosis, allergic bronchopulmonary aspergillosis (ABPA) and chronic pulmonary aspergillosis. However, their utility in invasive forms of aspergillosis is uncertain, and at present their routine use not supported by experts.</para>
      <para id="ch0144s0011p0002">A number of reviews detail the candidate<emphasis>Aspergillus</emphasis> antigens for incorporation into immunoassays (<link linkend="ch0144s0025s0001li0178">178</link>, <link linkend="ch0144s0025s0001li0179">179</link>). Antigens tested include somatic preparations, either crude or purified whole-cell mycelial extracts, <emphasis>Aspergillus</emphasis> metabolites, mannoproteins, and expressed and purified recombinant antigens. One purified somatic antigen, a 19-kDa basic protein, was shown to be a major circulating antigen in the urine of patients with invasive aspergillosis (<link linkend="ch0144s0025s0001li0178">178</link>). This protein was also present in the serum of patients with aspergillomas. Molecular characterization has shown it to be Aspf1, an IgE-binding protein (and potent allergen) related to the mitogillin family of cytotoxins. Other potential serodiagnostic antigens include an 18-kDa ribonuclease, 88-kDa dipeptidyl peptidase, 33-kDa alkaline protease, the recombinant mannoproteins antigens Afmp1 and Afmp2, and a recombinant 19-kDa Cu-Zn superoxide dismutase (<link linkend="ch0144s0025s0001li0178">178</link>, <link linkend="ch0144s0025s0001li0180">180</link>, <link linkend="ch0144s0025s0001li0181">181</link>). Another <emphasis>Aspergillus</emphasis> protein, chitosanase CnsB, has also attracted attention as a potential antigen for antibody-based diagnostics (<link linkend="ch0144s0025s0001li0182">182</link>). Various test formats have been exploited to detect antibodies to these antigens. Double immunodiffusion and counterimmunoelectrophoresis were initially used, but these have now been replaced by commercial ELISAs and immunofluorescence assays (<link linkend="ch0144s0025s0001li0178">178</link>, <link linkend="ch0144s0025s0001li0182">182</link>).</para>
      <para id="ch0144s0011p0003">However, rather than detecting antigen, most serological evaluations have focused on detecting antibody responses to these antigens. Although many assays proved sensitive, their routine use has been limited by substantial interlaboratory variability, cross-reactivity between different fungi, the type of antigen used in the assay, and, importantly, the inability of immunocompromised hosts to mount diagnostic antibody responses. Nonetheless, in one study, IgG anti-<emphasis>A. fumigatus</emphasis>-specific mitogillin was detected by ELISA in the serum of all (32 of 32) patients with aspergilloma and in 64% (31 of 42) of patients with invasive pulmonary aspergillosis (<link linkend="ch0144s0025s0001li0183">183</link>); serum IgG and IgM antibodies were found in only 1.3% of healthy volunteers. However, the optimal cutoff value for the ELISA is not clearly established. Humoral antibody responses to Afmp1 detected by ELISA were demonstrated with high sensitivity (100%) for patients with aspergilloma, whereas in invasive aspergillosis, the sensitivity was only 33.3% (<link linkend="ch0144s0025s0001li0181">181</link>). Combined immune responses to Afmp1 and Afmp2 may increase sensitivity (<link linkend="ch0144s0025s0001li0184">184</link>). Recent work showed that total antibody specific to <emphasis>Aspergillus</emphasis>-specific thioredoxin reductase (GliT) was detected in nonneutropenic patients with invasive aspergillosis with a sensitivity of 81% and specificity of 96% (<link linkend="ch0144s0025s0001li0185">185</link>). Whether the detection of <emphasis>Aspergillus</emphasis> IgG antibodies is of clinical value in the diagnosis of invasive aspergillosis in high-risk patients is uncertain; one study found that baseline IgG responses to a number of recombinant antigens were higher in patients with aspergillosis than in controls (<link linkend="ch0144s0025s0001li0186">186</link>), while another concluded that measuring <emphasis>Aspergillus</emphasis> IgG levels is of little value (<link linkend="ch0144s0025s0001li0187">187</link>).</para>
      <para id="ch0144s0011p0004">Measurement of<emphasis>Aspergillus</emphasis>-specific antibody responses, however, has greater utility in chronic and allergic forms of aspergillosis and aspergilloma. For example, detection of circulating antibodies may aid diagnosis of ABPA in patients with cystic fibrosis and in those with severe asthma with fungal sensitization (<link linkend="ch0144s0005a0004">Table 3</link>). Anti-<emphasis>A. fumigatus</emphasis> IgE and IgG and <emphasis>A. fumigatus</emphasis> precipitins are established markers of ABPA and are criteria included in its diagnosis (reviewed in reference <link linkend="ch0144s0025s0001li0178">178</link>). Further, immunoglobulin subclass measurements may add valuable information. Recently, detection of specific IgE to recombinant <emphasis>A. fumigatus</emphasis> allergens, such as those of the rAspf family, and detection of the thymus activation-regulated chemokine TARC/CCL17 have been identified as new biomarkers of ABPA (<link linkend="ch0144s0025s0001li0188">188</link>). Consensus opinion indicates that measurements of serum IgG subclasses, especially IgG4, against <emphasis>A. fumigatus</emphasis> are useful in screening for and classifying ABPA, at least in cystic fibrosis patients, whereas IgA measurement could be useful to determine prognosis of ABPA (<link linkend="ch0144s0025s0001li0188">188</link>, <link linkend="ch0144s0025s0001li0189">189</link>). Quantitation of serum IgG4 may improve specificity of diagnosis. Further, the biomarker TARC has shown greater test accuracy for ABPA diagnosis than antibody responses. Anti-<emphasis>A. fumigatus</emphasis> IgE and IgG may be measured by commercial assays, such as the ImmunoCap assay (Phadia, Uppsala, Sweden) and the Platelia <emphasis>Aspergillus</emphasis> IgG assay (Bio-Rad, Marnes-la-Coquette, France); in a recent study, both these ELISAs were more sensitive than counterimmunoelectrophoresis (&gt;93% versus 63%) in diagnosing ABPA (<link linkend="ch0144s0025s0001li0190">190</link>).</para>
      <para id="ch0144s0011p0005">Newer assays for measuring<emphasis>Aspergillus</emphasis> antibodies have become available. One study compared the efficacy of an indirect hemagglutination assay designed to detect <emphasis>Aspergillus</emphasis> agglutinating antibodies (ELI.H.A. <emphasis>Aspergillus</emphasis> indirect hemagglutination; ELITechGroup, Signes, France) with an agar double-diffusion system to detect <emphasis>Aspergillus</emphasis> precipitins to diagnose chronic pulmonary aspergillosis. Concordance of a positive or negative test result was good, although titers varied with method. The ELITech assay (ELITechGroup Microbiology) was rapid and user friendly but was not easy to read (<link linkend="ch0144s0025s0001li0178">178</link>). The <emphasis>Aspergillus</emphasis> Western blot IgG kit (LDBiIO Diagnostics, Lyon, France) has been shown to have a sensitivity of 88.6% and specificity of 84% for the diagnosis of chronic forms of aspergillosis in nonimmunocompromised hosts (<link linkend="ch0144s0025s0001li0191">191</link>). Many of these assays have not yet been cleared by the FDA for diagnostic use.</para>
    </sect1>
    <sect1 id="ch0144s0012">
      <title>Antimicrobial Susceptibilities</title>
      <anchor id="ch0144s0012a0001"/>
      <anchor id="ch0144s0012a0002"/>
      <sect2 id="ch0144s0012s0001">
        <title>Drugs Used to Treat Invasive Aspergillosis</title>
        <anchor id="ch0144s0012s0001a0001"/>
        <anchor id="ch0144s0012s0001a0002"/>
        <para id="ch0144s0012s0001p0001">Amphotericin B, the triazoles (voriconazole, posaconazole, and isavuconazole), and echinocandins form the backbone for treatment of invasive aspergillosis, although itraconazole can be useful in the more chronic forms of disease. Consensus opinion informed by a landmark randomized, controlled trial recommends voriconazole as first-line therapy (<link linkend="ch0144s0025s0001li0192">192</link>) for invasive pulmonary aspergillosis as well as extrapulmonary and disseminated infection (<link linkend="ch0144s0025s0001li0193">193</link>). Oral voriconazole is preferred for step-down or maintenance therapy. Other antifungals approved for treating aspergillosis are lipid amphotericin B formulations (e.g., the liposomal compound, for primary therapy or salvage treatment) (<link linkend="ch0144s0025s0001li0193">193</link>) and the echinocandins, although only caspofungin is licensed for this indication in many countries (<link linkend="ch0144s0025s0001li0194">194</link>) (also for primary and salvage therapy). Posaconazole, amphotericin B, and caspofungin have been used in salvage therapy, all with response rates between 40 and 50%. More recently, both isavuconazole and posaconazole were shown to be noninferior to voriconazole for the primary treatment of invasive aspergillosis (<link linkend="ch0144s0025s0001li0195">195</link>, <link linkend="ch0144s0025s0001li0196">196</link>), and isavuconazole is licensed by the FDA as an alternative to voriconazole for first-line treatment of these infections. Though there are insufficient data to recommend antifungal combinations for primary and salvage treatment, a clinical trial of voriconazole versus voriconazole-anidulafungin for initial treatment of proven or probable aspergillosis showed a trend towards improved survival in hematology patients (<link linkend="ch0144s0025s0001li0197">197</link>). For detailed treatment practices for aspergillosis, the reader is referred to the 2016 Infectious Diseases Society of America guidelines document (<link linkend="ch0144s0025s0001li0193">193</link>).</para>
        <anchor id="ch0144s0012s0001a0003"/>
        <beginpage pagenum="2395"/>
      </sect2>
      <sect2 id="ch0144s0012s0002">
        <title>In Vitro Antifungal Susceptibility Testing</title>
        <anchor id="ch0144s0012s0002a0001"/>
        <anchor id="ch0144s0012s0002a0002"/>
        <para id="ch0144s0012s0002p0001"><emphasis>In vitro</emphasis> susceptibility testing of <emphasis>Aspergillus</emphasis> isolates may help guide therapy. Resistance to azoles, the only orally active group of antifungals for aspergillosis, used to be uncommon and was limited to patients receiving long-term azole therapy or prophylaxis; in an earlier study, there was a positive correlation between prolonged itraconazole use and high MICs of posaconazole (<link linkend="ch0144s0025s0001li0198">198</link>). Given the increasing azole resistance among both clinical and environmental <emphasis>A. fumigatus</emphasis> complex isolates in some countries (<link linkend="ch0144s0025s0001li0199">199</link>), routine testing of aspergilli for antifungal susceptibility in these regions is important for clinical decisions and to monitor trends. The prevalence of azole resistance is relatively high in Europe (up to 30%) and variable in the rest of the world (0.55 to 11.2%) (<link linkend="ch0144s0025s0001li0200">200</link>, <link linkend="ch0144s0025s0001li0201">201</link>). Rates of azole resistance were 5.8% in the ARTEMIS global surveillance study (<link linkend="ch0144s0025s0001li0202">202</link>, <link linkend="ch0144s0025s0001li0203">203</link>), up to 20% in the United Kingdom (<link linkend="ch0144s0025s0001li0173">173</link>), and 20 to 30% in the Netherlands and Germany (<link linkend="ch0144s0025s0001li0200">200</link>, <link linkend="ch0144s0025s0001li0204">204</link>). Knowledge of susceptibility patterns for both <emphasis>A. fumigatus</emphasis> complex isolates and for new and cryptic species other than <emphasis>A. fumigatus</emphasis> is important, as resistance rates can reach 40% (<link linkend="ch0144s0025s0001li0034">34</link>).</para>
        <para id="ch0144s0012s0002p0002">The majority of azole-resistant<emphasis>A. fumigatus</emphasis> (and other <emphasis>Aspergillus</emphasis> species) isolates were found to contain an alteration in the target protein sterol 14a-demethylase (or Cyp51), inhibiting drug binding. These changes are a result of single nucleotide polymorphisms in the gene <emphasis>CYP51A</emphasis>, encoding the protein leading to amino acid substitutions. Mutational hot spots confirmed to cause resistance have been located at amino acid positions G54 and L98, among others, and the L98 alterations require a tandem repeat (TR) in the promoter region of <emphasis>CYP51A</emphasis> to cause resistance; this is referred to as the TR/L98 mutation (<link linkend="ch0144s0025s0001li0199">199</link>). Mechanisms of azole and echinocandin resistance are detailed in <ulink url="ch0156#ch0156s0001">chapter 134</ulink> of this <emphasis>Manual</emphasis>.</para>
      </sect2>
      <sect2 id="ch0144s0012s0003">
        <title>Methods and MIC Determinations</title>
        <anchor id="ch0144s0012s0003a0001"/>
        <anchor id="ch0144s0012s0003a0002"/>
        <para id="ch0144s0012s0003p0001">In the past few years, standardization of two reference methods for susceptibility testing of conidium-forming moulds has provided guidelines for antifungal susceptibility testing of<emphasis>Aspergillus.</emphasis> These methods are (i) the Clinical and Laboratory Standards Institute (CLSI) M38-A3 method and (ii) the European Committee on Antimicrobial Susceptibility Testing (EUCAST) standard (<link linkend="ch0144s0025s0001li0205">205</link>, <link linkend="ch0144s0025s0001li0206">206</link>) (see <ulink url="ch0157#ch0157s0001">chapter 135</ulink> of this <emphasis>Manual</emphasis>). With either approach, MIC determinations (and minimum fungicidal concentration determinations) are relatively straightforward for azoles and amphotericin B due to the growth-versus-no-growth pattern of inhibition, and MICs obtained by these reference methods are in close agreement.</para>
        <para id="ch0144s0012s0003p0002">Interpretative CLSI clinical breakpoints (CBPs) to recognize susceptibility or resistance had not yet been established for any drugs for<emphasis>Aspergillus</emphasis> until the breakpoint for voriconazole for <emphasis>A. fumigatus</emphasis> was published recently (<link linkend="ch0144s0025s0001li0207">207</link>). There are epidemiological cutoff values (ECVs) for some drug-species combinations (<link linkend="ch0144s0025s0001li0208">208</link>). Nonetheless, amphotericin B, itraconazole, voriconazole, posaconazole, and the echinocandins are active <emphasis>in vitro</emphasis> and demonstrate the lowest MICs (<link linkend="ch0144s0025s0001li0034">34</link>, <link linkend="ch0144s0025s0001li0207">207</link>). Using the EUCAST method, CBPs for amphotericin B, voriconazole, posaconazole, itraconazole, and isavuconazole have been published, primarily for <emphasis>A. fumigatus</emphasis> (<link linkend="ch0144s0025s0001li0209">209</link>–<link linkend="ch0144s0025s0001li0211">211</link>); epidemiological cutoff (ECOFF) MICs of wild-type <emphasis>Aspergillus</emphasis> strains have also been published (<link linkend="ch0144s0025s0001li0210">210</link>–<link linkend="ch0144s0025s0001li0212">212</link>) (see <ulink url="ch0157#ch0157s0001">chapter 135</ulink>).</para>
        <para id="ch0144s0012s0003p0003">Importantly, MICs may vary with species and with geographic region. However,<emphasis>A. terreus</emphasis> is considered resistant to amphotericin B, as this species is a poor target for this drug; MICs are as high as 16 μg/ml, and routine susceptibility testing is not required for this species. Infections due to <emphasis>A. terreus</emphasis> are associated with poorer responses to amphotericin B than those caused by, e.g., <emphasis>A. fumigatus</emphasis>, although overall, there is no clear correlation of amphotericin B MICs with clinical response, since there is a narrow distribution of MICs with no clear resistance phenotype (<link linkend="ch0144s0025s0001li0213">213</link>).</para>
        <para id="ch0144s0012s0003p0004">With regard to the correlation of azole MICs and clinical outcomes, earlier work observed good correlation between high MICs and treatment failure in animal models of invasive aspergillosis (<link linkend="ch0144s0025s0001li0214">214</link>). Recently, voriconazole MICs were predictive of treatment results in <emphasis>A. terreus</emphasis> murine infections (<link linkend="ch0144s0025s0001li0215">215</link>). However, in another study, there was no relationship between increasing MICs and response to voriconazole in mice with <emphasis>A. fumigatus</emphasis> infection (<link linkend="ch0144s0025s0001li0216">216</link>). Baddley et al. observed that voriconazole MICs exceeding the ECOFF value (i.e., 1 μg/ml) were not associated with increased mortality in patients with <emphasis>A. fumigatus</emphasis> infection receiving voriconazole (<link linkend="ch0144s0025s0001li0217">217</link>), and for other <emphasis>Aspergillus</emphasis> species, correlation of azole MICs and outcome is also uncertain (<link linkend="ch0144s0025s0001li0218">218</link>). Nonetheless, in patients with very high MICs (e.g., a MIC of 16 μg/ml for itraconazole), case-fatality rates may be as high as 88%.</para>
        <para id="ch0144s0012s0003p0005">Susceptibility endpoints for the echinocandins against<emphasis>A. fumigatus</emphasis> by the CLSI method may be uncertain due to significant trailing growth. Thus, a minimum effective concentration (MEC) is employed, where the MEC is the lowest concentration leading to macroscopically aberrant growth in the form of microcolonies or granular growth compared to the growth control wells. MEC determination is time-consuming and requires a microscope to determine morphological changes, and interlaboratory reproducibility is suboptimal. Correlation between MECs and <emphasis>in vivo</emphasis> outcomes is uncertain. One report found clinical failure and <emphasis>in vivo</emphasis> resistance in an animal model for an isolate with an MEC in the wild-type range (<link linkend="ch0144s0025s0001li0219">219</link>). There are no CBPs for the echinocandins with EUCAST.</para>
        <para id="ch0144s0012s0003p0006">In practice, both reference methods, although easily performed by specialist mycology laboratories, may not be suitable for use in most clinical laboratories, as they require extensive training. Commercial kits for susceptibility testing of<emphasis>Aspergillus</emphasis>, such as the Etest (AB Biodisk, Solna, Sweden) or other gradient strip methods, are useful. The Etest has excellent correlation with the CLSI reference method for voriconazole (<link linkend="ch0144s0025s0001li0220">220</link>) and between 80 and 100% agreement for itraconazole and posaconazole (<link linkend="ch0144s0025s0001li0221">221</link>, <link linkend="ch0144s0025s0001li0222">222</link>). For isavuconazole, when comparing the EUCAST methodology with the MIC strip from Liofilchem (Roseto degli Abrizzia TE, Italy), one study showed that essential agreement and categorical agreement were 80 to 90% and 91 to 92%, respectively, when MICs were read at 100% inhibition (<link linkend="ch0144s0025s0001li0223">223</link>). The Sensititre Yeast YO10 system (incorporating prefilled trays of nine antifungal agents [Trek ThermoFisher Diagnostics, Cleveland, OH]) is based on the CLSI method. The visual endpoint allows easier reading, and it shows good correlation with the azoles and amphotericin and the echinocandins (<link linkend="ch0144s0025s0001li0222">222</link>). Another approach is to use azole-containing agars, such as multiwell surveillance plates (VIPcheck, Nijmegen, The Netherlands) (see <ulink url="ch0157#ch0157s0001">chapter 135</ulink>), to screen for azole resistance; this technique has been evaluated for <emphasis>A. fumigatus</emphasis> (<link linkend="ch0144s0025s0001li0199">199</link>). The EUCAST committee has developed document EDEF 10.2 to define the methodology for performing these screening tests for detecting resistance to azoles and echinocandins in <emphasis>Aspergillus</emphasis> spp. (<link linkend="ch0144s0025s0001li0224">224</link>). Cross-resistance between azoles occurs in up to 74% of cases (<link linkend="ch0144s0025s0001li0199">199</link>, <link linkend="ch0144s0025s0001li0203">203</link>). Research methods include isothermal microcalorimetry for real-time susceptibility testing (<link linkend="ch0144s0025s0001li0225">225</link>). Genotypic susceptibility testing of <emphasis>A. fumigatus</emphasis> is performed in specialist laboratories.</para>
        <anchor id="ch0144s0012s0003a0003"/>
        <beginpage pagenum="2396"/>
      </sect2>
    </sect1>
    <sect1 id="ch0144s0013">
      <title>Evaluation, Interpretation, and Reporting of Results</title>
      <anchor id="ch0144s0013a0001"/>
      <anchor id="ch0144s0013a0002"/>
      <para id="ch0144s0013p0001">The diagnostic mycology laboratory’s aim is to provide timely, clinically meaningful information using accurate and up-to-date methods. The criteria proposed by the EORTC/MSGERC for the analysis of patient data in clinical trials will help to standardize result interpretation. Identification of<emphasis>Aspergillus</emphasis> fungi to species level should be undertaken when they are recovered from sterile specimens and from patients at high risk of invasive aspergillosis. Certain species may be more resistant to antifungal agents. The <emphasis>A. terreus</emphasis> complex is resistant to amphotericin B, while the <emphasis>A. nidulans</emphasis> complex and <emphasis>A. ustus</emphasis> are less susceptible to many agents than <emphasis>A. fumigatus</emphasis> (<link linkend="ch0144s0025s0001li0056">56</link>, <link linkend="ch0144s0025s0001li0226">226</link>). <emphasis>Aspergillus</emphasis> recovered from nonsterile specimens, including BAL fluid and sputum, in immunocompetent patients may not be responsible for disease and may not require species identification. Workup of isolates should involve dialogue between the requesting clinician and the microbiologist.</para>
      <para id="ch0144s0013p0002">Diagnosis of invasive aspergillosis remains difficult, as clinical and radiological features are nonspecific. Although diagnosis is more straightforward when<emphasis>Aspergillus</emphasis> is visualized in and cultured from clinical specimens, more often it relies collectively on non-culture-based tests in the setting of appropriate host risk factors, clinical presentation, and radiological findings. The conventional approach for patients at risk for aspergillosis is to administer antifungal agents empirically when a diagnosis has not yet been made. However, the increasing availability and use of biomarkers of infection, in particular <emphasis>Aspergillus</emphasis> GM and PCR, either alone or in combination, have led to the increasing adoption of a preemptive diagnostic-driven management approach incorporating the use of antifungal drugs. Using these biomarkers, prospective screening for infection in feasibility studies, including one randomized, controlled clinical trial, demonstrates the utility of further diagnostic workup (<link linkend="ch0144s0025s0001li0115">115</link>, <link linkend="ch0144s0025s0001li0123">123</link>) and has led to earlier diagnosis of aspergillosis without decreasing mortality.</para>
      <para id="ch0144s0013p0003">Despite progress made by the CLSI and EUCAST organisations in defining CBPs and ECV/ECOFF values for antifungal agents, correlation between MICs and clinical outcomes is not yet established. Interpretation of MIC testing of<emphasis>Aspergillus</emphasis> remains uncertain. Nonetheless, given the rise in azole resistance among <emphasis>A. fumigatus</emphasis> in many countries, susceptibility testing of azoles against this species is warranted in these regions and in cases where there is therapeutic failure. Details of the presence of <emphasis>cyp51</emphasis> gene mutations, and their relationship to elevated azole MIC values and patient outcomes, are described in <ulink url="ch0157#ch0157s0001">chapter 135</ulink> of this <emphasis>Manual.</emphasis> The widespread use of CLSI or EUCAST methods is limited by the expertise and training needed to perform these tests. Useful information regarding expected antifungal susceptibility may be obtained by identifying the fungus to species level (e.g., <emphasis>A. lentulus</emphasis>).</para>
      <sect2 id="ch0144s0013s0001">
        <title>TALAROMYCES AND PENICILLIUM SPECIES</title>
        <anchor id="ch0144s0013s0001a0001"/>
        <anchor id="ch0144s0013s0001a0002"/>
      </sect2>
    </sect1>
    <sect1 id="ch0144s0014">
      <title>Taxonomy and Position of Talaromyces marneffei (formerly Penicillium marneffei)</title>
      <anchor id="ch0144s0014a0001"/>
      <anchor id="ch0144s0014a0002"/>
      <para id="ch0144s0014p0001">Early work on the taxonomy of the genus<emphasis>Penicillium</emphasis> (otherwise referred to as <emphasis>Penicillium sensu lato</emphasis>) is based on the studies of Thom (<link linkend="ch0144s0025s0001li0227">227</link>) and Raper and Thom (<link linkend="ch0144s0025s0001li0228">228</link>). The genus contains over 250 species (<ulink url="http://www.aspergilluspenicillium.org">http://www.aspergilluspenicillium.org</ulink>). These species have traditionally been separated based on their morphology, specifically conidiophore branching, into four anamorphic subgenera—<emphasis>Aspergilloides, Furcatum, Penicillium</emphasis>, and <emphasis>Biverticillium—</emphasis>within the family Trichocomaceae (<link linkend="ch0144s0025s0001li0004">4</link>, <link linkend="ch0144s0025s0001li0229">229</link>). However, more recent multigene phylogenetic analyses have shown that three of these subgenera, <emphasis>Aspergilloides, Furcatum</emphasis>, and <emphasis>Penicillium</emphasis> (i.e., <emphasis>Penicillium sensu stricto</emphasis>), are polyphyletic, whereas the fourth, <emphasis>Biverticillium</emphasis>, forms a monophyletic group (<link linkend="ch0144s0025s0001li0230">230</link>), which is characterized by the presence of symmetrical biverticillate conidiophores (<link linkend="ch0144s0025s0001li0231">231</link>). The distinctive morphological and physiological features of <emphasis>Biverticillium</emphasis> have resulted in its evolving taxonomic status and suggestions to separate the subgenus <emphasis>Biverticillium</emphasis> from <emphasis>Penicillium sensu stricto</emphasis> (<link linkend="ch0144s0025s0001li0004">4</link>, <link linkend="ch0144s0025s0001li0229">229</link>–<link linkend="ch0144s0025s0001li0231">231</link>).</para>
      <sect2 id="ch0144s0014s0001">
        <title>Rationale for Separation of Members of Biverticillium from Penicillium sensu lato</title>
        <anchor id="ch0144s0014s0001a0001"/>
        <anchor id="ch0144s0014s0001a0002"/>
        <para id="ch0144s0014s0001p0001"><emphasis>Penicillium sensu lato</emphasis> is associated with two teleomorphic genera: <emphasis>Eupenicillium</emphasis> (now synonymous with <emphasis>Penicillium senso stricto</emphasis>) and <emphasis>Talaromyces</emphasis> (now the teleomorph stage of <emphasis>Biverticillium</emphasis>). These two teleomorph genera are distinguished by distinctive ascomata. The sclerotium-like ascomata of <emphasis>Penicillium sensu stricto</emphasis> are thick-walled isodiametric cells maturing over several months and forming in most cases no ascospores, whereas <emphasis>Talaromyces</emphasis> cells are characterized by soft ascomatal walls comprising multiple layers of interwoven hyphae leading to mature ascomata within weeks. In comparison with <emphasis>Penicillium sensu stricto</emphasis>, the members of <emphasis>Talaromyces</emphasis> often have darker green conidia, produce pigmented and encrusted aerial hyphae, and show yellow, orange, or red to purple colony color on reverse. Additionally, phylogenetic studies have increasingly provided evidence that <emphasis>Penicillium sensu stricto</emphasis> and <emphasis>Talaromyces</emphasis> should be considered subfamilies, as demonstrated by genetic relatedness analysis employing the fungal rRNA and calmodulin genes (<link linkend="ch0144s0025s0001li0232">232</link>–<link linkend="ch0144s0025s0001li0235">235</link>). The subdivision of these genera was finally confirmed using a multigene approach (<link linkend="ch0144s0025s0001li0230">230</link>).</para>
        <para id="ch0144s0014s0001p0002">As mentioned above for “<emphasis>Aspergillus</emphasis>,” the ability to correlate anamorphic and teleomorphic genera with modern taxonomic tools has led to the “one fungus, one name” concept (<link linkend="ch0144s0025s0001li0010">10</link>). By removing the primacy of the teleomorph name over the anamorph-typified name (<link linkend="ch0144s0025s0001li0011">11</link>), this has likewise had a major impact on what was known as the genus <emphasis>Penicillium.</emphasis> The name <emphasis>Penicillium</emphasis> is now used for <emphasis>Penicillium sensu stricto</emphasis> (i.e., comprising the subgenera <emphasis>Aspergilloides, Furcatum</emphasis>, and <emphasis>Penicillium</emphasis>), while the term <emphasis>Talaromyces</emphasis> is now defined as a pleomorphic genus name, representative of the anamorphic species formerly within the <emphasis>Penicillium</emphasis> subgenus <emphasis>Biverticillium</emphasis> (<link linkend="ch0144s0025s0001li0236">236</link>).</para>
        <anchor id="ch0144s0014s0001a0003"/>
        <beginpage pagenum="2397"/>
        <para id="ch0144s0014s0001p0003">It is notable that the only species known to be a human and animal pathogen is<emphasis>Talaromyces</emphasis> (formerly <emphasis>Penicillium</emphasis>) <emphasis>marneffei</emphasis>, a member of the subgenus <emphasis>Biverticillium.</emphasis> This species is dimorphic, growing as a fission yeast at 37°C in the host and as a filamentous fungus at 25°C in the environment. As a result of the revised nomenclature, <emphasis>P. marneffei</emphasis> is now correctly classified as <emphasis>T. marneffei</emphasis> (Segretain, Capponi &amp; Sureau) Samson, Yilmaz, Frisvad &amp; Seifert, comb. nov. MycoBank MB560656 (<link linkend="ch0144s0025s0001li0236">236</link>, <link linkend="ch0144s0025s0001li0237">237</link>), rendering <emphasis>P. marneffei</emphasis> (<link linkend="ch0144s0025s0001li0237">237</link>) the basonym of the new taxonomic assignment.</para>
      </sect2>
    </sect1>
    <sect1 id="ch0144s0015">
      <title>Epidemiology and Transmission</title>
      <anchor id="ch0144s0015a0001"/>
      <anchor id="ch0144s0015a0002"/>
      <para id="ch0144s0015p0001"><emphasis>T. marneffei</emphasis> is a particular health problem in areas of endemicity for this organism in tropical Asia, especially Thailand, northeastern India, China, Hong Kong, Vietnam, and Taiwan (<link linkend="ch0144s0025s0001li0238">238</link>–<link linkend="ch0144s0025s0001li0241">241</link>). Although the disease is found predominantly in HIV/AIDS patients (<link linkend="ch0144s0025s0001li0238">238</link>, <link linkend="ch0144s0025s0001li0240">240</link>), with the highest burden of infection in this patient group in areas of endemicity, its epidemiology is changing with better control of HIV infection globally and increasing infections encountered in non-HIV-infected individuals. At-risk patient groups include those with cell-mediated immunodeficiency, patients receiving monoclonal antibody therapies (e.g., anti CD-20) and kinase inhibitors, and individuals with autoantibodies against interferon-gamma, as well as certain genetic mutations, e.g., in the caspase recruitment domain-containing protein 9 (CARD9) and STAT3 (<link linkend="ch0144s0025s0001li0242">242</link>–<link linkend="ch0144s0025s0001li0244">244</link>). Its presence in HIV infection is an AIDS-defining illness.</para>
      <para id="ch0144s0015p0002">The ecological reservoir of<emphasis>T. marneffei</emphasis> remains an enigma. A key question is whether human disease occurs as a result of zoonotic (animal) or sapronotic (environmental) transmission. Although <emphasis>T. marneffei</emphasis> was initially isolated from a bamboo rat, <emphasis>Rhizomys sinensis</emphasis>, in Vietnam in 1956 (<link linkend="ch0144s0025s0001li0245">245</link>), exposure to soil and decaying material, especially under humid and rainy conditions, is likely the critical risk factor (<link linkend="ch0144s0025s0001li0238">238</link>); agricultural occupations have been independently associated with increased risk (<link linkend="ch0144s0025s0001li0246">246</link>). Yet, despite extensive efforts, attempts to recover the organism from soil have met with only limited success (<link linkend="ch0144s0025s0001li0238">238</link>, <link linkend="ch0144s0025s0001li0247">247</link>), and proof of an environmental reservoir is still lacking. Conversely, it has been recovered from environments associated with bamboo rats of the genera <emphasis>Rhizomy</emphasis>s (species <emphasis>sinensis</emphasis>) and <emphasis>Cannomys</emphasis>, suggesting that these rodents are a key facet of the <emphasis>T. marneffei</emphasis> life cycle. Up to 75% of wild bamboo rats in Thailand have been found to be infected with this fungus, with the rats demosnatrating no clinical symptoms; this implicates the rat as an ecological niche for <emphasis>T. marneffei</emphasis> (<link linkend="ch0144s0025s0001li0248">248</link>). When MLMT analysis was used to genotype this fungus, isolates from bamboo rats and humans shared identical genotypes (<link linkend="ch0144s0025s0001li0238">238</link>, <link linkend="ch0144s0025s0001li0249">249</link>). This suggests that either rodents are vectors for human infections or both humans and rodents are infected from an as-yet-unidentified environmental source.</para>
      <para id="ch0144s0015p0003">Patients are infected by inhalation of<emphasis>T. marneffei</emphasis> conidia; thus, pulmonary alveolar macrophages are the primary host defense. The fungus proliferates within phagocytic cells, resulting in granulomas in immunocompetent hosts. Depending on host immune status, after establishing infection in alveolar phagocytes, the fungus (predominantly in the parasite yeast form) can readily spread within host cells, resulting in systemic infection. In HIV/AIDS, infection typically develops in advanced HIV infection, where the CD4<superscript>+</superscript> cell count is &lt;50 cells/ml. The pathogenesis of <emphasis>T. marneffei</emphasis> talaromycosis is detailed in a recent review (<link linkend="ch0144s0025s0001li0248">248</link>).</para>
    </sect1>
    <sect1 id="ch0144s0016">
      <title>Clinical Significance</title>
      <anchor id="ch0144s0016a0001"/>
      <anchor id="ch0144s0016a0002"/>
      <para id="ch0144s0016p0001"><emphasis>T. marneffei</emphasis> now ranks as the third most common opportunistic infection in HIV/AIDS in regions of endemicity. Its prevalence has increased in areas where HIV infection is on the rise (<link linkend="ch0144s0025s0001li0238">238</link>, <link linkend="ch0144s0025s0001li0240">240</link>, <link linkend="ch0144s0025s0001li0250">250</link>). Although uncommon, infections have been reported in other immunocompromised patients, including those with kidney transplants and systemic lupus erythematosus and those with primary or acquired immunodeficiency (<link linkend="ch0144s0025s0001li0242">242</link>, <link linkend="ch0144s0025s0001li0250">250</link>–<link linkend="ch0144s0025s0001li0252">252</link>) (see also "Epidemiology and Transmission"). Immunosuppressed patients traveling to areas of endemicity should be vigilant with regard to risks of <emphasis>T. marneffei</emphasis> infection (<link linkend="ch0144s0025s0001li0253">253</link>). Disseminated infection in HIV/AIDS, especially in those with CD4 counts below 100 × 10<superscript>9</superscript>/liter, is typical, with involvement of the skin (60 to 85% of cases), lungs (pneumonia, including cavitation), intestines, liver, and joints (<link linkend="ch0144s0025s0001li0248">248</link>). Infection can mimic lymphoma and tuberculosis. Most cases present with fever, weight loss, lymphadenopathy, and skin lesions—these are most often on the face, neck, and oral cavity, but they can affect any region, including the trunk and genitalia (<link linkend="ch0144s0025s0001li0238">238</link>). The rash is typically an umbilicated papular rash with central necrosis but can be atypical, being flesh-colored with no necrosis (<link linkend="ch0144s0025s0001li0254">254</link>). Granulomatous anterior uveitis has been described rarely (<link linkend="ch0144s0025s0001li0255">255</link>).</para>
      <para id="ch0144s0016p0002">The fungus can be isolated from skin lesions or from blood, bone, bone marrow, or tissue. Presumptive diagnosis is made by visualization of yeast-like<emphasis>T. marneffei</emphasis> cells in Wright-Giemsa-stained smears of skin lesions or in biopsy specimens from these sites (<link linkend="ch0144s0025s0001li0256">256</link>–<link linkend="ch0144s0025s0001li0258">258</link>).</para>
    </sect1>
    <sect1 id="ch0144s0017">
      <title>Collection, Transport, and Storage of Specimens</title>
      <anchor id="ch0144s0017a0001"/>
      <anchor id="ch0144s0017a0002"/>
      <para id="ch0144s0017p0001">The methods of collection, transport, and storage of specimens are similar to those for other fungal pathogens (see<ulink url="ch0139#ch0139s0001">chapter 118</ulink> of this <emphasis>Manual</emphasis>).</para>
    </sect1>
    <sect1 id="ch0144s0018">
      <title>Direct Examination</title>
      <anchor id="ch0144s0018a0001"/>
      <anchor id="ch0144s0018a0002"/>
      <sect2 id="ch0144s0018s0001">
        <title>Microscopy</title>
        <anchor id="ch0144s0018s0001a0001"/>
        <anchor id="ch0144s0018s0001a0002"/>
        <para id="ch0144s0018s0001p0001">Direct visualization of the organism in tissue or fine-needle aspiration samples of affected sites establishes presumptive diagnosis. Rapid diagnosis is enabled through cytological examination of lung biopsy imprint smears, lung aspirates, lymph node aspirates, skin smears, and even sputum. The yeast form is typically stained by methenamine silver or periodic acid-Schiff stain but can also be visualized by Wright-Giemsa and H&amp;E stains (<link linkend="ch0144s0025s0001li0129">129</link>, <link linkend="ch0144s0025s0001li0258">258</link>). Wright- or Giemsa-stained bone marrow aspirates, often examined in the workup of HIV-positive patients with unexplained fever, are useful in these patients. Histiocytes are seen, with or without granuloma formation, and may contain few to many intracellular yeast-form cells (<link linkend="ch0144s0025s0001li0258">258</link>); these are oval to elliptical (3 to 8 μm in diameter) with a distinctive clear central septum typical of cell division in a fission yeast (<link linkend="ch0144s0025s0001li0129">129</link>). This and the absence of budding help distinguish the condition from histoplasmosis and toxoplasmosis (<link linkend="ch0144s0025s0001li0014">14</link>, <link linkend="ch0144s0025s0001li0257">257</link>). A specific indirect fluorescent-antibody reagent for rapid identification of <emphasis>T. marneffei</emphasis> in histologic sections, using rabbit antiglobulin against yeast antigens of <emphasis>T. marneffei</emphasis>, has also been developed (<link linkend="ch0144s0025s0001li0259">259</link>). Dermatoscopy, a simple noninvasive diagnostic technique, may aid in the diagnosis of <emphasis>T. marneffei</emphasis> skin lesions based on morphological features. Characteristics of disseminated <emphasis>T. marneffei</emphasis> include the finding of circular or quasicircular whitish amorphous structures with a central brownish keratin plug, also termed the "white jade coin pendant" sign (<link linkend="ch0144s0025s0001li0260">260</link>).</para>
        <anchor id="ch0144s0018s0001a0003"/>
        <beginpage pagenum="2398"/>
      </sect2>
      <sect2 id="ch0144s0018s0002">
        <title>Nucleic Acid Detection</title>
        <anchor id="ch0144s0018s0002a0001"/>
        <anchor id="ch0144s0018s0002a0002"/>
        <para id="ch0144s0018s0002p0001">A number of molecular techniques have been developed to directly detect and identify<emphasis>T. marneffei</emphasis> in clinical specimens. Many are in-house assays. Methods include single-step PCR and nested PCR assays to detect <emphasis>T. marneffei</emphasis> in PE tissue, skin, blood, BAL fluid, and other specimens. Most assays target the <emphasis>T. marneffei</emphasis> 18S rRNA and ITS gene region (<link linkend="ch0144s0025s0001li0261">261</link>–<link linkend="ch0144s0025s0001li0263">263</link>). The ability of one nested 18S rRNA PCR assay to directly identify the fungus in PE tissue was evaluated using inner primers (Pm1 and Pm2) specific to <emphasis>T. marneffei.</emphasis> Amplification of a species-specific fragment of ~400 bp was successful for tissue from all 14 patients studied as well as for tissue from 10 bamboo rats with <emphasis>T. marneffei</emphasis> infection, with an analytical sensitivity of 14 fg/μl (<link linkend="ch0144s0025s0001li0262">262</link>). In a follow-up study, the same assay successfully detected <emphasis>T. marneffei</emphasis> DNA in BAL fluid and fresh lung tissue with good sensitivity and specificity in a mouse model of infection (<link linkend="ch0144s0025s0001li0263">263</link>). In other studies, a multiplex ligation-dependent probe amplification assay detected <emphasis>T. marneffei</emphasis> DNA in PE tissue with high specificity (<link linkend="ch0144s0025s0001li0264">264</link>), as has a loop-mediated isothermal amplification assay (<link linkend="ch0144s0025s0001li0265">265</link>). Hien et al. evaluated a real-time PCR assay for the detection of the <emphasis>T. marneffei MP1</emphasis> gene in the plasma of AIDS patients with penicillosis; the diagnostic sensitivity was 70.4% and the specificity was 100%, with a limit of detection of 100 <emphasis>T. marneffei</emphasis> cells per ml of plasma (<link linkend="ch0144s0025s0001li0266">266</link>). The <emphasis>MP1</emphasis> gene encodes a <emphasis>T. marneffei-</emphasis>specific cell wall mannoprotein (<link linkend="ch0144s0025s0001li0267">267</link>).</para>
      </sect2>
    </sect1>
    <sect1 id="ch0144s0019">
      <title>Isolation Procedures</title>
      <anchor id="ch0144s0019a0001"/>
      <anchor id="ch0144s0019a0002"/>
      <para id="ch0144s0019p0001">Culture remains the gold standard method of diagnosis, even though it is slow and requires collection of clinical specimens with invasive procedures.<emphasis>T. marneffei</emphasis> is easily cultured from clinical specimens and grows well on Sabouraud dextrose agar without cycloheximide; culture of bone marrow is the most sensitive (100%), followed by skin culture (90%) and blood culture (76%) (<link linkend="ch0144s0025s0001li0241">241</link>). Mould-to-yeast conversion is achieved by subculturing onto brain heart infusion agar and incubating at 37°C (<link linkend="ch0144s0025s0001li0129">129</link>). Identification of <emphasis>T. marneffei</emphasis> is based on colony morphology (see below). In Europe, Australia, and New Zealand, <emphasis>T. marneffei</emphasis> is classed as a hazard group 3 pathogen. Therefore, specimens and cultures should be handled in a containment level 3 (or above) facility to avoid inhalation of conidia or accidental inoculation into skin.</para>
    </sect1>
    <sect1 id="ch0144s0020">
      <title>Identification</title>
      <anchor id="ch0144s0020a0001"/>
      <anchor id="ch0144s0020a0002"/>
      <para id="ch0144s0020p0001">Members of the genus<emphasis>Talaromyces</emphasis> are ubiquitous laboratory moulds and are grown easily from most nonsterile specimens, especially respiratory specimens. Differentiation of <emphasis>T. marneffei</emphasis> from other penicillia is not usually problematic, since <emphasis>T. marneffei</emphasis> is thermally dimorphic. Diagnosis is made by observing the conversion of the mould to yeast form at 37°C or the reverse at 25°C.</para>
      <para id="ch0144s0020p0002">Colonies on Sabouraud dextrose agar at 25°C are fast growing, downy, and white with yellowish-green conidial heads. Colonies become grayish pink to brown with age and produce a diffusible brown-red pigment that is particularly evident on the reverse (<anchor id="ch0144s0020a0003"/><link linkend="ch0144s0020a0004">Fig. 4</link>), which is an early indication that an isolate may be <emphasis>T. marneffei.</emphasis> However, red pigment may be produced by nonpathogenic <emphasis>Penicillium</emphasis> species, including <emphasis>P. citrinum, P. janthellum, P. purpurogenum</emphasis>, and <emphasis>P. rubrum.</emphasis> Colonies on brain heart infusion agar (37°C) are rough, glabrous, and tan colored. Microscopic yeast-like cells are spherical to elliptical and are 2 to 6 μm in diameter.</para>
      <figure id="ch0144s0020f0001"><title><phrase role="figureLabel"><anchor id="ch0144s0020a0004"/><link linkend="ch0144s0020a0003"><emphasis role="strong">FIGURE 4</emphasis></link></phrase> White colonies of <emphasis>Talaromyces marneffei</emphasis> on Sabouraud dextrose agar (25°C) with yellow-green conidial heads. With age, the diffusible brownish-red to wine-red pigment is evident.
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0144f09.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
      <para id="ch0144s0020p0003">Morphology of<emphasis>T. marneffei</emphasis> is distinctive: hyaline smooth-walled conidiophores with terminal verticils comprising three to five metulae (secondary branches) with conidia, each bearing three to seven phialides. Conidia are globose to subglobose, 2 to 3 μm in diameter, smooth walled, and produced in basipetal succession, spaced out by prominent disjunctor regions, from the phialides, producing a typical “penicillus” or brush-like fruiting structure (<link linkend="ch0144s0025s0001li0014">14</link>, <link linkend="ch0144s0025s0001li0129">129</link>).</para>
      <para id="ch0144s0020p0004">Together with direct detection of the fungus in clinical specimens, molecular tools enable<emphasis>T. marneffei</emphasis> cultures to be identified by PCR in combination with DNA sequencing or probe hybridization and to be distinguished from other <emphasis>Penicillium</emphasis> species that may be incidentally present. Since species identification can be problematic within the genera <emphasis>Penicillium</emphasis> and <emphasis>Talaromyces</emphasis>, a polyphasic approach is recommended. Morphological approaches should be combined with molecular strategies. Assays typically amplify one or more of the 18S rRNA, ITS region, β-tubulin, calmodulin, actin, or RNA polymerase genes (<link linkend="ch0144s0025s0001li0238">238</link>, <link linkend="ch0144s0025s0001li0254">254</link>). Introduction of molecular methods of identification would depend on clinical need. More recently, the approach of next-generation sequencing (NGS), either of strains or by direct metagenomic NGS, can provide identification but may not be widely available (<link linkend="ch0144s0025s0001li0268">268</link>). Nonetheless, among 11 patients with talaromycosis diagnosed by NGS, 5 had been clinically diagnosed as tuberculosis (<link linkend="ch0144s0025s0001li0269">269</link>). MALDI-TOF MS has been investigated for its utility in identification of both the mould and yeast forms. However, correct identification is reliant on access to reference spectra, which are currently not available in commercial databases (<link linkend="ch0144s0025s0001li0270">270</link>).</para>
    </sect1>
    <sect1 id="ch0144s0021">
      <title>Typing Systems</title>
      <anchor id="ch0144s0021a0001"/>
      <anchor id="ch0144s0021a0002"/>
      <anchor id="ch0144s0021a0003"/>
      <para id="ch0144s0021p0001">Genotyping systems have been developed (i) to study the population structure and genetic diversity of<emphasis>T. marneffei</emphasis> and (ii) to investigate clusters of infection should they arise. An MLMT system was developed using 23 genetic loci (<link linkend="ch0144s0025s0001li0271">271</link>) and applied to clinical isolates from Southeast Asia; 21 of 23 tested loci were polymorphic, revealing a high degree of genetic diversity. A clear separation between the population of strains from the eastern region (China, Hong Kong, and Indonesia) and from the western region (Thailand and India) was evident, with the eastern clade being more polymorphic than the western clade (<link linkend="ch0144s0025s0001li0271">271</link>). An independent study confirmed the clustering of isolates from these regions into two clades (<link linkend="ch0144s0025s0001li0272">272</link>). The separation of these clades may be due to potential isolation of these populations or for reasons not yet known.</para>
      <para id="ch0144s0021p0002">In addition to MLMT, MLST analysis incorporating nine genetic loci (transcription factor [<emphasis>AbaA</emphasis>], catalase [<emphasis>CpeA</emphasis>], homeodomain transcription factor [<emphasis>StlA</emphasis>], isocitrate lyase [<emphasis>Icl1</emphasis>], polyaromatic amino acid biosynthesis [<emphasis>PAA</emphasis>], NADH-dependent glutamate synthase [<emphasis>NGS</emphasis>], lovastatin nonaketide synthase [<emphasis>LNS</emphasis>], cell wall mannoprotein [<emphasis>MP1</emphasis>], and a gene fragment of the cytochrome oxidase subunit 1 gene [<emphasis>COX1</emphasis>] of the <emphasis>T. marneffei</emphasis> mitochondrial genome) has also been valuated as a typing tool. In one study, no nucleotide polymorphisms were observed within the <emphasis>COX1, AbaA</emphasis>, and <emphasis>NGS</emphasis> loci; however. The remaining loci showed a high degree of genetic diversity and again indicated geographic separation between isolates from China and Thailand, but also mixed clades. Identical MLST types between different patients have been shown, supporting an asexual mode of reproduction (<link linkend="ch0144s0025s0001li0273">273</link>). For diagnosis (see above), NGS technologies have good potential to offer greater discrimination to study genetic relationships, although data are few as yet.</para>
    </sect1>
    <sect1 id="ch0144s0022">
      <title>Serologic Tests</title>
      <anchor id="ch0144s0022a0001"/>
      <anchor id="ch0144s0022a0002"/>
      <para id="ch0144s0022p0001">Serologic tests may help in diagnosis of infection, although no standardized commercial tests are available, limiting their wide routine use. Assays have been developed to detect antibodies to<emphasis>T. marneffei, T. marneffei</emphasis> antigen, or both in serum and other body fluids in various test formats, including immunodiffusion, indirect immunofluorescence, and ELISA (<link linkend="ch0144s0025s0001li0238">238</link>, <link linkend="ch0144s0025s0001li0256">256</link>, <link linkend="ch0144s0025s0001li0274">274</link>).</para>
      <para id="ch0144s0022p0002">Immunodiffusion tests to detect precipitin antibodies using<emphasis>T. marneffei</emphasis> mycelial exoantigens had low sensitivities when they were used with serum in HIV-positive patients (<link linkend="ch0144s0025s0001li0275">275</link>). When an indirect fluorescent approach for detecting IgG antibodies against germinating conidia and yeast forms was used, patients with <emphasis>T. marneffei</emphasis> infection were shown to have higher titers (&gt;160) than those without (≤40) (<link linkend="ch0144s0025s0001li0274">274</link>). An ELISA-based antibody test using recombinant <emphasis>T. marneffei</emphasis> mannoprotein Mp1p diagnosed infection with 65 to 80% sensitivity and 100% specificity (<link linkend="ch0144s0025s0001li0267">267</link>, <link linkend="ch0144s0025s0001li0276">276</link>); however, combining Mp1p-based antigen and antibody testing yielded a sensitivity of 88%, a PPV of 100%, and an NPV of 96% (<link linkend="ch0144s0025s0001li0277">277</link>). Subsequently, Pongpom et al., using a recombinant Mp1p6 mannoprotein to detect specific antibody, showed that 19 of 20 (95%) sera from patients with culture-proven <emphasis>T. marneffei</emphasis> infection contained specific antibody against the Mp1p6 protein (<link linkend="ch0144s0025s0001li0277">277</link>). In another study, a similar double-antibody sandwich ELISA for Mp1p antigen enabled diagnosis of disseminated penicilliosis in 9.3% of HIV-infected patients (<link linkend="ch0144s0025s0001li0278">278</link>).</para>
      <para id="ch0144s0022p0003">Other methods of serum antigen detection include a<emphasis>T. marneffei-</emphasis>specific latex agglutination test (sensitivity, 76%). When this test was used with the immunodiffusion test, the sensitivity increased to 82%. The specificity of both test formats is 100% (<link linkend="ch0144s0025s0001li0275">275</link>). False-positive results have been rarely observed using the Platelia <emphasis>Aspergillus</emphasis> ELISA for GM, which uses a MAb to <emphasis>A. fumigatus</emphasis> (<link linkend="ch0144s0025s0001li0279">279</link>). In-house ELISAs and latex agglutination formats have also been used to detect and quantitate <emphasis>T. marneffei</emphasis> antigen in urine with high sensitivity (94.6 to 97.3%) and specificity (&gt;97%) at a cutoff titer of 1:40 for the ELISA (<link linkend="ch0144s0025s0001li0280">280</link>). However, patients with <emphasis>T. marneffei</emphasis> infection may also test positive for <emphasis>Histoplasma</emphasis> and <emphasis>Blastomyces</emphasis> urine antigen (<link linkend="ch0144s0025s0001li0281">281</link>). In one study, a capture ELISA was evaluated with 53 patients with culture-confirmed penicilliosis and 240 controls. When the ELISA was tested on serum, the diagnostic sensitivity, specificity, and accuracy were 92.45%, 97.5%, and 96.59%, respectively (<link linkend="ch0144s0025s0001li0282">282</link>).</para>
      <para id="ch0144s0022p0004">Recent progress in characterizing both mycelial culture filtrate antigens and yeast phase antigens have led to various monoclonal antibodies against both sets of antigens (<link linkend="ch0144s0025s0001li0274">274</link>). Their utlity has been limited by significant cross-reactions with other fungi—other <emphasis>Penicillium, Aspergillus</emphasis>, and other molds. Recently, a novel yeast phase specific monoclonal antibody 4D1 (Mab 4D1) against the <emphasis>T. marneffei</emphasis> cytoplasmic yeast antigen (CYA) was incorporated into a rapid lateral flow immunochromatographic test (ICT) to detect <emphasis>T. marneffei</emphasis> antigen in urine samples. The diagnostic sensitivity was 87.8%, specificity was 100%, and accuracy was 90.5% (<link linkend="ch0144s0025s0001li0283">283</link>).</para>
    </sect1>
    <sect1 id="ch0144s0023">
      <title>Antimicrobial Susceptibilities</title>
      <anchor id="ch0144s0023a0001"/>
      <anchor id="ch0144s0023a0002"/>
      <para id="ch0144s0023p0001">Early treatment of<emphasis>T. marneffei</emphasis> infection is critical to reduce mortality of this infection. <emphasis>In vitro</emphasis> susceptibilities help guide therapy despite the absence of formal interpretative clinical breakpoints for antifungal drugs. <emphasis>T. marneffei</emphasis> appears to be susceptible <emphasis>in vitro</emphasis> to itraconazole, the older azole ketoconazole, flucytosine, voriconazole, and posaconazole. Amphotericin B is less active, and fluconazole is the least active. Some strains have high MICs of fluconazole (up to 16 mg/liter) and are considered resistant (<link linkend="ch0144s0025s0001li0284">284</link>, <link linkend="ch0144s0025s0001li0285">285</link>). Testing of 39 <emphasis>T. marneffei</emphasis> strains from China revealed that voriconazole MICs were low (MIC range, 0.004 to 0.25 mg/liter; geometric mean, 0.04 mg/liter), with geometric mean MICs of itraconazole, terbinafine, amphotericin B, and fluconazole of 0.11, 0.15, &lt;0.65, and 4.1 mg/liter, respectively (<link linkend="ch0144s0025s0001li0286">286</link>). Another study evaluated the susceptibility of <emphasis>T. marneffei</emphasis> to posaconazole in comparison with other agents; posaconazole showed good activity against both yeast and mycelial forms (MIC ranges, 0.001 to 0.002 mg/liter and 0.004 to 0.063 mg/liter, respectively) (<link linkend="ch0144s0025s0001li0284">284</link>). In a more recent study of 32 strains, the geometric mean MICs of all of itraconazole, voriconazole, and posaconazole were &lt; 0.5 mg/liter (<link linkend="ch0144s0025s0001li0287">287</link>). Clinical responses appear to correlate with susceptibility to azoles. A retrospective study in HIV patients has shown voriconazole to be effective and well tolerated for disseminated infection (<link linkend="ch0144s0025s0001li0288">288</link>). The results for amphotericin B are difficult to assess, but amphotericin B, voriconazole, and itraconazole have all been used to treat penicillosis. The echinocandins are also active against <emphasis>T. marneffei</emphasis>; <emphasis>in vitro</emphasis>, however, the drugs are more active against the mycelial, rather than the yeast, form (<link linkend="ch0144s0025s0001li0284">284</link>, <link linkend="ch0144s0025s0001li0285">285</link>, <link linkend="ch0144s0025s0001li0287">287</link>, <link linkend="ch0144s0025s0001li0289">289</link>), where in one study of 32 strains, the MEC<subscript>90</subscript>s for the mycelial and yeast forms were 4 mg/liter and 16 mg/liter, respectively. Micafungin has demonstrated synergy with itraconazole (65% of strains) and amphotericin B (50%) but not with fluconazole (<link linkend="ch0144s0025s0001li0290">290</link>). Of note, the new antifungal olorofim (formerly F901318) had good activity against <emphasis>T. marneffei</emphasis>; of 32 isolates, the MIC range, MIC<subscript>50</subscript>, and MIC<subscript>90</subscript> were 0.0005 to 0.002, 0.0005, and 0.0005 mg/liter, respectively (<link linkend="ch0144s0025s0001li0287">287</link>).</para>
      <figure id="ch0144s0023f0001"><title><phrase role="figureLabel"><anchor id="ch0144s0023a0003"/><link linkend="ch0144s0024a0004"><emphasis role="strong">FIGURE 5</emphasis></link></phrase> Neighbor-joining tree of pathogenic <emphasis>Penicillium</emphasis> and <emphasis>Talaromyces</emphasis> species according to the <emphasis>Atlas of Clinical Fungi,</emphasis> version 4.1 (<ulink url="http://www.clinicalfungi.org">http://www.clinicalfungi.org</ulink>), based on ITS1 and ITS2 sequences of the rDNA gene cluster obtained from GenBank using MEGA, version 7.0 (<link linkend="ch0144s0025s0001li0293">293</link>).
</title>
        
        <mediaobject>
          <imageobject>
            <imagedata fileref="Ch0144f05.jpg" width="100%" scalefit="1"/>
          </imageobject>
        </mediaobject>
      </figure>
    </sect1>
    <sect1 id="ch0144s0024">
      <title>Other Penicillium (and Talaromyces) Species</title>
      <anchor id="ch0144s0024a0001"/>
      <anchor id="ch0144s0024a0002"/>
      <anchor id="ch0144s0024a0003"/>
      <para id="ch0144s0024p0001">As many<emphasis>Penicillium</emphasis> species are completely or strongly inhibited at 37°C, they rarely cause human infection. Even repeated isolation of <emphasis>Penicillium</emphasis> from patient specimens does not necessarily indicate an etiological role. This includes the isolation of the fungus from patients with chronic lung disorders, including bronchiectasis and cystic fibrosis, where <emphasis>Penicillium</emphasis> can colonize airways for prolonged periods. The role of penicillia in allergy and hypersensitivity pneumonitis is well established (<link linkend="ch0144s0025s0001li0291">291</link>). Nonetheless, infections due to a range of <emphasis>Penicillium</emphasis> and <emphasis>Talaromyces</emphasis> species, resulting in keratitis, otomycosis, peritonitis, pneumonia, and endocarditis, are reported, typically after the fungus is repeatedly isolated. Species implicated in infection include <emphasis>P. citrinum, P. commune, P. chrysogenum, P. aurantiogriseum, P. brevicompactum, T. verrucosum, T. piceus, T. pururogenus</emphasis>, and <emphasis>T. rugulosus</emphasis> (<link linkend="ch0144s0025s0001li0014">14</link>, <link linkend="ch0144s0025s0001li0292">292</link>).</para>
      <para id="ch0144s0024p0002">Identification of<emphasis>Penicillium</emphasis> species requires expertise with growth of an isolate on several media and careful microscopic examination. No thermal dimorphism is displayed. Isolates are inoculated at three points on Czapek Dox agar, 2% malt extract agar, and/or 25% glycerol nitrate agar and incubated at 25°C. Colonies are fast growing, in shades of green (sometimes white), consisting of a dense felt of conidiophores. Most species sporulate within 7 days. Microscopic mounts are best made using a sticky tape flag or slide culture mounted in lactofuchsin or lactophenol cotton blue. A drop of alcohol is often needed to remove bubbles and excess conidia. Molecular techniques may be required for species identification. The phylogenetic relationships of penicillia based on sequence variation within the ITS1-ITS2 region are shown in <anchor id="ch0144s0024a0004"/><link linkend="ch0144s0023a0003">Fig. 5</link>.</para>
    </sect1>
    <sect1 id="ch0144s0025">
      <title>Evaluation, Interpretation, and Reporting of Results</title>
      <anchor id="ch0144s0025a0001"/>
      <anchor id="ch0144s0025a0002"/>
      <para id="ch0144s0025p0001"><emphasis>T. marneffei</emphasis> is the only member of the genus <emphasis>Talaromyces</emphasis> that has been linked unequivocally to human infection. For the present, diagnosis of infection caused by this fungus should include a minimum of a positive culture, direct smear, and molecular detection and identification in a patient with a plausible clinical and exposure history. Most other <emphasis>Penicillium/Talaromyces</emphasis> species have low potential for causing human infection.</para>
      <para id="ch0144s0025p0002"><emphasis>We thank David Ellis for his generous assistance with preparation of the photographs for <link linkend="ch0144s0008a0003">Fig. 3B</link>, <link linkend="ch0144s0004a0011">C</link>, <link linkend="ch0144s0004a0011">D</link>, <link linkend="ch0144s0004a0011">E</link>, <link linkend="ch0144s0004a0011">F</link>, and <link linkend="ch0144s0004a0011">G</link>and <link linkend="ch0144s0020a0004">Fig. 4</link>. We also thank Jos Houbraken, Sybren de Hoog, and John Taylor for their helpful comments on the current taxonomy, and Carolina Firacative for her help in the preparation of Fig</emphasis>. <emphasis>1 and 5</emphasis>.</para>
      <sect2 id="ch0144s0025s0001">
        <title>REFERENCES</title>
        <anchor id="ch0144s0025s0001a0001"/>
        <anchor id="ch0144s0025s0001a0002"/>
        <itemizedlist mark="none" role="biblioEntryList">
          <listitem id="ch0144s0025s0001li0001" role="bibliographyEntry">
            <para>1.<emphasis role="strong">Samson RA, Visagie CM, Houbraken J, Hong SB, Hubka V, Klaassen CHW, Perrone G, Seifert KA, Susca A, Tanney JB, Varga J, Kocsubé S, Szigeti G, Yaguchi T, Frisvad JC.</emphasis> 2014. Phylogeny, identification and nomenclature of the genus <citetitle><emphasis>Aspergillus. Stud Mycol</emphasis></citetitle> <emphasis role="strong">78:</emphasis>141–173.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0002" role="bibliographyEntry">
            <para>2.<emphasis role="strong">Chen AJ, Frisvad JC, Sun BD, Varga J, Kocsubé S, Dijksterhuis J, Kim DH, Hong SB, Houbraken J, Samson RA.</emphasis> 2016. <citetitle><emphasis>Aspergillus</emphasis></citetitle> section <citetitle><emphasis>Nidulantes</emphasis></citetitle> (formerly <citetitle><emphasis>Emericella</emphasis></citetitle>): polyphasic taxonomy, chemistry and biology. <citetitle><emphasis>Stud Mycol</emphasis></citetitle> <emphasis role="strong">84:</emphasis>1–118.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0003" role="bibliographyEntry">
            <para>3.<emphasis role="strong">Dyer PS, O’Gorman CM.</emphasis> 2011. A fungal sexual revolution: <citetitle><emphasis>Aspergillus</emphasis></citetitle> and <citetitle><emphasis>Penicillium</emphasis></citetitle> show the way. <citetitle><emphasis>Curr Opin Microbiol</emphasis></citetitle> <emphasis role="strong">14:</emphasis>649–654.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0004" role="bibliographyEntry">
            <para>4.<emphasis role="strong">Samson RA, Pitt JI.</emphasis> 2000. <citetitle><emphasis>Integration of Modern Taxonomic Methods for Penicilium and Aspergillus Classification.</emphasis></citetitle> Harwood Scientific Publishers, Amsterdam, The Netherlands.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0005" role="bibliographyEntry">
            <para>5.<emphasis role="strong">Raper KB, Fennell DI.</emphasis> 1965. <citetitle><emphasis>The Genus Aspergillus.</emphasis></citetitle> Williams &amp; Wilkins Co, Baltimore, MD.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0006" role="bibliographyEntry">
            <para>6.<emphasis role="strong">Peterson SW.</emphasis> 2008. Phylogenetic analysis of <citetitle><emphasis>Aspergillus</emphasis></citetitle> species using DNA sequences from four loci. <citetitle><emphasis>Mycologia</emphasis></citetitle> <emphasis role="strong">100:</emphasis>205–226.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0007" role="bibliographyEntry">
            <para>7.<emphasis role="strong">Balajee SA, Gribskov JL, Hanley E, Nickle D, Marr KA.</emphasis> 2005. <citetitle><emphasis>Aspergillus lentulus</emphasis></citetitle> sp. nov., a new sibling species of A. fumigatus. <citetitle><emphasis>Eukaryot Cell</emphasis></citetitle> <emphasis role="strong">4:</emphasis>625–632.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0008" role="bibliographyEntry">
            <para>8.<emphasis role="strong">Balajee SA, Baddley JW, Peterson SW, Nickle D, Varga J, Boey A, Lass-Flörl C, Frisvad JC, Samson RA, ISHAM Working Group on A. terreus.</emphasis> 2009. <citetitle><emphasis>Aspergillus alabamensis</emphasis></citetitle>, a new clinically relevant species in the section Terrei. <citetitle><emphasis>Eukaryot Cell</emphasis></citetitle> <emphasis role="strong">8:</emphasis>713–722.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0009" role="bibliographyEntry">
            <para>9.<emphasis role="strong">Kocsubé S, Perrone G, Magistà D, Houbraken J, Varga J, Szigeti G, Hubka V, Hong SB, Frisvad JC, Samson RA.</emphasis> 2016. <citetitle><emphasis>Aspergillus</emphasis></citetitle> is monophyletic: evidence from multiple gene phylogenies and extrolites profiles. <citetitle><emphasis>Stud Mycol</emphasis></citetitle> <emphasis role="strong">85:</emphasis>199–213.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0010" role="bibliographyEntry">
            <para>10.<emphasis role="strong">Hawksworth DL, et al.</emphasis> 2011. The Amsterdam declaration on fungal nomenclature. <citetitle><emphasis>IMA Fungus</emphasis></citetitle> <emphasis role="strong">2:</emphasis>105–112.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0011" role="bibliographyEntry">
            <para>11.<emphasis role="strong">Norvell LL.</emphasis> 2011. Fungal nomenclature. 1. Melbourne approves a new code. <citetitle><emphasis>Mycotaxon</emphasis></citetitle> <emphasis role="strong">116:</emphasis>481–490.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0012" role="bibliographyEntry">
            <para>12.<emphasis role="strong">Pitt JI, Taylor JW.</emphasis> 2014. <citetitle><emphasis>Aspergillus</emphasis></citetitle>, its sexual states and the new International Code of Nomenclature. <citetitle><emphasis>Mycologia</emphasis></citetitle> <emphasis role="strong">106:</emphasis>1051–1062.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0013" role="bibliographyEntry">
            <anchor id="ch0144s0025s0001a0003"/>
            <para>13.<emphasis role="strong">Taylor JW, Göker M, Pitt JI.</emphasis> 2016. Choosing one name for pleomorphic fungi: the example of <citetitle><emphasis>Aspergillus</emphasis></citetitle> versus Eurotium, Neosartorya and Emericella. <citetitle><emphasis>Taxon</emphasis></citetitle> <emphasis role="strong">65:</emphasis>593–601.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0014" role="bibliographyEntry">
            <para>14.<emphasis role="strong">de Hoog GS, Guarro J, Gene J, Figueras MJ.</emphasis> 2011. <citetitle><emphasis>Atlas of Clinical Fungi</emphasis></citetitle>, version 4.1.4. Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0015" role="bibliographyEntry">
            <para>15.<emphasis role="strong">Dagenais TRT, Keller NP.</emphasis> 2009. Pathogenesis of <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> in invasive aspergillosis. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">22:</emphasis>447–465.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0016" role="bibliographyEntry">
            <para>16.<emphasis role="strong">Thompson GR III, Young JH.</emphasis> 2021. <citetitle><emphasis>Aspergillus</emphasis></citetitle> infections. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">385:</emphasis>1496–1509.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0017" role="bibliographyEntry">
            <para>17.<emphasis role="strong">Baddley JW.</emphasis> 2011. Clinical risk factors for invasive aspergillosis. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">49</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>S7–S12.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0018" role="bibliographyEntry">
            <para>18.<emphasis role="strong">van Arkel ALE, Rijpstra TA, Belderbos HNA, van Wijngaarden P, Verweij PE, Bentvelsen RG.</emphasis> 2020. COVID-19-associated pulmonary aspergillosis. <citetitle><emphasis>Am J Respir Crit Care Med</emphasis></citetitle> <emphasis role="strong">202:</emphasis>132–135.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0019" role="bibliographyEntry">
            <para>19.<emphasis role="strong">Koehler P, Bassetti M, Chakrabarti A, Chen SCA, Colombo AL, Hoenigl M, Klimko N, Lass-Flörl C, Oladele RO, Vinh DC, Zhu LP, Böll B, Brüggemann R, Gangneux JP, Perfect JR, Patterson TF, Persigehl T, Meis JF, Ostrosky-Zeichner L, White PL, Verweij PE, Cornely OA, European Confederation of Medical Mycology, International Society for Human Animal Mycology, Asia Fungal Working Group, INFOCUS LATAM/ISHAM Working Group, ISHAM Pan Africa Mycology Working Group, European Society for Clinical Microbiology, Infectious Diseases Fungal Infection Study Group, ESCMID Study Group for Infections in Critically Ill Patients, Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy, Medical Mycology Society of Nigeria, Medical Mycology Society of China Medicine Education Association, Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology, Association of Medical Microbiology, Infectious Disease Canada.</emphasis> 2021. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">21:</emphasis>e149–e162.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0020" role="bibliographyEntry">
            <para>20.<emphasis role="strong">Vonberg RP, Gastmeier P.</emphasis> 2006. Nosocomial aspergillosis in outbreak settings. <citetitle><emphasis>J Hosp Infect</emphasis></citetitle> <emphasis role="strong">63:</emphasis>246–254.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0021" role="bibliographyEntry">
            <para>21.<emphasis role="strong">Warris A, Gaustad P, Meis JF, Voss A, Verweij PE, Abrahamsen TG.</emphasis> 2001. Recovery of filamentous fungi from water in a paediatric bone marrow transplantation unit. <citetitle><emphasis>J Hosp Infect</emphasis></citetitle> <emphasis role="strong">47:</emphasis>143–148.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0022" role="bibliographyEntry">
            <para>22.<emphasis role="strong">Kidd SE, Ling LM, Meyer W, Orla Morrissey C, Chen SCA, Slavin MA.</emphasis> 2009. Molecular epidemiology of invasive aspergillosis: lessons learned from an outbreak investigation in an Australian hematology unit. <citetitle><emphasis>Infect Control Hosp Epidemiol</emphasis></citetitle> <emphasis role="strong">30:</emphasis>1223–1226.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0023" role="bibliographyEntry">
            <para>23.<emphasis role="strong">Warris A, Verweij PE.</emphasis> 2005. Clinical implications of environmental sources for <citetitle><emphasis>Aspergillus. Med Mycol</emphasis></citetitle> <emphasis role="strong">43</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>S59–S65.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0024" role="bibliographyEntry">
            <para>24.<emphasis role="strong">Gastmeier P, Stamm-Balderjahn S, Hansen S, Nitzschke-Tiemann F, Zuschneid I, Groneberg K, Rüden H.</emphasis> 2005. How outbreaks can contribute to prevention of nosocomial infection: analysis of 1,022 outbreaks. <citetitle><emphasis>Infect Control Hosp Epidemiol</emphasis></citetitle> <emphasis role="strong">26:</emphasis>357–361.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0025" role="bibliographyEntry">
            <para>25.<emphasis role="strong">Guinea J, García de Viedma D, Peláez T, Escribano P, Muñoz P, Meis JF, Klaassen CH, Bouza E.</emphasis> 2011. Molecular epidemiology of <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle>: an in-depth genotypic analysis of isolates involved in an outbreak of invasive aspergillosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>3498–3503.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0026" role="bibliographyEntry">
            <para>26.<emphasis role="strong">Falvey DG, Streifel AJ.</emphasis> 2007. Ten-year air sample analysis of Aspergillus prevalence in a university hospital. <citetitle><emphasis>J Hosp Infect</emphasis></citetitle> <emphasis role="strong">67:</emphasis>35–41.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0027" role="bibliographyEntry">
            <para>27.<emphasis role="strong">Weber DJ, Peppercorn A, Miller MB, Sickbert-Benett E, Rutala WA.</emphasis> 2009. Preventing healthcare-associated <citetitle><emphasis>Aspergillus</emphasis></citetitle> infections: review of recent CDC/HICPAC recommendations. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">47</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>S199–S209.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0028" role="bibliographyEntry">
            <para>28.<emphasis role="strong">Burgos A, Zaoutis TE, Dvorak CC, Hoffman JA, Knapp KM, Nania JJ, Prasad P, Steinbach WJ.</emphasis> 2008. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. <citetitle><emphasis>Pediatrics</emphasis></citetitle> <emphasis role="strong">121:</emphasis>e1286–e1294.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0029" role="bibliographyEntry">
            <para>29.<emphasis role="strong">Chakrabarti A, Chatterjee SS, Das A, Shivaprakash MR.</emphasis> 2011. Invasive aspergillosis in developing countries. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">49</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>S35–S47.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0030" role="bibliographyEntry">
            <para>30.<emphasis role="strong">Steinbach WJ, Marr KA, Anaissie EJ, Azie N, Quan SP, Meier-Kriesche HU, Apewokin S, Horn DL.</emphasis> 2012. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. <citetitle><emphasis>J Infect</emphasis></citetitle> <emphasis role="strong">65:</emphasis>453–464.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0031" role="bibliographyEntry">
            <para>31.<emphasis role="strong">Balajee SA, Kano R, Baddley JW, Moser SA, Marr KA, Alexander BD, Andes D, Kontoyiannis DP, Perrone G, Peterson S, Brandt ME, Pappas PG, Chiller T.</emphasis> 2009. Molecular identification of <citetitle><emphasis>Aspergillus</emphasis></citetitle> species collected for the Transplant-Associated Infection Surveillance Network. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>3138–3141.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0032" role="bibliographyEntry">
            <para>32.<emphasis role="strong">Van Der Linden JW, Warris A, Verweij PE.</emphasis> 2011. Aspergillus species intrinsically resistant to antifungal agents. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">49</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>S82–S89.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0033" role="bibliographyEntry">
            <para>33.<emphasis role="strong">Binder U, Lass-Flörl C.</emphasis> 2013. New insights into invasive aspergillosis—from the pathogen to the disease. <citetitle><emphasis>Curr Pharm Des</emphasis></citetitle> <emphasis role="strong">19:</emphasis>3679–3688.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0034" role="bibliographyEntry">
            <para>34.<emphasis role="strong">Alastruey-Izquierdo A, Mellado E, Peláez T, Pemán J, Zapico S, Alvarez M, Rodríguez-Tudela JL, Cuenca-Estrella M, FILPOP Study Group.</emphasis> 2013. Population-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study). <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">57:</emphasis>3380–3387.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0035" role="bibliographyEntry">
            <para>35.<emphasis role="strong">Chakrabarti A, Shivaprakash MR, Singh R, Tarai B, George VK, Fomda BA, Gupta A.</emphasis> 2008. Fungal endophthalmitis: fourteen years’ experience from a center in India. <citetitle><emphasis>Retina</emphasis></citetitle> <emphasis role="strong">28:</emphasis>1400–1407.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0036" role="bibliographyEntry">
            <para>36.<emphasis role="strong">Slavin MA, Chakrabarti A.</emphasis> 2012. Opportunistic fungal infections in the Asia-Pacific region. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>18–25.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0037" role="bibliographyEntry">
            <para>37.<emphasis role="strong">Lackner M, Coassin S, Haun M, Binder U, Kronenberg F, Haas H, Jank M, Maurer E, Meis JF, Hagen F, Lass-Flörl C.</emphasis> 2016. Geographically predominant genotypes of <citetitle><emphasis>Aspergillus terreus</emphasis></citetitle> species complex in Austria: s microsatellite typing study. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">22:</emphasis>270–276.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0038" role="bibliographyEntry">
            <para>38.<emphasis role="strong">Armstrong-James D, Youngs J, Bicanic T, Abdolrasouli A, Denning DW, Johnson E, Mehra V, Pagliuca T, Patel B, Rhodes J, Schelenz S, Shah A, van de Veerdonk FL, Verweij PE, White PL, Fisher MC.</emphasis> 2020. Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis. <citetitle><emphasis>Eur Respir J</emphasis></citetitle> <emphasis role="strong">56:</emphasis>2002554.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0039" role="bibliographyEntry">
            <para>39.<emphasis role="strong">Lamoth F.</emphasis> 2016. <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle>-related species in clinical practice. <citetitle><emphasis>Front Microbiol</emphasis></citetitle> <emphasis role="strong">7:</emphasis>683.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0040" role="bibliographyEntry">
            <para>40.<emphasis role="strong">Hope WW, Walsh TJ, Denning DW.</emphasis> 2005. The invasive and saprophytic syndromes due to <citetitle><emphasis>Aspergillus</emphasis></citetitle> spp. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">43</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>S207–S238.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0041" role="bibliographyEntry">
            <para>41.<emphasis role="strong">Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, Pappas PG.</emphasis> 2010. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">50:</emphasis>1091–1100.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0042" role="bibliographyEntry">
            <para>42.<emphasis role="strong">Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Perl TM, Oster RA, Schuster MG, Walker R, Walsh TJ, Wannemuehler KA, Chiller TM.</emphasis> 2010. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">50:</emphasis>1101–1111.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0043" role="bibliographyEntry">
            <para>43.<emphasis role="strong">Baddley JW, Stephens JM, Ji X, Gao X, Schlamm HT, Tarallo M.</emphasis> 2013. Aspergillosis in Intensive Care Unit (ICU) patients: epidemiology and economic outcomes. <citetitle><emphasis>BMC Infect Dis</emphasis></citetitle> <emphasis role="strong">13:</emphasis>29.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0044" role="bibliographyEntry">
            <anchor id="ch0144s0025s0001a0004"/>
            <para>44.<emphasis role="strong">Schauwvlieghe AFAD, Rijnders BJA, Philips N, Verwijs R, Vanderbeke L, Van Tienen C, Lagrou K, Verweij PE, Van de Veerdonk FL, Gommers D, Spronk P, Bergmans DCJJ, Hoedemaekers A, Andrinopoulou ER, van den Berg CHSB, Juffermans NP, Hodiamont CJ, Vonk AG, Depuydt P, Boelens J, Wauters J, Dutch-Belgian Mycosis Study Group.</emphasis> 2018. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. <citetitle><emphasis>Lancet Respir Med</emphasis></citetitle> <emphasis role="strong">6:</emphasis>782–792.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0045" role="bibliographyEntry">
            <para>45.<emphasis role="strong">Guinea J, Torres-Narbona M, Gijón P, Muñoz P, Pozo F, Peláez T, de Miguel J, Bouza E.</emphasis> 2010. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">16:</emphasis>870–877.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0046" role="bibliographyEntry">
            <para>46.<emphasis role="strong">Solé A, Morant P, Salavert M, Pemán J, Morales P, Valencia Lung Transplant Group.</emphasis> 2005. <citetitle><emphasis>Aspergillus</emphasis></citetitle> infections in lung transplant recipients: risk factors and outcome. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">11:</emphasis>359–365.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0047" role="bibliographyEntry">
            <para>47.<emphasis role="strong">Donnelly JP, et al.</emphasis> 2020. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">71:</emphasis>1367–1376.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0048" role="bibliographyEntry">
            <para>48.<emphasis role="strong">Bulpa P, Dive A, Sibille Y.</emphasis> 2007. Invasive pulmonary aspergillosis in patients with chronic obstructive pulmonary disease. <citetitle><emphasis>Eur Respir J</emphasis></citetitle> <emphasis role="strong">30:</emphasis>782–800.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0049" role="bibliographyEntry">
            <para>49.<emphasis role="strong">Felton TW, Baxter C, Moore CB, Roberts SA, Hope WW, Denning DW.</emphasis> 2010. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">51:</emphasis>1383–1391.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0050" role="bibliographyEntry">
            <para>50.<emphasis role="strong">Barton RC, Hobson RP, McLoughlin H, Morris A, Datta B.</emphasis> 2013. Assessment of the significance of respiratory culture of <citetitle><emphasis>Aspergillus</emphasis></citetitle> in the non-neutropenic patient. A critique of published diagnostic criteria. <citetitle><emphasis>Eur J Clin Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">32:</emphasis>923–928.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0051" role="bibliographyEntry">
            <para>51.<emphasis role="strong">Bouza E, Guinea J, Peláez T, Pérez-Molina J, Alcalá L, Muñoz P.</emphasis> 2005. Workload due to <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> and significance of the organism in the microbiology laboratory of a general hospital. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>2075–2079.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0052" role="bibliographyEntry">
            <para>52.<emphasis role="strong">Simoneau E, Kelly M, Labbe AC, Roy J, Laverdière M.</emphasis> 2005. What is the clinical significance of positive blood cultures with <citetitle><emphasis>Aspergillus</emphasis></citetitle> sp. in hematopoietic stem cell transplant recipients? A 23 year experience. <citetitle><emphasis>Bone Marrow Transplant</emphasis></citetitle> <emphasis role="strong">35:</emphasis>303–306.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0053" role="bibliographyEntry">
            <para>53.<emphasis role="strong">Giannella M, Muñoz P, Guinea J, Escribano P, Rodríguez-Créixems M, Bouza E.</emphasis> 2013. Growth of <citetitle><emphasis>Aspergillus</emphasis></citetitle> in blood cultures: proof of invasive aspergillosis in patients with chronic obstructive pulmonary disease? <citetitle><emphasis>Mycoses</emphasis></citetitle> <emphasis role="strong">56:</emphasis>488–490.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0054" role="bibliographyEntry">
            <para>54.<emphasis role="strong">Lau A, Chen S, Sorrell T, Carter D, Malik R, Martin P, Halliday C.</emphasis> 2007. Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>380–385.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0055" role="bibliographyEntry">
            <para>55.<emphasis role="strong">Chandler FW, Watts JC.</emphasis> 1987. <citetitle><emphasis>Pathologic Description of Fungal Infections.</emphasis></citetitle> American Society of Clinical Pathologists, Inc, Chicago, IL.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0056" role="bibliographyEntry">
            <para>56.<emphasis role="strong">Walsh TJ, Petraitis V, Petraitiene R, Field-Ridley A, Sutton D, Ghannoum M, Sein T, Schaufele R, Peter J, Bacher J, Casler H, Armstrong D, Espinel-Ingroff A, Rinaldi MG, Lyman CA.</emphasis> 2003. Experimental pulmonary aspergillosis due to <citetitle><emphasis>Aspergillus terreus</emphasis></citetitle>: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. <citetitle><emphasis>J Infect Dis</emphasis></citetitle> <emphasis role="strong">188:</emphasis>305–319.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0057" role="bibliographyEntry">
            <para>57.<emphasis role="strong">Severo LC, Geyer GR, Porto NS, Wagner MB, Londero AT.</emphasis> 1997. Pulmonary <citetitle><emphasis>Aspergillus niger</emphasis></citetitle> intracavitary colonization. Report of 23 cases and a review of the literature. <citetitle><emphasis>Rev Iberoam Micol</emphasis></citetitle> <emphasis role="strong">14:</emphasis>104–110.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0058" role="bibliographyEntry">
            <para>58.<emphasis role="strong">Shah AA, Hazen KC.</emphasis> 2013. Diagnostic accuracy of histopathologic and cytopathologic examination of <citetitle><emphasis>Aspergillus</emphasis></citetitle> species. <citetitle><emphasis>Am J Clin Pathol</emphasis></citetitle> <emphasis role="strong">139:</emphasis>55–61.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0059" role="bibliographyEntry">
            <para>59.<emphasis role="strong">Hayden RT, Isotalo PA, Parrett T, Wolk DM, Qian X, Roberts GD, Lloyd RV.</emphasis> 2003. In situ hybridization for the differentiation of <citetitle><emphasis>Aspergillus, Fusarium</emphasis></citetitle>, and <citetitle><emphasis>Pseudallescheria</emphasis></citetitle> species in tissue section. <citetitle><emphasis>Diagn Mol Pathol</emphasis></citetitle> <emphasis role="strong">12:</emphasis>21–26.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0060" role="bibliographyEntry">
            <para>60.<emphasis role="strong">Lau A, Chen S, Sleiman S, Sorrell T.</emphasis> 2009. Current status and future perspectives on molecular and serological methods in diagnostic mycology. <citetitle><emphasis>Future Microbiol</emphasis></citetitle> <emphasis role="strong">4:</emphasis>1185–1222.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0061" role="bibliographyEntry">
            <para>61.<emphasis role="strong">Pfeiffer CD, Fine JP, Safdar N.</emphasis> 2006. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">42:</emphasis>1417–1427.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0062" role="bibliographyEntry">
            <para>62.<emphasis role="strong">Leeflang MM, Debets-Ossenkopp YJ, Wang J, Visser CE, Scholten RJ, Hooft L, Bijlmer HA, Reitsma JB, Zhang M, Bossuyt PM, Vandenbroucke-Grauls CM.</emphasis> 2015. Galactomannan detection for invasive aspergillosis in immunocompromised patients. <citetitle><emphasis>Cochrane Database Syst Rev</emphasis></citetitle> <emphasis role="strong">2017:</emphasis>CD007394.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0063" role="bibliographyEntry">
            <para>63.<emphasis role="strong">Zou M, Tang L, Zhao S, Zhao Z, Chen L, Chen P, Huang Z, Li J, Chen L, Fan X.</emphasis> 2012. Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">7:</emphasis>e43347.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0064" role="bibliographyEntry">
            <para>64.<emphasis role="strong">Heng SC, Morrissey O, Chen SC, Thursky K, Manser RL, Nation RL, Kong DC, Slavin M.</emphasis> 2015. Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: a systematic review and meta-analysis. <citetitle><emphasis>Crit Rev Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>124–134.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0065" role="bibliographyEntry">
            <para>65.<emphasis role="strong">Guo YL, Chen YQ, Wang K, Qin SM, Wu C, Kong JL.</emphasis> 2010. Accuracy of BAL galactomannan in diagnosing invasive aspergillosis: a bivariate metaanalysis and systematic review. <citetitle><emphasis>Chest</emphasis></citetitle> <emphasis role="strong">138:</emphasis>817–824.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0066" role="bibliographyEntry">
            <para>66.<emphasis role="strong">López-Medrano F, Fernández-Ruiz M, Silva JT, Carver PL, van Delden C, Merino E, Pérez-Saez MJ, Montero M, Coussement J, de Abreu Mazzolin M, Cervera C, Santos L, Sabé N, Scemla A, Cordero E, Cruzado-Vega L, Martín-Moreno PL, Len Ó, Rudas E, de León AP, Arriola M, Lauzurica R, David M, González-Rico C, Henríquez-Palop F, Fortún J, Nucci M, Manuel O, Paño-Pardo JR, Montejo M, Muñoz P, Sánchez-Sobrino B, Mazuecos A, Pascual J, Horcajada JP, Lecompte T, Moreno A, Carratalà J, Blanes M, Hernández D, Fariñas MC, Andrés A, Aguado JM, Spanish Network for Research in Infectious Diseases (REIPI), the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC), the Study Group for Infections in Compromised Hosts (ESGICH) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and the Swiss Transplant Cohort Study (STCS).</emphasis> 2016. Clinical presentation and determinants of mortality of invasive pulmonary aspergillosis in kidney transplant recipients: a multinational cohort study. <citetitle><emphasis>Am J Transplant</emphasis></citetitle> <emphasis role="strong">16:</emphasis>3220–3234.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0067" role="bibliographyEntry">
            <para>67.<emphasis role="strong">Mercier T, Castagnola E, Marr KA, Wheat LJ, Verweij PE, Maertens JA.</emphasis> 2021. Defining galactomannan positivity in the updated EORTC/MSGERC consensus definitions of invasive fungal diseases. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">72</emphasis>(Suppl 2)<emphasis role="strong">:</emphasis>S89–S94.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0068" role="bibliographyEntry">
            <para>68.<emphasis role="strong">Fortún J, Martín-Dávila P, Alvarez ME, Norman F, Sánchez-Sousa A, Gajate L, Bárcena R, Nuño SJ, Moreno S.</emphasis> 2009. False-positive results of <citetitle><emphasis>Aspergillus</emphasis></citetitle> galactomannan antigenemia in liver transplant recipients. <citetitle><emphasis>Transplantation</emphasis></citetitle> <emphasis role="strong">87:</emphasis>256–260.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0069" role="bibliographyEntry">
            <para>69.<emphasis role="strong">Husain S, Kwak EJ, Obman A, Wagener MM, Kusne S, Stout JE, McCurry KR, Singh N.</emphasis> 2004. Prospective assessment of Platelia Aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. <citetitle><emphasis>Am J Transplant</emphasis></citetitle> <emphasis role="strong">4:</emphasis>796–802.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0070" role="bibliographyEntry">
            <para>70.<emphasis role="strong">Marchetti O, Lamoth F, Mikulska M, Viscoli C, Verweij P, Bretagne S, European Conference on Infections in Leukemia (ECIL) Laboratory Working Groups.</emphasis> 2012. ECIL recommendations for the use of biological markers for the diagnosis of invasive fungal diseases in leukemic patients and hematopoietic SCT recipients. <citetitle><emphasis>Bone Marrow Transplant</emphasis></citetitle> <emphasis role="strong">47:</emphasis>846–854.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0071" role="bibliographyEntry">
            <para>71.<emphasis role="strong">Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E.</emphasis> 2004. Invasive aspergillosis in critically ill patients without malignancy. <citetitle><emphasis>Am J Respir Crit Care Med</emphasis></citetitle> <emphasis role="strong">170:</emphasis>621–625.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0072" role="bibliographyEntry">
            <para>72.<emphasis role="strong">Lamoth F.</emphasis> 2016. Galactomannan and 1,3-beta-d-glucan testing for the diagnosis of invasive aspergillosis. <citetitle><emphasis>J Fungi (Basel)</emphasis></citetitle> <emphasis role="strong">2:</emphasis>22.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0073" role="bibliographyEntry">
            <para>73.<emphasis role="strong">Maertens JA, Klont R, Masson C, Theunissen K, Meersseman W, Lagrou K, Heinen C, Crépin B, Van Eldere J, Tabouret M, Donnelly JP, Verweij PE.</emphasis> 2007. Optimization of the cutoff value for the Aspergillus double-sandwich enzyme immunoassay. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">44:</emphasis>1329–1336.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0074" role="bibliographyEntry">
            <anchor id="ch0144s0025s0001a0005"/>
            <para>74.<emphasis role="strong">Duarte RF, Sánchez-Ortega I, Cuesta I, Arnan M, Patiño B, Fernández de Sevilla A, Gudiol C, Ayats J, Cuenca-Estrella M.</emphasis> 2014. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">59:</emphasis>1696–1702.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0075" role="bibliographyEntry">
            <para>75.<emphasis role="strong">Lehrnbecher T, Robinson PD, Fisher BT, Castagnola E, Groll AH, Steinbach WJ, Zaoutis TE, Negeri ZF, Beyene J, Phillips B, Sung L.</emphasis> 2016. Galactomannan, β-D-glucan, and polymerase chain reaction-based assays for the diagnosis of invasive fungal disease in pediatric cancer and hematopoietic stem cell transplantation: a systematic review and meta-analysis. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">63:</emphasis>1340–1348.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0076" role="bibliographyEntry">
            <para>76.<emphasis role="strong">Zhang SX, Balada-Llasat J-M, Pancholi P, Sullivan KV, Riedel S, Fungal Diagnostic Laboratories Consortium (FDLC).</emphasis> 2021. COVID-associated pulmonary aspergillosis in the United States: is it rare or have we missed the diagnosis? <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">59:</emphasis>e0113521.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0077" role="bibliographyEntry">
            <para>77.<emphasis role="strong">Chong WH, Neu KP.</emphasis> 2021. Incidence, diagnosis and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA): a systematic review. <citetitle><emphasis>J Hosp Infect</emphasis></citetitle> <emphasis role="strong">113:</emphasis>115–129.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0078" role="bibliographyEntry">
            <para>78.<emphasis role="strong">Janssen NAF, Nyga R, Vanderbeke L, Jacobs C, Ergün M, Buil JB, van Dijk K, Altenburg J, Bouman CSC, van der Spoel HI, Rijnders BJA, Dunbar A, Schouten JA, Lagrou K, Bourgeois M, Reynders M, van Regenmortel N, Rutsaert L, Lormans P, Feys S, Debavaye Y, Tamion F, Costa D, Maizel J, Dupont H, Chouaki T, Nseir S, Sendid B, Brüggemann RJM, van de Veerdonk FL, Wauters J, Verweij PE.</emphasis> 2021. Multinational observational cohort study of COVID-19-associated pulmonary aspergillosis. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">27:</emphasis>2892–2898.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0079" role="bibliographyEntry">
            <para>79.<emphasis role="strong">de Heer K, Gerritsen MG, Visser CE, Leeflang MM.</emphasis> 2019. Galactomannan detection in broncho-alveolar lavage fluid for invasive aspergillosis in immunocompromised patients. <citetitle><emphasis>Cochrane Database Syst Rev</emphasis></citetitle> <emphasis role="strong">5:</emphasis>CD012399.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0080" role="bibliographyEntry">
            <para>80.<emphasis role="strong">He H, Ding L, Sun B, Li F, Zhan Q.</emphasis> 2012. Role of galactomannan determinations in bronchoalveolar lavage fluid samples from critically ill patients with chronic obstructive pulmonary disease for the diagnosis of invasive pulmonary aspergillosis: a prospective study. <citetitle><emphasis>Crit Care</emphasis></citetitle> <emphasis role="strong">16:</emphasis>R138.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0081" role="bibliographyEntry">
            <para>81.<emphasis role="strong">White PL, Dhillon R, Cordey A, Hughes H, Faggian F, Soni S, Pandey M, Whitaker H, May A, Morgan M, Wise MP, Healy B, Blyth I, Price JS, Vale L, Posso R, Kronda J, Blackwood A, Rafferty H, Moffitt A, Tsitsopoulou A, Gaur S, Holmes T, Backx M.</emphasis> 2021. A national strategy to diagnose coronavirus disease 2019-associated invasive fungal disease in the intensive care unit. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">73:</emphasis>e1634–e1644.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0082" role="bibliographyEntry">
            <para>82.<emphasis role="strong">Mercier T, Dunbar A, de Kort E, Schauwvlieghe A, Reynders M, Guldentops E, Blijlevens NMA, Vonk AG, Rijnders B, Verweij PE, Lagrou K, Maertens J.</emphasis> 2020. Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: a comparative multicenter study. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">58:</emphasis>444–452.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0083" role="bibliographyEntry">
            <para>83.<emphasis role="strong">White PL, Price JS, Posso R, Cutlan-Vaughan M, Vale L, Backx M.</emphasis> 2020. Evaluation of the performance of the IMMY sona <citetitle><emphasis>Aspergillus</emphasis></citetitle> galactomannan lateral flow assay when testing serum to aid in diagnosis of invasive aspergillosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">58:</emphasis>e00053–e20.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0084" role="bibliographyEntry">
            <para>84.<emphasis role="strong">Mercier T, Guldentops E, Lagrou K, Maertens J.</emphasis> 2021. Prospective evaluation of the turbidimetric β-D-glucan assay and 2 lateral flow assays on serum in invasive aspergillosis. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">72:</emphasis>1577–1584.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0085" role="bibliographyEntry">
            <para>85.<emphasis role="strong">Pan Z, Fu M, Zhang J, Zhou H, Fu Y, Zhou J.</emphasis> 2015. Diagnostic accuracy of a novel lateral-flow device in invasive aspergillosis: a meta-analysis. <citetitle><emphasis>J Med Microbiol</emphasis></citetitle> <emphasis role="strong">64:</emphasis>702–707.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0086" role="bibliographyEntry">
            <para>86.<emphasis role="strong">Held J, Schmidt T, Thornton CR, Kotter E, Bertz H.</emphasis> 2013. Comparison of a novel <citetitle><emphasis>Aspergillus</emphasis></citetitle> lateral-flow device and the Platelia<superscript>®</superscript> galactomannan assay for the diagnosis of invasive aspergillosis following haematopoietic stem cell transplantation. <citetitle><emphasis>Infection</emphasis></citetitle> <emphasis role="strong">41:</emphasis>1163–1169.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0087" role="bibliographyEntry">
            <para>87.<emphasis role="strong">White PL, Parr C, Thornton C, Barnes RA.</emphasis> 2013. Evaluation of real-time PCR, galactomannan enzyme-linked immunosorbent assay (ELISA), and a novel lateral-flow device for diagnosis of invasive aspergillosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>1510–1516.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0088" role="bibliographyEntry">
            <para>88.<emphasis role="strong">Mercier T, Dunbar A, Veldhuizen V, Holtappels M, Schauwvlieghe A, Maertens J, Rijnders B, Wauters J.</emphasis> 2020. Point of care aspergillus testing in intensive care patients. <citetitle><emphasis>Crit Care</emphasis></citetitle> <emphasis role="strong">24:</emphasis>642.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0089" role="bibliographyEntry">
            <para>89.<emphasis role="strong">Jenks JD, Prattes J, Frank J, Spiess B, Mehta SR, Boch T, Buchheidt D, Hoenigl M.</emphasis> 2021. Performance of the bronchoalveolar lavage fluid <citetitle><emphasis>Aspergillus</emphasis></citetitle> galactomannan lateral flow assay with cube reader for diagnosis of invasive pulmonary aspergillosis: a multicenter cohort study. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">73:</emphasis>e1737–e1744.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0090" role="bibliographyEntry">
            <para>90.<emphasis role="strong">Jenks JD, Mehta SR, Taplitz R, Aslam S, Reed SL, Hoenigl M.</emphasis> 2019. Point-of-care diagnosis of invasive aspergillosis in non-neutropenic patients: <citetitle><emphasis>Aspergillus</emphasis></citetitle> Galactomannan Lateral Flow Assay versus Aspergillus-specific Lateral Flow Device test in bronchoalveolar lavage. <citetitle><emphasis>Mycoses</emphasis></citetitle> <emphasis role="strong">62:</emphasis>230–236.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0091" role="bibliographyEntry">
            <para>91.<emphasis role="strong">Lamoth F, Cruciani M, Mengoli C, Castagnola E, Lortholary O, Richardson M, Marchetti O, Third European Conference on Infections in Leukemia (ECIL-3)</emphasis>. 2012. β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">54:</emphasis>633–643.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0092" role="bibliographyEntry">
            <para>92.<emphasis role="strong">Persat F, Ranque S, Derouin F, Michel-Nguyen A, Picot S, Sulahian A.</emphasis> 2008. Contribution of the (1→3)-β-<emphasis role="smallcaps">D</emphasis>-glucan assay for diagnosis of invasive fungal infections. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>1009–1013.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0093" role="bibliographyEntry">
            <para>93.<emphasis role="strong">Lu Y, Chen YQ, Guo YL, Qin SM, Wu C, Wang K.</emphasis> 2011. Diagnosis of invasive fungal disease using serum (1→3)-β-D-glucan: a bivariate meta-analysis. <citetitle><emphasis>Intern Med</emphasis></citetitle> <emphasis role="strong">50:</emphasis>2783–2791.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0094" role="bibliographyEntry">
            <para>94.<emphasis role="strong">Onishi A, Sugiyama D, Kogata Y, Saegusa J, Sugimoto T, Kawano S, Morinobu A, Nishimura K, Kumagai S.</emphasis> 2012. Diagnostic accuracy of serum 1,3-β-<emphasis role="smallcaps">D</emphasis>-glucan for <citetitle><emphasis>Pneumocystis jiroveci</emphasis></citetitle> pneumonia, invasive candidiasis, and invasive aspergillosis: systematic review and meta-analysis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>7–15.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0095" role="bibliographyEntry">
            <para>95.<emphasis role="strong">Karageorgopoulos DE, Vouloumanou EK, Ntziora F, Michalopoulos A, Rafailidis PI, Falagas ME.</emphasis> 2011. β-D-glucan assay for the diagnosis of invasive fungal infections: a meta-analysis. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">52:</emphasis>750–770.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0096" role="bibliographyEntry">
            <para>96.<emphasis role="strong">He S, Hang JP, Zhang L, Wang F, Zhang DC, Gong FH.</emphasis> 2015. A systematic review and meta-analysis of diagnostic accuracy of serum 1,3-β-D-glucan for invasive fungal infection: focus on cutoff levels. <citetitle><emphasis>J Microbiol Immunol Infect</emphasis></citetitle> <emphasis role="strong">48:</emphasis>351–361.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0097" role="bibliographyEntry">
            <para>97.<emphasis role="strong">White SK, Walker BS, Hanson KE, Schmidt RL.</emphasis> 2019. Diagnostic accuracy of β-d-glucan (Fungitell) testing among patients with hematologic malignancies or solid organ tumors: a systematic review and meta-analysis. <citetitle><emphasis>Am J Clin Pathol</emphasis></citetitle> <emphasis role="strong">151:</emphasis>275–285.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0098" role="bibliographyEntry">
            <para>98.<emphasis role="strong">Lamoth F, Akan H, Andes D, Cruciani M, Marchetti O, Ostrosky-Zeichner L, Racil Z, Clancy CJ.</emphasis> 2021. Assessment of the role of 1,3-β-d-glucan testing for the diagnosis of invasive fungal infections in adults. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">72</emphasis>(Suppl 2)<emphasis role="strong">:</emphasis>S102–S108.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0099" role="bibliographyEntry">
            <para>99.<emphasis role="strong">Weinbergerova B, Kabut T, Kocmanova I, Lengerova M, Pospisil Z, Kral Z, Mayer J.</emphasis> 2020. Bronchoalveolar lavage fluid and serum 1,3-β-D-glucan testing for invasive pulmonary aspergillosis diagnosis in hematological patients: the role of factors affecting assay performance. <citetitle><emphasis>Sci Rep</emphasis></citetitle> <emphasis role="strong">10:</emphasis>17963.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0100" role="bibliographyEntry">
            <para>100.<emphasis role="strong">Warris A, Lehrnbecher T, Roilides E, Castagnola E, Brüggemann RJM, Groll AH.</emphasis> 2019. ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">25:</emphasis>1096–1113.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0101" role="bibliographyEntry">
            <para>101.<emphasis role="strong">Hendolin PH, Paulin L, Koukila-Kähkölä P, Anttila VJ, Malmberg H, Richardson M, Ylikoski J.</emphasis> 2000. Panfungal PCR and multiplex liquid hybridization for detection of fungi in tissue specimens. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">38:</emphasis>4186–4192.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0102" role="bibliographyEntry">
            <para>102.<emphasis role="strong">Hummel M, Spiess B, Kentouche K, Niggemann S, Böhm C, Reuter S, Kiehl M, Mörz H, Hehlmann R, Buchheidt D.</emphasis> 2006. Detection of <citetitle><emphasis>Aspergillus</emphasis></citetitle> DNA in cerebrospinal fluid from patients with cerebral aspergillosis by a nested PCR assay. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>3989–3993.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0103" role="bibliographyEntry">
            <anchor id="ch0144s0025s0001a0006"/>
            <para>103.<emphasis role="strong">Badiee P, Kordbacheh P, Alborzi A, Ramzi M, Shakiba E.</emphasis> 2008. Molecular detection of invasive aspergillosis in hematologic malignancies. <citetitle><emphasis>Infection</emphasis></citetitle> <emphasis role="strong">36:</emphasis>580–584.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0104" role="bibliographyEntry">
            <para>104.<emphasis role="strong">Halliday CL, Kidd SE, Sorrell TC, Chen SC-A.</emphasis> 2015. Molecular diagnostic methods for invasive fungal disease: the horizon draws nearer? <citetitle><emphasis>Pathology</emphasis></citetitle> <emphasis role="strong">47:</emphasis>257–269.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0105" role="bibliographyEntry">
            <para>105.<emphasis role="strong">Alonso M, Escribano P, Guinea J, Recio S, Simon A, Peláez T, Bouza E, García de Viedma D.</emphasis> 2012. Rapid detection and identification of <citetitle><emphasis>Aspergillus</emphasis></citetitle> from lower respiratory tract specimens by use of a combined probe-high-resolution melting analysis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">50:</emphasis>3238–3243.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0106" role="bibliographyEntry">
            <para>106.<emphasis role="strong">Alanio A, Bretagne S.</emphasis> 2014. Difficulties with molecular diagnostic tests for mould and yeast infections: where do we stand? <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">20</emphasis>(Suppl 6)<emphasis role="strong">:</emphasis>36–41.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0107" role="bibliographyEntry">
            <para>107.<emphasis role="strong">Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP.</emphasis> 2009. Use of PCR for diagnosis of invasive aspergillosis: systematic review and meta-analysis. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">9:</emphasis>89–96.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0108" role="bibliographyEntry">
            <para>108.<emphasis role="strong">Cruciani M, Mengoli C, Barnes R, Donnelly JP, Loeffler J, Jones BL, Klingspor L, Maertens J, Morton CO, White LP.</emphasis> 2019. Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people. <citetitle><emphasis>Cochrane Database Syst Rev</emphasis></citetitle> <emphasis role="strong">9:</emphasis>CD009551.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0109" role="bibliographyEntry">
            <para>109.<emphasis role="strong">Suarez F, Lortholary O, Buland S, Rubio MT, Ghez D, Mahé V, Quesne G, Poirée S, Buzyn A, Varet B, Berche P, Bougnoux ME.</emphasis> 2008. Detection of circulating <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> DNA by real-time PCR assay of large serum volumes improves early diagnosis of invasive aspergillosis in high-risk adult patients under hematologic surveillance. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">46:</emphasis>3772–3777.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0110" role="bibliographyEntry">
            <para>110.<emphasis role="strong">Luong ML, Clancy CJ, Vadnerkar A, Kwak EJ, Silveira FP, Wissel MC, Grantham KJ, Shields RK, Crespo M, Pilewski J, Toyoda Y, Kleiboeker SB, Pakstis D, Reddy SK, Walsh TJ, Nguyen MH.</emphasis> 2011. Comparison of an <citetitle><emphasis>Aspergillus</emphasis></citetitle> real-time polymerase chain reaction assay with galactomannan testing of bronchoalvelolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">52:</emphasis>1218–1226.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0111" role="bibliographyEntry">
            <para>111.<emphasis role="strong">White PL, Bretagne S, Klingspor L, Melchers WJG, McCulloch E, Schulz B, Finnstrom N, Mengoli C, Barnes RA, Donnelly JP, Loeffler J, European Aspergillus PCR Initiative.</emphasis> 2010. <citetitle><emphasis>Aspergillus</emphasis></citetitle> PCR: one step closer to standardization. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>1231–1240.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0112" role="bibliographyEntry">
            <para>112.<emphasis role="strong">White PL, Mengoli C, Bretagne S, Cuenca-Estrella M, Finnstrom N, Klingspor L, Melchers WJG, McCulloch E, Barnes RA, Donnelly JP, Loeffler J, European Aspergillus PCR Initiative (EAPCRI).</emphasis> 2011. Evaluation of <citetitle><emphasis>Aspergillus</emphasis></citetitle> PCR protocols for testing serum specimens. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>3842–3848.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0113" role="bibliographyEntry">
            <para>113.<emphasis role="strong">Springer J, Morton CO, Perry M, Heinz WJ, Paholcsek M, Alzheimer M, Rogers TR, Barnes RA, Einsele H, Loeffler J, White PL.</emphasis> 2013. Multicenter comparison of serum and whole-blood specimens for detection of <citetitle><emphasis>Aspergillus</emphasis></citetitle> DNA in high-risk hematological patients. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>1445–1450.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0114" role="bibliographyEntry">
            <para>114.<emphasis role="strong">Springer J, White PL, Hamilton S, Michel D, Barnes RA, Einsele H, Löffler J.</emphasis> 2016. Comparison of performance characteristics of <citetitle><emphasis>Aspergillus</emphasis></citetitle> PCR in a range of blood-based samples in accordance with international methodological recommendations. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>705–711.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0115" role="bibliographyEntry">
            <para>115.<emphasis role="strong">Arvanitis M, Anagnostou T, Mylonakis E.</emphasis> 2015. Galactomannan and polymerase chain reaction-based screening for invasive aspergillosis among high risk hematology patients: a diagnostic meta-analysis. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">61:</emphasis>1263–1272.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0116" role="bibliographyEntry">
            <para>116.<emphasis role="strong">White PL, Bretagne S, Caliendo AM, Loeffler J, Patterson TF, Slavin M, Wingard JR.</emphasis> 2021. <citetitle><emphasis>Aspergillus</emphasis></citetitle> polymerase chain reaction—an update on technical recommendations, clinical applications, and justification for inclusion in the second revision of the EORTC/MSGERC definitions of invasive fungal disease. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">72</emphasis>(Suppl 2)<emphasis role="strong">:</emphasis>S95–S101.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0117" role="bibliographyEntry">
            <para>117.<emphasis role="strong">Boch T, Spiess B, Cornely OA, Vehreschild JJ, Rath PM, Steinmann J, Heinz WJ, Hahn J, Krause SW, Kiehl MG, Egerer G, Liebregts T, Koldehoff M, Klein M, Nolte F, Mueller MC, Merker N, Will S, Mossner M, Popp H, Hofmann WK, Reinwald M, Buchheidt D.</emphasis> 2016. Diagnosis of invasive fungal infections in haematological patients by combined use of galactomannan, 1,3-β-D-glucan, <citetitle><emphasis>Aspergillus</emphasis></citetitle> PCR, multifungal DNA-microarray, and <citetitle><emphasis>Aspergillus</emphasis></citetitle> azole resistance PCRs in blood and bronchoalveolar lavage samples: results of a prospective multicentre study. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">22:</emphasis>862–868.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0118" role="bibliographyEntry">
            <para>118.<emphasis role="strong">Chong GL, van de Sande WW, Dingemans GJ, Gaajetaan GR, Vonk AG, Hayette M-P, van Tegelen DW, Simons GF, Rijnders BJ.</emphasis> 2015. Validation of a new <citetitle><emphasis>Aspergillus</emphasis></citetitle> real-time PCR assay for direct detection of <citetitle><emphasis>Aspergillus</emphasis></citetitle> and azole resistance of <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> on bronchoalveolar lavage fluid. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">53:</emphasis>868–874.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0119" role="bibliographyEntry">
            <para>119.<emphasis role="strong">Dannaoui E, Gabriel F, Gaboyard M, Lagardere G, Audebert L, Quesne G, Godichaud S, Verweij PE, Accoceberry I, Bougnoux M-E.</emphasis> 2017. Molecular diagnosis of invasive aspergillosis and detection of azole resistance by a newly commercialized PCR kit. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>3210–3218.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0120" role="bibliographyEntry">
            <para>120.<emphasis role="strong">Rath PM, Steinmann J.</emphasis> 2018. Overview of commercially available PCR assays for the detection of <citetitle><emphasis>Aspergillus</emphasis></citetitle> spp. DNA in patient samples. <citetitle><emphasis>Front Microbiol</emphasis></citetitle> <emphasis role="strong">9:</emphasis>740.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0121" role="bibliographyEntry">
            <para>121.<emphasis role="strong">Scharmann U, Kirchhoff L, Hain A, Buer J, Koldehoff M, Steinmann J, Rath PM.</emphasis> 2021. Evaluation of three commercial PCR assays for the detection of azole-resistant <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> from respiratory samples of immunocompromised patients. <citetitle><emphasis>J Fungi (Basel)</emphasis></citetitle> <emphasis role="strong">7:</emphasis>132.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0122" role="bibliographyEntry">
            <para>122.<emphasis role="strong">White PL, Perry MD, Moody A, Follett SA, Morgan G, Barnes RA.</emphasis> 2011. Evaluation of analytical and preliminary clinical performance of Myconostica MycAssay <citetitle><emphasis>Aspergillus</emphasis></citetitle> when testing serum specimens for diagnosis of invasive aspergillosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>2169–2174.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0123" role="bibliographyEntry">
            <para>123.<emphasis role="strong">Guinea J, Padilla C, Escribano P, Muñoz P, Padilla B, Gijón P, Bouza E.</emphasis> 2013. Evaluation of MycAssay™ <citetitle><emphasis>Aspergillus</emphasis></citetitle> for diagnosis of invasive pulmonary aspergillosis in patients without hematological cancer. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">8:</emphasis>e61545.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0124" role="bibliographyEntry">
            <para>124.<emphasis role="strong">Morrissey CO, Chen SC, Sorrell TC, Milliken S, Bardy PG, Bradstock KF, Szer J, Halliday CL, Gilroy NM, Moore J, Schwarer AP, Guy S, Bajel A, Tramontana AR, Spelman T, Slavin MA, Australasian Leukaemia Lymphoma Group and the Australia and New Zealand Mycology Interest Group.</emphasis> 2013. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. <citetitle><emphasis>Lancet Infect Dis</emphasis></citetitle> <emphasis role="strong">13:</emphasis>519–528.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0125" role="bibliographyEntry">
            <para>125.<emphasis role="strong">Rogers TR, Morton CO, Springer J, Conneally E, Heinz W, Kenny C, Frost S, Einsele H, Loeffler J.</emphasis> 2013. Combined real-time PCR and galactomannan surveillance improves diagnosis of invasive aspergillosis in high risk patients with haematological malignancies. <citetitle><emphasis>Br J Haematol</emphasis></citetitle> <emphasis role="strong">161:</emphasis>517–524.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0126" role="bibliographyEntry">
            <para>126.<emphasis role="strong">Aguado JM, Vázquez L, Fernández-Ruiz M, Villaescusa T, Ruiz-Camps I, Barba P, Silva JT, Batlle M, Solano C, Gallardo D, Heras I, Polo M, Varela R, Vallejo C, Olave T, López-Jiménez J, Rovira M, Parody R, Cuenca-Estrella M, PCRAGA Study Group, Spanish Stem Cell Transplantation Group, Study Group of Medical Mycology of the Spanish Society of Clinical Microbiology and Infectious Diseases, Spanish Network for Research in Infectious Diseases.</emphasis> 2015. Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">60:</emphasis>405–414.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0127" role="bibliographyEntry">
            <para>127.<emphasis role="strong">Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL, Maziarz RT, Stadtmauer EA, Bolaños-Meade J, Brown J, Dipersio JF, Boeckh M, Marr KA, Blood and Marrow Transplant Clinical Trials Network.</emphasis> 2010. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. <citetitle><emphasis>Blood</emphasis></citetitle> <emphasis role="strong">116:</emphasis>5111–5118.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0128" role="bibliographyEntry">
            <para>128.<emphasis role="strong">Rainer J, Kaltseis J, de Hoog SG, Summerbell RC.</emphasis> 2008. Efficacy of a selective isolation procedure for members of the <citetitle><emphasis>Pseudallescheria boydii</emphasis></citetitle> complex. <citetitle><emphasis>Antonie van Leeuwenhoek</emphasis></citetitle> <emphasis role="strong">93:</emphasis>315–322.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0129" role="bibliographyEntry">
            <anchor id="ch0144s0025s0001a0007"/>
            <para>129.<emphasis role="strong">Kidd S, Halliday C, Alexiou H, Ellis D.</emphasis> 2016. <citetitle><emphasis>Descriptions of Medical Fungi</emphasis></citetitle>, 3rd ed. Newstyle Printing, Mile End, Australia.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0130" role="bibliographyEntry">
            <para>130.<emphasis role="strong">Balajee SA, Gribskov J, Brandt M, Ito J, Fothergill A, Marr KA.</emphasis> 2005. Mistaken identity: <citetitle><emphasis>Neosartorya pseudofischeri</emphasis></citetitle> and its anamorph masquerading as <citetitle><emphasis>Aspergillus fumigatus. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>5996–5999.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0131" role="bibliographyEntry">
            <para>131.<emphasis role="strong">Balajee SA, Lindsley MD, Iqbal N, Ito J, Pappas PG, Brandt ME.</emphasis> 2007. Nonsporulating clinical isolate identified as <citetitle><emphasis>Petromyces alliaceus</emphasis></citetitle> (anamorph <citetitle><emphasis>Aspergillus alliaceus</emphasis></citetitle>) by morphological and sequence-based methods. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>2701–2703.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0132" role="bibliographyEntry">
            <para>132.<emphasis role="strong">Talbot JJ, Barrs VR.</emphasis> 2018. One-health pathogens in the <citetitle><emphasis>Aspergillus viridinutans</emphasis></citetitle> complex. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>1–12.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0133" role="bibliographyEntry">
            <para>133.<emphasis role="strong">Álvarez-Pérez S, Mellado E, Serrano D, Blanco JL, Garcia ME, Kwon M, Muñoz P, Cuenca-Estrella M, Bouza E, Peláez T.</emphasis> 2013. Polyphasic characterization of fungal isolates from a published case of invasive aspergillosis reveals misidentification of <citetitle><emphasis>Aspergillus felis</emphasis></citetitle> as <citetitle><emphasis>Aspergillus viridinutans. J Med Microbiol</emphasis></citetitle> <emphasis role="strong">62:</emphasis>474–478.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0134" role="bibliographyEntry">
            <para>134.<emphasis role="strong">Ciardo DE, Lucke K, Imhof A, Bloemberg GV, Böttger EC.</emphasis> 2010. Systematic internal transcribed spacer sequence analysis for identification of clinical mold isolates in diagnostic mycology: a 5-year study. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">48:</emphasis>2809–2813.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0135" role="bibliographyEntry">
            <para>135.<emphasis role="strong">Hinrikson HP, Hurst SF, De Aguirre L, Morrison CJ.</emphasis> 2005. Molecular methods for the identification <citetitle><emphasis>of Aspergillus</emphasis></citetitle> species. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">43</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>S129–S137.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0136" role="bibliographyEntry">
            <para>136.<emphasis role="strong">Schoch CL, Seifert KA, Huhndorf S, Robert V, Spouge JL, Levesque CA, Chen W, Fungal Barcoding Consortium, Fungal Barcoding Consortium Author List.</emphasis> 2012. Nuclear ribosomal internal transcribed spacer (ITS) region as a universal DNA barcode marker for Fungi. <citetitle><emphasis>Proc Natl Acad Sci USA</emphasis></citetitle> <emphasis role="strong">109:</emphasis>6241–6246.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0137" role="bibliographyEntry">
            <para>137.<emphasis role="strong">Balajee SA, Houbraken J, Verweij PE, Hong SB, Yaghuchi T, Varga J, Samson RA.</emphasis> 2007. Aspergillus species identification in the clinical setting. <citetitle><emphasis>Stud Mycol</emphasis></citetitle> <emphasis role="strong">59:</emphasis>39–46.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0138" role="bibliographyEntry">
            <para>138.<emphasis role="strong">Hubka V, Kolarik M.</emphasis> 2012. β-Tubulin paralogue tubC is frequently misidentified as the benA gene in <citetitle><emphasis>Aspergillus</emphasis></citetitle> section Nigri taxonomy: primer specificity testing and taxonomic consequences. <citetitle><emphasis>Persoonia</emphasis></citetitle> <emphasis role="strong">29:</emphasis>1–10.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0139" role="bibliographyEntry">
            <para>139.<emphasis role="strong">Schoch CL, et al.</emphasis> 2014. Finding needles in haystacks: linking scientific names, reference specimens and molecular data for Fungi. <citetitle><emphasis>Database (Oxford)</emphasis></citetitle> <emphasis role="strong">2014:</emphasis>bau061.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0140" role="bibliographyEntry">
            <para>140.<emphasis role="strong">Staab JF, Balajee SA, Marr KA.</emphasis> 2009. <citetitle><emphasis>Aspergillus</emphasis></citetitle> section <citetitle><emphasis>Fumigati</emphasis></citetitle> typing by PCR-restriction fragment polymorphism. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>2079–2083.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0141" role="bibliographyEntry">
            <para>141.<emphasis role="strong">Etienne KA, Gade L, Lockhart SR, Diekema DJ, Messer SA, Pfaller MA, Balajee SA.</emphasis> 2009. Screening of a large global <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> species complex collection by using a species-specific microsphere-based Luminex assay. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>4171–4172.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0142" role="bibliographyEntry">
            <para>142.<emphasis role="strong">Lau AF, Drake SK, Calhoun LB, Henderson CM, Zelazny AM.</emphasis> 2013. Development of a clinically comprehensive database and a simple procedure for identification of molds from solid media by matrix-assisted laser desorption ionization-time of flight mass spectrometry. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>828–834.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0143" role="bibliographyEntry">
            <para>143.<emphasis role="strong">Cassagne C, Ranque S, Normand A-C, Fourquet P, Thiebault S, Planard C, Hendrickx M, Piarroux R.</emphasis> 2011. Mould routine identification in the clinical laboratory by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">6:</emphasis>e28425.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0144" role="bibliographyEntry">
            <para>144.<emphasis role="strong">Bader O.</emphasis> 2013. MALDI-TOF-MS-based species identification and typing approaches in medical mycology. <citetitle><emphasis>Proteomics</emphasis></citetitle> <emphasis role="strong">13:</emphasis>788–799.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0145" role="bibliographyEntry">
            <para>145.<emphasis role="strong">Rizzato C, Lombardi L, Zoppo M, Lupetti A, Tavanti A.</emphasis> 2015. Pushing the limits of MALDI-TOF mass spectrometry: beyond fungal species identification. <citetitle><emphasis>J Fungi (Basel)</emphasis></citetitle> <emphasis role="strong">1:</emphasis>367–383.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0146" role="bibliographyEntry">
            <para>146.<emphasis role="strong">Becker PT, de Bel A, Martiny D, Ranque S, Piarroux R, Cassagne C, Detandt M, Hendrickx M.</emphasis> 2014. Identification of filamentous fungi isolates by MALDI-TOF mass spectrometry: clinical evaluation of an extended reference spectra library. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>826–834.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0147" role="bibliographyEntry">
            <para>147.<emphasis role="strong">Sleiman S, Halliday CL, Chapman B, Brown M, Nitschke J, Lau AF, Chen SC-A.</emphasis> 2016. Performance of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of <citetitle><emphasis>Aspergillus</emphasis></citetitle>, <citetitle><emphasis>Scedosporium</emphasis></citetitle>, and <citetitle><emphasis>Fusarium</emphasis></citetitle> spp. in the Australian clinical setting. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">54:</emphasis>2182–2186.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0148" role="bibliographyEntry">
            <para>148.<emphasis role="strong">Alanio A, Beretti JL, Dauphin B, Mellado E, Quesne G, Lacroix C, Amara A, Berche P, Nassif X, Bougnoux ME.</emphasis> 2011. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry for fast and accurate identification of clinically relevant <citetitle><emphasis>Aspergillus</emphasis></citetitle> species. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">17:</emphasis>750–755.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0149" role="bibliographyEntry">
            <para>149.<emphasis role="strong">Salah H, Kolecka A, Rozaliyani A, Wahyuningsih R, Taj-Aldeen SJ, Boekhout T, Houbraken J.</emphasis> 2022. A new filtee-based cultivation approach for improving <citetitle><emphasis>Aspergillus</emphasis></citetitle> identification using matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). <citetitle><emphasis>Mycopathologia</emphasis></citetitle> <emphasis role="strong">187:</emphasis>39–52.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0150" role="bibliographyEntry">
            <para>150.<emphasis role="strong">Motteu N, Goemaere B, Bladt S, Packeu A.</emphasis> 2022. Implementation of MALDI TOF mass spectrometry to identifiy fungi from the indoor environment as an added value to the classical morphology-based identification tool. <citetitle><emphasis>Front Allergy</emphasis></citetitle> <emphasis role="strong">3:</emphasis>826148.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0151" role="bibliographyEntry">
            <para>151.<emphasis role="strong">Bille E, Dauphin B, Leto J, Bougnoux ME, Beretti JL, Lotz A, Suarez S, Meyer J, Join-Lambert O, Descamps P, Grall N, Mory F, Dubreuil L, Berche P, Nassif X, Ferroni A.</emphasis> 2012. MALDI-TOF MS Andromas strategy for the routine identification of bacteria, mycobacteria, yeasts, <citetitle><emphasis>Aspergillus</emphasis></citetitle> spp. and positive blood cultures. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">18:</emphasis>1117–1125.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0152" role="bibliographyEntry">
            <para>152.<emphasis role="strong">Hettick JM, Green BJ, Buskirk AD, Kashon ML, Slaven JE, Janotka E, Blachere FM, Schmechel D, Beezhold DH.</emphasis> 2008. Discrimination of <citetitle><emphasis>Aspergillus</emphasis></citetitle> isolates at the species and strain level by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry fingerprinting. <citetitle><emphasis>Anal Biochem</emphasis></citetitle> <emphasis role="strong">380:</emphasis>276–281.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0153" role="bibliographyEntry">
            <para>153.<emphasis role="strong">Singh A, Goering RV, Simjee S, Foley SL, Zervos MJ.</emphasis> 2006. Application of molecular techniques to the study of hospital infection. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">19:</emphasis>512–530.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0154" role="bibliographyEntry">
            <para>154.<emphasis role="strong">de Valk HA, Meis JFGM, Curfs IM, Muehlethaler K, Mouton JW, Klaassen CHW.</emphasis> 2005. Use of a novel panel of nine short tandem repeats for exact and high-resolution fingerprinting of <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> isolates. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">43:</emphasis>4112–4120.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0155" role="bibliographyEntry">
            <para>155.<emphasis role="strong">Aufauvre-Brown A, Cohen J, Holden DW.</emphasis> 1992. Use of randomly amplified polymorphic DNA markers to distinguish isolates of <citetitle><emphasis>Aspergillus fumigatus. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">30:</emphasis>2991–2993.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0156" role="bibliographyEntry">
            <para>156.<emphasis role="strong">Diaz-Guerra TM, Mellado E, Cuenca-Estrella M, Gaztelurrutia L, Navarro JI, Tudela JL.</emphasis> 2000. Genetic similarity among one <citetitle><emphasis>Aspergillus flavus</emphasis></citetitle> strain isolated from a patient who underwent heart surgery and two environmental strains obtained from the operating room. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">38:</emphasis>2419–2422.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0157" role="bibliographyEntry">
            <para>157.<emphasis role="strong">Lass-Flörl C, Grif K, Kontoyiannis DP.</emphasis> 2007. Molecular typing of <citetitle><emphasis>Aspergillus terreus</emphasis></citetitle> isolates collected in Houston, Texas, and Innsbruck, Austria: evidence of great genetic diversity. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>2686–2690.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0158" role="bibliographyEntry">
            <para>158.<emphasis role="strong">Moody SF, Tyler BM.</emphasis> 1990. Restriction enzyme analysis of mitochondrial DNA of the <citetitle><emphasis>Aspergillus flavus</emphasis></citetitle> group: <citetitle><emphasis>A. flavus</emphasis></citetitle>, <citetitle><emphasis>A. parasiticus</emphasis></citetitle>, and <citetitle><emphasis>A. nomius. Appl Environ Microbiol</emphasis></citetitle> <emphasis role="strong">56:</emphasis>2441–2452.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0159" role="bibliographyEntry">
            <para>159.<emphasis role="strong">Neuveglise C, Sarfati J, Latge JP, Paris S.</emphasis> 1996. Afut1, a retrotransposon-like element from <citetitle><emphasis>Aspergillus fumigatus. Nucleic Acids Res</emphasis></citetitle> <emphasis role="strong">24:</emphasis>1428–1434.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0160" role="bibliographyEntry">
            <para>160.<emphasis role="strong">Paris S, Latgé JP.</emphasis> 2001. Afut2, a new family of degenerate gypsy-like retrotransposon from <citetitle><emphasis>Aspergillus fumigatus. Med Mycol</emphasis></citetitle> <emphasis role="strong">39:</emphasis>195–198.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0161" role="bibliographyEntry">
            <para>161.<emphasis role="strong">Semighini CP, Delmas G, Park S, Amstrong D, Perlin D, Goldman GH.</emphasis> 2001. New restriction fragment length polymorphism (RFLP) markers for <citetitle><emphasis>Aspergillus fumigatus. FEMS Immunol Med Microbiol</emphasis></citetitle> <emphasis role="strong">31:</emphasis>15–19.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0162" role="bibliographyEntry">
            <anchor id="ch0144s0025s0001a0008"/>
            <para>162.<emphasis role="strong">James MJ, Lasker BA, McNeil MM, Shelton M, Warnock DW, Reiss E.</emphasis> 2000. Use of a repetitive DNA probe to type clinical and environmental isolates of <citetitle><emphasis>Aspergillus flavus</emphasis></citetitle> from a cluster of cutaneous infections in a neonatal intensive care unit. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">38:</emphasis>3612–3618.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0163" role="bibliographyEntry">
            <para>163.<emphasis role="strong">Warris A, Klaassen CHW, Meis JFGM, De Ruiter MT, De Valk HA, Abrahamsen TG, Gaustad P, Verweij PE.</emphasis> 2003. Molecular epidemiology of <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> isolates recovered from water, air, and patients shows two clusters of genetically distinct strains. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>4101–4106.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0164" role="bibliographyEntry">
            <para>164.<emphasis role="strong">Montiel D, Dickinson MJ, Lee HA, Dyer PS, Jeenes DJ, Roberts IN, James S, Fuller LJ, Matsuchima K, Archer DB.</emphasis> 2003. Genetic differentiation of the Aspergillus section Flavi complex using AFLP fingerprints. <citetitle><emphasis>Mycol Res</emphasis></citetitle> <emphasis role="strong">107:</emphasis>1427–1434.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0165" role="bibliographyEntry">
            <para>165.<emphasis role="strong">Perrone G, Mulè G, Susca A, Battilani P, Pietri A, Logrieco A.</emphasis> 2006. Ochratoxin A production and amplified fragment length polymorphism analysis of <citetitle><emphasis>Aspergillus carbonarius</emphasis></citetitle>, <citetitle><emphasis>Aspergillus tubingensis</emphasis></citetitle>, and <citetitle><emphasis>Aspergillus niger</emphasis></citetitle> strains isolated from grapes in Italy. <citetitle><emphasis>Appl Environ Microbiol</emphasis></citetitle> <emphasis role="strong">72:</emphasis>680–685.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0166" role="bibliographyEntry">
            <para>166.<emphasis role="strong">Tran-Dinh N, Carter D.</emphasis> 2000. Characterization of microsatellite loci in the aflatoxigenic fungi <citetitle><emphasis>Aspergillus flavus</emphasis></citetitle> and <citetitle><emphasis>Aspergillus parasiticus. Mol Ecol</emphasis></citetitle> <emphasis role="strong">9:</emphasis>2170–2172.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0167" role="bibliographyEntry">
            <para>167.<emphasis role="strong">Hadrich I, Neji S, Drira I, Trabelsi H, Mahfoud N, Ranque S, Makni F, Ayadi A.</emphasis> 2013. Microsatellite typing of <citetitle><emphasis>Aspergillus flavus</emphasis></citetitle> in patients with various clinical presentations of aspergillosis. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">51:</emphasis>586–591.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0168" role="bibliographyEntry">
            <para>168.<emphasis role="strong">Hosid E, Grishkan I, Frenkel Z, Wasser SP, Nevo E, Korol A.</emphasis> 2005. Microsatellite markers for assessing DNA polymorphism of <citetitle><emphasis>Emericella nidulans</emphasis></citetitle> in nature. <citetitle><emphasis>Mol Ecol Notes</emphasis></citetitle> <emphasis role="strong">5:</emphasis>647–649.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0169" role="bibliographyEntry">
            <para>169.<emphasis role="strong">Esteban A, Leong SL, Tran-Dinh N.</emphasis> 2005. Isolation and characterization of six polymorphic microsatellite loci in <citetitle><emphasis>Aspergillus niger. Mol Ecol Notes</emphasis></citetitle> <emphasis role="strong">5:</emphasis>375–377.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0170" role="bibliographyEntry">
            <para>170.<emphasis role="strong">Rudramurthy SM, de Valk HA, Chakrabarti A, Meis JF, Klaassen CH.</emphasis> 2011. High resolution genotyping of clinical <citetitle><emphasis>Aspergillus flavus</emphasis></citetitle> isolates from India using microsatellites. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">6:</emphasis>e16086.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0171" role="bibliographyEntry">
            <para>171.<emphasis role="strong">Kathuria S, Sharma C, Singh PK, Agarwal P, Agarwal K, Hagen F, Meis JF, Chowdhary A.</emphasis> 2015. Molecular epidemiology and in-vitro antifungal susceptibility of <citetitle><emphasis>Aspergillus terreus</emphasis></citetitle> species complex isolates in Delhi, India: evidence of genetic diversity by amplified fragment length polymorphism and microsatellite typing. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">10:</emphasis>e0118997.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0172" role="bibliographyEntry">
            <para>172.<emphasis role="strong">Bain JM, Tavanti A, Davidson AD, Jacobsen MD, Shaw D, Gow NAR, Odds FC.</emphasis> 2007. Multilocus sequence typing of the pathogenic fungus <citetitle><emphasis>Aspergillus fumigatus. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">45:</emphasis>1469–1477.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0173" role="bibliographyEntry">
            <para>173.<emphasis role="strong">Garcia-Rubio R, Gil H, Monteiro MC, Pelaez T, Mellado E.</emphasis> 2016. A new <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> typing method based on hypervariable tandem repeats located within exons of surface protein coding genes (TRESP). <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">11:</emphasis>e0163869.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0174" role="bibliographyEntry">
            <para>174.<emphasis role="strong">Hagiwara D, Takahashi H, Watanabe A, Takahashi-Nakaguchi A, Kawamoto S, Kamei K, Gonoi T.</emphasis> 2014. Whole-genome comparison of <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> strains serially isolated from patients with aspergillosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">52:</emphasis>4202–4209.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0175" role="bibliographyEntry">
            <para>175.<emphasis role="strong">Palanivel M, Mac Aogáin M, Purbojati RW, Uchida A, Aung NW, Lim SBY, Putra A, Drautz-Moses DI, Seaton S, Rogers TR, Schuster SC, Chotirmall SH.</emphasis> 2020. Whole-genome sequencing of <citetitle><emphasis>Aspergillus terreus</emphasis></citetitle> complex. <citetitle><emphasis>Mycopathologia</emphasis></citetitle> <emphasis role="strong">185:</emphasis>405–408.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0176" role="bibliographyEntry">
            <para>176.<emphasis role="strong">Barber AE, Sae-Ong T, Kang K, Seelbinder B, Li J, Walther G, Panagiotou G, Kurzai O.</emphasis> 2021. <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> pan-genome analysis identifies genetic variants associated with human infection. <citetitle><emphasis>Nat Microbiol</emphasis></citetitle> <emphasis role="strong">6:</emphasis>1526–1536.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0177" role="bibliographyEntry">
            <para>177.<emphasis role="strong">Rhodes J, Abdolrasouli A, Dunne K, Sewell TR, Zhang Y, Ballard E, Brackin AP, van Rhijn N, Chown H, Tsitsopoulou A, Posso RB, Chotirmall SH, McElvaney NG, Murphy PG, Talento AF, Renwick J, Dyer PS, Szekely A, Bowyer P, Bromley MJ, Johnson EM, Lewis White P, Warris A, Barton RC, Schelenz S, Rogers TR, Armstrong-James D, Fisher MC.</emphasis> 2022. Population genomics confirms acquisition of drug-resistant <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> infection by humans from the environment. <citetitle><emphasis>Nat Microbiol</emphasis></citetitle> <emphasis role="strong">7:</emphasis>663–674.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0178" role="bibliographyEntry">
            <para>178.<emphasis role="strong">Richardson MD, Page ID.</emphasis> 2017. Aspergillus serology: have we arrived yet? <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">55:</emphasis>48–55.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0179" role="bibliographyEntry">
            <para>179.<emphasis role="strong">Lindsley MD, Warnock DW, Morrison CJ.</emphasis> 2006. Serological and molecular diagnosis of fungal infection, p 569–605. <citetitle><emphasis>In</emphasis></citetitle> Detrick B, Hamilton RG, Folds JD (ed), <citetitle><emphasis>Manual of Molecular and Clinical Laboratory Immunology</emphasis></citetitle>, 7th ed. ASM Press, Washington, DC.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0180" role="bibliographyEntry">
            <para>180.<emphasis role="strong">Holdom MD, Lechenne B, Hay RJ, Hamilton AJ, Monod M.</emphasis> 2000. Production and characterization of recombinant <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> Cu, Zn superoxide dismutase and its recognition by immune human sera. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">38:</emphasis>558–562.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0181" role="bibliographyEntry">
            <para>181.<emphasis role="strong">Chan CM, Woo PCY, Leung ASP, Lau SKP, Che XY, Cao L, Yuen KY.</emphasis> 2002. Detection of antibodies specific to an antigenic cell wall galactomannoprotein for serodiagnosis of <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> aspergillosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>2041–2045.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0182" role="bibliographyEntry">
            <para>182.<emphasis role="strong">Beck J, Broniszewska M, Schwienbacher M, Ebel F.</emphasis> 2014. Characterization of the <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> chitosanase CsnB and evaluation of its potential use in serological diagnostics. <citetitle><emphasis>Int J Med Microbiol</emphasis></citetitle> <emphasis role="strong">304:</emphasis>696–702.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0183" role="bibliographyEntry">
            <para>183.<emphasis role="strong">Weig M, Frosch M, Tintelnot K, Haas A, Gross U, Linsmeier B, Heesemann J.</emphasis> 2001. Use of recombinant mitogillin for improved serodiagnosis of <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle>-associated diseases. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">39:</emphasis>1721–1730.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0184" role="bibliographyEntry">
            <para>184.<emphasis role="strong">Chong KTK, Woo PCY, Lau SKP, Huang Y, Yuen KY.</emphasis> 2004. AFMP2 encodes a novel immunogenic protein of the antigenic mannoprotein superfamily in <citetitle><emphasis>Aspergillus fumigatus. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>2287–2291.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0185" role="bibliographyEntry">
            <para>185.<emphasis role="strong">Shi LN, Li FQ, Lu JF, Kong XX, Wang SQ, Huang M, Shao HF, Shao SH.</emphasis> 2012. Antibody specific to thioredoxin reductase as a new biomarker for serodiagnosis of invasive aspergillosis in non-neutropenic patients. <citetitle><emphasis>Clin Chim Acta</emphasis></citetitle> <emphasis role="strong">413:</emphasis>938–943.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0186" role="bibliographyEntry">
            <para>186.<emphasis role="strong">Du C, Wingard JR, Cheng S, Nguyen MH, Clancy CJ.</emphasis> 2012. Serum IgG responses against Aspergillus proteins before hematopoietic stem cell transplantation or chemotherapy identify patients who develop invasive aspergillosis. <citetitle><emphasis>Biol Blood Marrow Transplant</emphasis></citetitle> <emphasis role="strong">18:</emphasis>1927–1934.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0187" role="bibliographyEntry">
            <para>187.<emphasis role="strong">Erdmann JH, Graf B, Blau IW, Fischer F, Timm G, Hemmati P, Arnold R, Penack O.</emphasis> 2016. Anti-Aspergillus immunoglobulin-G testing in serum of hematopoietic stem cell transplant recipients. <citetitle><emphasis>Transpl Infect Dis</emphasis></citetitle> <emphasis role="strong">18:</emphasis>354–360.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0188" role="bibliographyEntry">
            <para>188.<emphasis role="strong">Delhaes L, Frealle E, Pinel C.</emphasis> 2010. Serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis: state of the art and further challenges. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">48</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>S77–S87.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0189" role="bibliographyEntry">
            <para>189.<emphasis role="strong">Baxter CG, Dunn G, Jones AM, Webb K, Gore R, Richardson MD, Denning DW.</emphasis> 2013. Novel immunologic classification of aspergillosis in adult cystic fibrosis. <citetitle><emphasis>J Allergy Clin Immunol</emphasis></citetitle> <emphasis role="strong">132:</emphasis>560–566.e10.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0190" role="bibliographyEntry">
            <para>190.<emphasis role="strong">Baxter CG, Denning DW, Jones AM, Todd A, Moore CB, Richardson MD.</emphasis> 2013. Performance of two Aspergillus IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosis. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">19:</emphasis>E197–E204.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0191" role="bibliographyEntry">
            <para>191.<emphasis role="strong">Fukutomi Y, Tanimoto H, Yasueda H, Taniguchi M.</emphasis> 2016. Serological diagnosis of allergic bronchopulmonary mycosis: progress and challenges. <citetitle><emphasis>Allergol Int</emphasis></citetitle> <emphasis role="strong">65:</emphasis>30–36.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0192" role="bibliographyEntry">
            <para>192.<emphasis role="strong">Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann J-W, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B, Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group.</emphasis> 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. <citetitle><emphasis>N Engl J Med</emphasis></citetitle> <emphasis role="strong">347:</emphasis>408–415.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0193" role="bibliographyEntry">
            <para>193.<emphasis role="strong">Patterson TF, Thompson GR III, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young J-AH, Bennett JE.</emphasis> 2016. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">63:</emphasis>e1–e60.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0194" role="bibliographyEntry">
            <anchor id="ch0144s0025s0001a0009"/>
            <para>194.<emphasis role="strong">Herbrecht R, Maertens J, Baila L, Aoun M, Heinz W, Martino R, Schwartz S, Ullmann AJ, Meert L, Paesmans M, Marchetti O, Akan H, Ameye L, Shivaprakash M, Viscoli C.</emphasis> 2010. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. <citetitle><emphasis>Bone Marrow Transplant</emphasis></citetitle> <emphasis role="strong">45:</emphasis>1227–1233.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0195" role="bibliographyEntry">
            <para>195.<emphasis role="strong">Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR III, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ.</emphasis> 2016. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">387:</emphasis>760–769.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0196" role="bibliographyEntry">
            <para>196.<emphasis role="strong">Maertens JA, Rahav G, Lee DG, Ponce-de-León A, Ramírez Sánchez IC, Klimko N, Sonet A, Haider S, Diego Vélez J, Raad I, Koh LP, Karthaus M, Zhou J, Ben-Ami R, Motyl MR, Han S, Grandhi A, Waskin H, study investigators.</emphasis> 2021. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial. <citetitle><emphasis>Lancet</emphasis></citetitle> <emphasis role="strong">397:</emphasis>499–509.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0197" role="bibliographyEntry">
            <para>197.<emphasis role="strong">Marr KA, Schlamm H, Rottinghaus S, Jagannatha S, Bow EJ, Wingard JR, Pappas P, Herbrecht R, Walsh TJ, Maertens J, Mycoses Study Group.</emphasis> 2012. A randomized double blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis, abstr LB-2812. <citetitle><emphasis>Abstr 22nd Eur Congr Microbiol Infect Dis.</emphasis></citetitle> Congrex Switzerland Ltd., Basel, Switzerland.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0198" role="bibliographyEntry">
            <para>198.<emphasis role="strong">Tashiro M, Izumikawa K, Hirano K, Ide S, Mihara T, Hosogaya N, Takazono T, Morinaga Y, Nakamura S, Kurihara S, Imamura Y, Miyazaki T, Nishino T, Tsukamoto M, Kakeya H, Yamamoto Y, Yanagihara K, Yasuoka A, Tashiro T, Kohno S.</emphasis> 2012. Correlation between triazole treatment history and susceptibility in clinically isolated <citetitle><emphasis>Aspergillus fumigatus. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">56:</emphasis>4870–4875.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0199" role="bibliographyEntry">
            <para>199.<emphasis role="strong">Howard SJ, Arendrup MC.</emphasis> 2011. Acquired antifungal drug resistance in <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle>: epidemiology and detection. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">49</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>S90–S95.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0200" role="bibliographyEntry">
            <para>200.<emphasis role="strong">Garcia-Rubio R, Cuenca-Estrella M, Mellado E.</emphasis> 2017. Triazole resistance in <citetitle><emphasis>Aspergillus</emphasis></citetitle> species: an emerging problem. <citetitle><emphasis>Drugs</emphasis></citetitle> <emphasis role="strong">77:</emphasis>599–613.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0201" role="bibliographyEntry">
            <para>201.<emphasis role="strong">Douglas AP, Smibert OC, Bajel A, Halliday CL, Lavee O, McMullan B, Yong MK, van Hal SJ, Chen SC, Australasian Antifungal Guidelines Steering Committee.</emphasis> 2021. Consensus guidelines for the diagnosis and management of invasive aspergillosis, 2021. <citetitle><emphasis>Intern Med J</emphasis></citetitle> <emphasis role="strong">51</emphasis>(Suppl 7)<emphasis role="strong">:</emphasis>143–176.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0202" role="bibliographyEntry">
            <para>202.<emphasis role="strong">van der Linden JW, Snelders E, Kampinga GA, Rijnders BJ, Mattsson E, Debets-Ossenkopp YJ, Kuijper EJ, Van Tiel FH, Melchers WJ, Verweij PE.</emphasis> 2011. Clinical implications of azole resistance in <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle>, The Netherlands, 2007-2009. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">17:</emphasis>1846–1854.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0203" role="bibliographyEntry">
            <para>203.<emphasis role="strong">Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, Balajee SA.</emphasis> 2011. Azole resistance in <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the <citetitle><emphasis>cyp51A</emphasis></citetitle> gene. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">55:</emphasis>4465–4468.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0204" role="bibliographyEntry">
            <para>204.<emphasis role="strong">Steinmann J, Hamprecht A, Vehreschild MJGT, Cornely OA, Buchheidt D, Spiess B, Koldehoff M, Buer J, Meis JF, Rath PM.</emphasis> 2015. Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">70:</emphasis>1522–1526.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0205" role="bibliographyEntry">
            <para>205.<emphasis role="strong">Clinical and Laboratory Standards Institute.</emphasis> 2017. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. 3rd ed. Approved standard M38–A3. Clinical and Laboratory Standards Institute, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0206" role="bibliographyEntry">
            <para>206.<emphasis role="strong">Guinea J, Meletiadis J, Arikan-Akdagli S, Muehlethaler K, Kahlmeter G, Arendrup M, European Committee on Antimicrobial Susceptibility Testing (EUCAST) Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESMID European Committee on Antimicrobial Susceptibility Testing.</emphasis> 2022. EUCAST definitive document E.DEF9.4: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming molds. <ulink url="https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Files/EUCAST_EDef_9.4_method_for_susceptibility_testing_of_moulds.pdf">https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Files/EUCAST_EDef_9.4_method_for_susceptibility_testing_of_moulds.pdf</ulink>. Accessed 13 December 2022.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0207" role="bibliographyEntry">
            <para>207.<emphasis role="strong">Clinical and Laboratory Standards Institute.</emphasis> 2022. Performance standards for antifungal susceptibility testing of filamentous fungi. 3rd ed. CLSI Supplement M381751S. Clinical and Laboratory Standards Institute, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0208" role="bibliographyEntry">
            <para>208.<emphasis role="strong">Clinical and Laboratory Standards Institute.</emphasis> 2020. Epidemiological cutoff values for antifungal susceptibility testing. 3rd ed. CLSI Supplement M59. Clinical and Laboratory Standards Institute, Wayne, PA.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0209" role="bibliographyEntry">
            <para>209.<emphasis role="strong">Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope WW.</emphasis> 2013. Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against <citetitle><emphasis>Candida</emphasis></citetitle> spp. and triazoles against <citetitle><emphasis>Aspergillus</emphasis></citetitle> spp. <citetitle><emphasis>Drug Resist Updat</emphasis></citetitle> <emphasis role="strong">16:</emphasis>81–95.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0210" role="bibliographyEntry">
            <para>210.<emphasis role="strong">Verweij PE, Howard SJ, Melchers WJ, Denning DW.</emphasis> 2009. Azole-resistance in <citetitle><emphasis>Aspergillus</emphasis></citetitle>: proposed nomenclature and breakpoints. <citetitle><emphasis>Drug Resist Updat</emphasis></citetitle> <emphasis role="strong">12:</emphasis>141–147.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0211" role="bibliographyEntry">
            <para>211.<emphasis role="strong">Rodriguez-Tudela JL, Alcazar-Fuoli L, Mellado E, Alastruey-Izquierdo A, Monzon A, Cuenca-Estrella M.</emphasis> 2008. Epidemiological cutoffs and cross-resistance to azole drugs in <citetitle><emphasis>Aspergillus fumigatus. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">52:</emphasis>2468–2472.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0212" role="bibliographyEntry">
            <para>212.<emphasis role="strong">Espinel-Ingroff A, Chowdhary A, Gonzalez GM, Lass-Flörl C, Martin-Mazuelos E, Meis J, Peláez T, Pfaller MA, Turnidge J.</emphasis> 2013. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for <citetitle><emphasis>Aspergillus</emphasis></citetitle> spp. for the CLSI M38-A2 broth microdilution method. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">57:</emphasis>3823–3828.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0213" role="bibliographyEntry">
            <para>213.<emphasis role="strong">Johnson EM, Oakley KL, Radford SA, Moore CB, Warn P, Warnock DW, Denning DW.</emphasis> 2000. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of <citetitle><emphasis>Aspergillus</emphasis></citetitle> infection. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">45:</emphasis>85–93.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0214" role="bibliographyEntry">
            <para>214.<emphasis role="strong">Denning DW, Radford SA, Oakley KL, Hall L, Johnson EM, Warnock DW.</emphasis> 1997. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> infection. <citetitle><emphasis>J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">40:</emphasis>401–414.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0215" role="bibliographyEntry">
            <para>215.<emphasis role="strong">Salas V, Pastor FJ, Sutton DA, Calvo E, Mayayo E, Fothergill AW, Rinaldi MG, Guarro J.</emphasis> 2013. MIC values of voriconazole are predictive of treatment results in murine infections by <citetitle><emphasis>Aspergillus terreus</emphasis></citetitle> species complex. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">57:</emphasis>1532–1534.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0216" role="bibliographyEntry">
            <para>216.<emphasis role="strong">Salas V, Pastor FJ, Calvo E, Sutton DA, Fothergill AW, Guarro J.</emphasis> 2013. Evaluation of the in vitro activity of voriconazole as predictive of in vivo outcome in a murine <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> infection model. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">57:</emphasis>1404–1408.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0217" role="bibliographyEntry">
            <para>217.<emphasis role="strong">Baddley JW, Marr KA, Andes DR, Walsh TJ, Kauffman CA, Kontoyiannis DP, Ito JI, Balajee SA, Pappas PG, Moser SA.</emphasis> 2009. Patterns of susceptibility of <citetitle><emphasis>Aspergillus</emphasis></citetitle> isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">47:</emphasis>3271–3275.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0218" role="bibliographyEntry">
            <para>218.<emphasis role="strong">Calvo E, Pastor FJ, Sutton DA, Fothergill AW, Rinaldi MG, Salas V, Guarro J.</emphasis> 2012. Are epidemiologic cut-off values predictors of the in vivo efficacy of azoles in experimental aspergillosis? <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">74:</emphasis>158–165.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0219" role="bibliographyEntry">
            <para>219.<emphasis role="strong">Arendrup MC, Perkhofer S, Howard SJ, Garcia-Effron G, Vishukumar A, Perlin D, Lass-Flörl C.</emphasis> 2008. Establishing in vitro-in vivo correlations for <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle>: the challenge of azoles versus echinocandins. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">52:</emphasis>3504–3511.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0220" role="bibliographyEntry">
            <para>220.<emphasis role="strong">Pfaller JB, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA.</emphasis> 2003. In vitro susceptibility testing of <citetitle><emphasis>Aspergillus</emphasis></citetitle> spp.: comparison of Etest and reference microdilution methods for determining voriconazole and itraconazole MICs. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>1126–1129.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0221" role="bibliographyEntry">
            <anchor id="ch0144s0025s0001a0010"/>
            <para>221.<emphasis role="strong">Meletiadis J, Mouton JW, Meis JF, Bouman BA, Verweij PE.</emphasis> 2002. Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of <citetitle><emphasis>Aspergillus</emphasis></citetitle> species. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>2876–2885.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0222" role="bibliographyEntry">
            <para>222.<emphasis role="strong">Espinel-Ingroff A.</emphasis> 2006. Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, <citetitle><emphasis>Aspergillus</emphasis></citetitle> spp., <citetitle><emphasis>Candida</emphasis></citetitle> spp., and <citetitle><emphasis>Cryptococcus neoformans</emphasis></citetitle> with posaconazole and amphotericin B. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>3616–3622.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0223" role="bibliographyEntry">
            <para>223.<emphasis role="strong">Arendrup MC, Verweij P, Nielsen HV.</emphasis> 2016. Susceptibility testing of wild-type and non wild-type <citetitle><emphasis>Aspergillus fumigatus</emphasis></citetitle> isolates. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">61:</emphasis>e01659–e16.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0224" role="bibliographyEntry">
            <para>224.<emphasis role="strong">Meletiadis J, Guinea J, Arikan-Akdagli S, Friberg N, Kahlmeter G, Arendrup M, Subcommittee on Antifungal Susceptibility Testing (AFST) of the ESCMID European Committee for Antimicrobial Susceptibility Testing (EUCAST).</emphasis> 2022. EUCAST definitive document E.Def 10.2: Screening method for the detection of azole and echinocandin resistance in <citetitle><emphasis>Aspergillus</emphasis></citetitle> using antifungal containing agar plates. <ulink url="https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Files/EUCAST_EDef_10.2_agar_screening_method_final.pdf">https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Files/EUCAST_EDef_10.2_agar_screening_method_final.pdf</ulink>. Accessed 13 December 2022.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0225" role="bibliographyEntry">
            <para>225.<emphasis role="strong">Furustrand Tafin U, Meis JF, Trampuz A.</emphasis> 2012. Isothermal microcalorimetry for antifungal susceptibility testing of <citetitle><emphasis>Mucorales</emphasis></citetitle>, <citetitle><emphasis>Fusarium</emphasis></citetitle> spp., and <citetitle><emphasis>Scedosporium</emphasis></citetitle> spp. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">73:</emphasis>330–337.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0226" role="bibliographyEntry">
            <para>226.<emphasis role="strong">Kontoyiannis DP, Lewis RE, May GS, Osherov N, Rinaldi MG.</emphasis> 2002. <citetitle><emphasis>Aspergillus nidulans</emphasis></citetitle> is frequently resistant to amphotericin B. <citetitle><emphasis>Mycoses</emphasis></citetitle> <emphasis role="strong">45:</emphasis>406–407.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0227" role="bibliographyEntry">
            <para>227.<emphasis role="strong">Thom C.</emphasis> 1930. <citetitle><emphasis>The Penicillia.</emphasis></citetitle> Williams &amp; Wilkins, Baltimore, MD.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0228" role="bibliographyEntry">
            <para>228.<emphasis role="strong">Raper KB, Thom C.</emphasis> 1949. <citetitle><emphasis>Manual of the Penicillia.</emphasis></citetitle> Williams &amp; Wilkins, Baltimore, MD.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0229" role="bibliographyEntry">
            <para>229.<emphasis role="strong">Pitt JI.</emphasis> 1980. <citetitle><emphasis>The Genus Penicillium and Its Teleomorphic States. Eupenicillium and Talaromyces.</emphasis></citetitle> Academic Press, London, United Kingdom.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0230" role="bibliographyEntry">
            <para>230.<emphasis role="strong">Houbraken J, Samson RA.</emphasis> 2011. Phylogeny of Penicillium and the segregation of Trichocomaceae into three families. <citetitle><emphasis>Stud Mycol</emphasis></citetitle> <emphasis role="strong">70:</emphasis>1–51.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0231" role="bibliographyEntry">
            <para>231.<emphasis role="strong">Visagie CM, Houbraken J, Frisvad JC, Hong SB, Klaassen CHW, Perrone G, Seifert KA, Varga J, Yaguchi T, Samson RA.</emphasis> 2014. Identification and nomenclature of the genus Penicillium. <citetitle><emphasis>Stud Mycol</emphasis></citetitle> <emphasis role="strong">78:</emphasis>343–371.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0232" role="bibliographyEntry">
            <para>232.<emphasis role="strong">Berbee ML, Yoshimura A, Sugiyama J, Taylor JW.</emphasis> 1995. Is Penicillium monophyletic? An evaluation of phylogeny in the family Trichocomaceae from 18S, 5.8S and ITS ribosomal DNA sequence data. <citetitle><emphasis>Mycologia</emphasis></citetitle> <emphasis role="strong">87:</emphasis>210–222.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0233" role="bibliographyEntry">
            <para>233.<emphasis role="strong">Ogawa H, Sugiyama J.</emphasis> 2000. Evolutionary relationships of the cleistothecial genera with Penicillium, Geosmithia, Merimbla and Sarophorum anamorphs as inferred from 18S rDNA sequence divergence, p 149–161. <citetitle><emphasis>In</emphasis></citetitle> Samson RA, Pitt JI (ed), <citetitle><emphasis>Integration of Modern Taxonomic Methods for Penicillium and Aspergillus Classification.</emphasis></citetitle> Plenum Press, New York, NY.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0234" role="bibliographyEntry">
            <para>234.<emphasis role="strong">Peterson SW.</emphasis> 2000. Phylogenetic analysis of Penicillium species based on ITS and LSU-rDNA nucleotide sequences, p 163–178. <citetitle><emphasis>In</emphasis></citetitle> Samson RA, Pitt JI (ed), <citetitle><emphasis>Integration of Modern Taxonomic Methods for Penicillium and Aspergillus Classification.</emphasis></citetitle> Plenum Press, New York, NY.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0235" role="bibliographyEntry">
            <para>235.<emphasis role="strong">Wang L, Zhuang WY.</emphasis> 2007. Phylogenetic analyses of penicillia based on partial calmodulin gene sequences. <citetitle><emphasis>Biosystems</emphasis></citetitle> <emphasis role="strong">88:</emphasis>113–126.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0236" role="bibliographyEntry">
            <para>236.<emphasis role="strong">Yilmaz N, Visagie CM, Houbraken J, Frisvad JC, Samson RA.</emphasis> 2014. Polyphasic taxonomy of the genus Talaromyces. <citetitle><emphasis>Stud Mycol</emphasis></citetitle> <emphasis role="strong">78:</emphasis>175–341.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0237" role="bibliographyEntry">
            <para>237.<emphasis role="strong">Segretain G.</emphasis> 1959. Description d’une nouvelle espèce de penicillium: Penicillium marneffei n. sp. <citetitle><emphasis>Bull Soc Mycol Fr</emphasis></citetitle> <emphasis role="strong">75:</emphasis>412–416.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0238" role="bibliographyEntry">
            <para>238.<emphasis role="strong">Vanittanakom N, Cooper CR Jr, Fisher MC, Sirisanthana T.</emphasis> 2006. <citetitle><emphasis>Penicillium marneffei</emphasis></citetitle> infection and recent advances in the epidemiology and molecular biology aspects. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">19:</emphasis>95–110.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0239" role="bibliographyEntry">
            <para>239.<emphasis role="strong">Le T, Wolbers M, Chi NH, Quang VM, Chinh NT, Lan NP, Lam PS, Kozal MJ, Shikuma CM, Day JN, Farrar J.</emphasis> 2011. Epidemiology, seasonality, and predictors of outcome of AIDS-associated <citetitle><emphasis>Penicillium marneffei</emphasis></citetitle> infection in Ho Chi Minh City, Viet Nam. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">52:</emphasis>945–952.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0240" role="bibliographyEntry">
            <para>240.<emphasis role="strong">Qin Y, Huang X, Chen H, Liu X, Li Y, Hou J, Li A, Yan X, Chen Y.</emphasis> 2020. Burden of <citetitle><emphasis>Talaromyces marneffei</emphasis></citetitle> infection in people living with HIV/AIDS in Asia during ART era: a systematic review and meta-analysis. <citetitle><emphasis>BMC Infect Dis</emphasis></citetitle> <emphasis role="strong">20:</emphasis>551.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0241" role="bibliographyEntry">
            <para>241.<emphasis role="strong">Chan JFW, Lau SKP, Yuen KY, Woo PCY.</emphasis> 2016. <citetitle><emphasis>Talaromyces</emphasis></citetitle> (<citetitle><emphasis>Penicillium</emphasis></citetitle>) <citetitle><emphasis>marneffei</emphasis></citetitle> infection in non-HIV-infected patients. <citetitle><emphasis>Emerg Microbes Infect</emphasis></citetitle> <emphasis role="strong">5:</emphasis>e19.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0242" role="bibliographyEntry">
            <para>242.<emphasis role="strong">Chan JFW, Chan TSY, Gill H, Lam FY, Trendell-Smith NJ, Sridhar S, Tse H, Lau SK, Hung IF, Yuen KY, Woo PCY.</emphasis> 2015. Disseminated infections with <citetitle><emphasis>Talaromyces marneffei</emphasis></citetitle> in non-AIDS patients given monoclonal antibodies against CD20 and kinase inhibitors. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">21:</emphasis>1101–1106.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0243" role="bibliographyEntry">
            <para>243.<emphasis role="strong">You CY, Hu F, Lu SW, Pi DD, Xu F, Liu CJ, Fu YQ.</emphasis> 2021. <citetitle><emphasis>Talaromcyes marneffei</emphasis></citetitle> infection in an HIV-negative child with a <citetitle><emphasis>CARD9</emphasis></citetitle> mutation in China: a case report and review of the literature. <citetitle><emphasis>Mycopathologia</emphasis></citetitle> <emphasis role="strong">186:</emphasis>553–561.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0244" role="bibliographyEntry">
            <para>244.<emphasis role="strong">Pan M, Qiu Y, Zeng W, Tang S, Wei X, Zhang J.</emphasis> 2020. Disseminated <citetitle><emphasis>Talaromyces marneffei</emphasis></citetitle> infection presenting as multiple intestinal perforations and diffuse hepatic granulomatous inflammation in an infant with STAT3 mutation: a case report. <citetitle><emphasis>BMC Infect Dis</emphasis></citetitle> <emphasis role="strong">20:</emphasis>394.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0245" role="bibliographyEntry">
            <para>245.<emphasis role="strong">Capponi M, Segretain G, Sureau P.</emphasis> 1956. [Penicillosis from Rhizomys sinensis]. <citetitle><emphasis>Bull Soc Pathol Exot</emphasis></citetitle> <emphasis role="strong">49:</emphasis>418–421.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0246" role="bibliographyEntry">
            <para>246.<emphasis role="strong">Bulterys PL, Le T, Quang VM, Nelson KE, Lloyd-Smith JO.</emphasis> 2013. Environmental predictors and incubation period of AIDS-associated <citetitle><emphasis>Penicillium marneffei</emphasis></citetitle> infection in Ho Chi Minh City, Vietnam. <citetitle><emphasis>Clin Infect Dis</emphasis></citetitle> <emphasis role="strong">56:</emphasis>1273–1279.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0247" role="bibliographyEntry">
            <para>247.<emphasis role="strong">Li X, Yang Y, Zhang X, Zhou X, Lu S, Ma L, Lu C, Xi L.</emphasis> 2011. Isolation of <citetitle><emphasis>Penicillium marneffei</emphasis></citetitle> from soil and wild rodents in Guangdong, SE China. <citetitle><emphasis>Mycopathologia</emphasis></citetitle> <emphasis role="strong">172:</emphasis>447–451.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0248" role="bibliographyEntry">
            <para>248.<emphasis role="strong">Pruksaphon K, Nosanchuk J, Ratanabanangkom K, Youngchim S.</emphasis> 2022. <citetitle><emphasis>Talaromcyes marneffei</emphasis></citetitle> inftecion: virulence, lifestyle and host defence mechanisms. <citetitle><emphasis>J Fungi (Basel)</emphasis></citetitle> <emphasis role="strong">8:</emphasis>200.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0249" role="bibliographyEntry">
            <para>249.<emphasis role="strong">Cao C, Liang L, Wang W, Luo H, Huang S, Liu D, Xu J, Henk DA, Fisher MC.</emphasis> 2011. Common reservoirs for <citetitle><emphasis>Penicillium marneffei</emphasis></citetitle> infection in humans and rodents, China. <citetitle><emphasis>Emerg Infect Dis</emphasis></citetitle> <emphasis role="strong">17:</emphasis>209–214.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0250" role="bibliographyEntry">
            <para>250.<emphasis role="strong">Huynh TX, Nguyen HC, Dinh Nguyen HM, Do MT, Odermatt-Biays S, Degrémont A, Malvy D.</emphasis> 2003. [<citetitle><emphasis>Penicillium marneffei</emphasis></citetitle> infection and AIDS. A review of 12 cases reported in the Tropical Diseases Centre, Ho Chi Minh City (Vietnam)]. <citetitle><emphasis>Sante</emphasis></citetitle> <emphasis role="strong">13:</emphasis>149–153.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0251" role="bibliographyEntry">
            <para>251.<emphasis role="strong">Chong YB, Tan LP, Robinson S, Lim SK, Ng KP, Keng TC, Kamarulzaman A.</emphasis> 2012. Penicilliosis in lupus patients presenting with unresolved fever: a report of 2 cases and literature review. <citetitle><emphasis>Trop Biomed</emphasis></citetitle> <emphasis role="strong">29:</emphasis>270–276.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0252" role="bibliographyEntry">
            <para>252.<emphasis role="strong">Tang BS, Chan JF-W, Chen M, Tsang OT-Y, Mok MY, Lai RW-M, Lee R, Que T-L, Tse H, Li IW-S, To KK-W, Cheng VC-C, Chan EY-T, Zheng B, Yuen K-Y.</emphasis> 2010. Disseminated penicilliosis, recurrent bacteremic nontyphoidal salmonellosis, and burkholderiosis associated with acquired immunodeficiency due to autoantibody against gamma interferon. <citetitle><emphasis>Clin Vaccine Immunol</emphasis></citetitle> <emphasis role="strong">17:</emphasis>1132–1138.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0253" role="bibliographyEntry">
            <para>253.<emphasis role="strong">Hart J, Dyer JR, Clark BM, McLellan DG, Perera S, Ferrari P.</emphasis> 2012. Travel-related disseminated <citetitle><emphasis>Penicillium marneffei</emphasis></citetitle> infection in a renal transplant patient. <citetitle><emphasis>Transpl Infect Dis</emphasis></citetitle> <emphasis role="strong">14:</emphasis>434–439.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0254" role="bibliographyEntry">
            <para>254.<emphasis role="strong">Xiang Y, Guo W, Liang K.</emphasis> 2015. An unusual appearing skin lesion from <citetitle><emphasis>Penicillium marneffei</emphasis></citetitle> infection in an AIDS patient in central China. <citetitle><emphasis>Am J Trop Med Hyg</emphasis></citetitle> <emphasis role="strong">93:</emphasis>3.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0255" role="bibliographyEntry">
            <para>255.<emphasis role="strong">Khieu C, Apivatthakakul A, Kunavisarut P, Pathanapitoon K.</emphasis> 2020. Bilateral granulomatous anterior uveitis in HIV patient with disseminated <citetitle><emphasis>Talaromcyes</emphasis></citetitle> (penicilliosis) <citetitle><emphasis>marneffei</emphasis></citetitle> infection. <citetitle><emphasis>Ocul Immunol Inflamm</emphasis></citetitle> <emphasis role="strong">28:</emphasis>1066–1068.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0256" role="bibliographyEntry">
            <para>256.<emphasis role="strong">Marques SA, Robles AM, Tortorano AM, Tuculet MA, Negroni R, Mendes RP.</emphasis> 2000. Mycoses associated with AIDS in the third world. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">38</emphasis>(Suppl 1)<emphasis role="strong">:</emphasis>269–279.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0257" role="bibliographyEntry">
            <anchor id="ch0144s0025s0001a0011"/>
            <para>257.<emphasis role="strong">Lim D, Lee YS, Chang AR.</emphasis> 2006. Rapid diagnosis of Penicillium marneffei infection by fine needle aspiration cytology. <citetitle><emphasis>J Clin Pathol</emphasis></citetitle> <emphasis role="strong">59:</emphasis>443–444.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0258" role="bibliographyEntry">
            <para>258.<emphasis role="strong">Wong KF.</emphasis> 2010. Marrow penicilliosis: a readily missed diagnosis. <citetitle><emphasis>Am J Clin Pathol</emphasis></citetitle> <emphasis role="strong">134:</emphasis>214–218.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0259" role="bibliographyEntry">
            <para>259.<emphasis role="strong">Kaufman L, Standard PG, Anderson SA, Jalbert M, Swisher BL.</emphasis> 1995. Development of specific fluorescent-antibody test for tissue form of <citetitle><emphasis>Penicillium marneffei. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">33:</emphasis>2136–2138.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0260" role="bibliographyEntry">
            <para>260.<emphasis role="strong">Li Q, Wang C, Zeng X, Wang F.</emphasis> 2018. AIDS-associated dissemaitned talaromycosis (penicilliosis) marneffei. <citetitle><emphasis>J Dtsch Dermatol Ges</emphasis></citetitle> <emphasis role="strong">16:</emphasis>1256–1259.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0261" role="bibliographyEntry">
            <para>261.<emphasis role="strong">Tsunemi Y, Takahashi T, Tamaki T.</emphasis> 2003. Penicillium marneffei infection diagnosed by polymerase chain reaction from the skin specimen. <citetitle><emphasis>J Am Acad Dermatol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>344–346.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0262" role="bibliographyEntry">
            <para>262.<emphasis role="strong">Zeng H, Li X, Chen X, Zhang J, Sun J, Xie Z, Xi L.</emphasis> 2009. Identification of Penicillium marneffei in paraffin-embedded tissue using nested PCR. <citetitle><emphasis>Mycopathologia</emphasis></citetitle> <emphasis role="strong">168:</emphasis>31–35.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0263" role="bibliographyEntry">
            <para>263.<emphasis role="strong">Liu Y, Huang X, Yi X, He Y, Mylonakis E, Xi L.</emphasis> 2016. Detection of <citetitle><emphasis>Talaromyces marneffei</emphasis></citetitle> from fresh tissue of an inhalational murine pulmonary model using nested PCR. <citetitle><emphasis>PLoS One</emphasis></citetitle> <emphasis role="strong">11:</emphasis>e0149634.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0264" role="bibliographyEntry">
            <para>264.<emphasis role="strong">Zhang JM, Sun JF, Feng PY, Li XQ, Lu CM, Lu S, Cai WY, Xi LY, de Hoog GS.</emphasis> 2011. Rapid identification and characterization of <citetitle><emphasis>Penicillium marneffei</emphasis></citetitle> using multiplex ligation-dependent probe amplification (MLPA) in paraffin-embedded tissue samples. <citetitle><emphasis>J Microbiol Methods</emphasis></citetitle> <emphasis role="strong">85:</emphasis>33–39.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0265" role="bibliographyEntry">
            <para>265.<emphasis role="strong">Sun J, Li X, Zeng H, Xie Z, Lu C, Xi L, de Hoog GS.</emphasis> 2010. Development and evaluation of loop-mediated isothermal amplification (LAMP) for the rapid diagnosis of <citetitle><emphasis>Penicillium marneffei</emphasis></citetitle> in archived tissue samples. <citetitle><emphasis>FEMS Immunol Med Microbiol</emphasis></citetitle> <emphasis role="strong">58:</emphasis>381–388.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0266" role="bibliographyEntry">
            <para>266.<emphasis role="strong">Hien HTA, Thanh TT, Thu NTM, Nguyen A, Thanh NT, Lan NPH, Simmons C, Shikuma C, Chau NVV, Thwaites G, Le T.</emphasis> 2016. Development and evaluation of a real-time polymerase chain reaction assay for the rapid detection of <citetitle><emphasis>Talaromyces marneffei</emphasis></citetitle> MP1 gene in human plasma. <citetitle><emphasis>Mycoses</emphasis></citetitle> <emphasis role="strong">59:</emphasis>773–780.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0267" role="bibliographyEntry">
            <para>267.<emphasis role="strong">Cao L, Chen DL, Lee C, Chan CM, Chan KM, Vanittanakom N, Tsang DN, Yuen KY.</emphasis> 1998. Detection of specific antibodies to an antigenic mannoprotein for diagnosis of <citetitle><emphasis>Penicillium marneffei</emphasis></citetitle> penicilliosis. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">36:</emphasis>3028–3031.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0268" role="bibliographyEntry">
            <para>268.<emphasis role="strong">Zhang J, Zhang D, Du J, Zhou Y, Cai Y, Sun R, Zhou J, Tian J, Wu H, Lu M, Xu Y, Yang Q.</emphasis> 2021. Rapid diagnosis of <citetitle><emphasis>Talaromyces marneffei</emphasis></citetitle> infection assisted by metagenomic next-generation sequencing in a HIV-negative patient. <citetitle><emphasis>IDCases</emphasis></citetitle> <emphasis role="strong">23:</emphasis>e01055.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0269" role="bibliographyEntry">
            <para>269.<emphasis role="strong">Tsang CC, Teng JLL, Lau SKP, Woo PCY.</emphasis> 2021. Rapid genomic diagnosis of fungal infections in the age of next generation sequencing. <citetitle><emphasis>J Fungi (Basel)</emphasis></citetitle> <emphasis role="strong">7:</emphasis>636.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0270" role="bibliographyEntry">
            <para>270.<emphasis role="strong">Lau SK, Lam CS, Ngan AH, Chow WN, Wu AK, Tsang DN, Tse CW, Que TL, Tang BS, Woo PC.</emphasis> 2016. Matrix-assisted laser desorption ionization time-of-flight mass spectrometry for rapid identification of mold and yeast cultures of <citetitle><emphasis>Penicillium marneffei. BMC Microbiol</emphasis></citetitle> <emphasis role="strong">16:</emphasis>36.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0271" role="bibliographyEntry">
            <para>271.<emphasis role="strong">Fisher MC, Aanensen D, de Hoog S, Vanittanakom N.</emphasis> 2004. Multilocus microsatellite typing system for <citetitle><emphasis>Penicillium marneffei</emphasis></citetitle> reveals spatially structured populations. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>5065–5069.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0272" role="bibliographyEntry">
            <para>272.<emphasis role="strong">Lasker BA, Ran Y.</emphasis> 2004. Analysis of polymorphic microsatellite markers for typing <citetitle><emphasis>Penicillium marneffei</emphasis></citetitle> isolates. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">42:</emphasis>1483–1490.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0273" role="bibliographyEntry">
            <para>273.<emphasis role="strong">Lasker BA.</emphasis> 2006. Nucleotide sequence-based analysis for determining the molecular epidemiology of <citetitle><emphasis>Penicillium marneffei. J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>3145–3153.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0274" role="bibliographyEntry">
            <para>274.<emphasis role="strong">Pruksaphon K, Intaramat A, Ratanabanangkoon K, Nosanchuk JD, Vanittanakom N, Youngchim S.</emphasis> 2020. Diagnostic laboratory immunology for talaromycosis (penicilliosis): review from the bench-top techniques to the point-of-care testing. <citetitle><emphasis>Diagn Microbiol Infect Dis</emphasis></citetitle> <emphasis role="strong">96:</emphasis>114959.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0275" role="bibliographyEntry">
            <para>275.<emphasis role="strong">Kaufman L, Standard PG, Jalbert M, Kantipong P, Limpakarnjanarat K, Mastro TD.</emphasis> 1996. Diagnostic antigenemia tests for penicilliosis marneffei. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">34:</emphasis>2503–2505.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0276" role="bibliographyEntry">
            <para>276.<emphasis role="strong">Cao L, Chan KM, Chen D, Vanittanakom N, Lee C, Chan CM, Sirisanthana T, Tsang DN, Yuen KY.</emphasis> 1999. Detection of cell wall mannoprotein Mp1p in culture supernatants of <citetitle><emphasis>Penicillium marneffei</emphasis></citetitle> and in sera of penicilliosis patients. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">37:</emphasis>981–986.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0277" role="bibliographyEntry">
            <para>277.<emphasis role="strong">Pongpom M, Vanittanakom N.</emphasis> 2011. Characterization of an MPLP6, a gene coding for a yeast phase specific, antigenic mannoprotein in <citetitle><emphasis>Penicillium marneffei. Med Mycol</emphasis></citetitle> <emphasis role="strong">49:</emphasis>32–39.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0278" role="bibliographyEntry">
            <para>278.<emphasis role="strong">Wang YF, Xu HF, Han ZG, Zeng L, Liang CY, Chen XJ, Chen YJ, Cai JP, Hao W, Chan JFW, Wang M, Fu N, Che XY.</emphasis> 2015. Serological surveillance for <citetitle><emphasis>Penicillium marneffei</emphasis></citetitle> infection in HIV-infected patients during 2004-2011 in Guangzhou, China. <citetitle><emphasis>Clin Microbiol Infect</emphasis></citetitle> <emphasis role="strong">21:</emphasis>484–489.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0279" role="bibliographyEntry">
            <para>279.<emphasis role="strong">Rimek D, Zimmermann T, Hartmann M, Prariyachatigul C, Kappe R.</emphasis> 1999. Disseminated <citetitle><emphasis>Penicillium marneffei</emphasis></citetitle> infection in an HIV-positive female from Thailand in Germany. <citetitle><emphasis>Mycoses</emphasis></citetitle> <emphasis role="strong">42</emphasis>(Suppl 2)<emphasis role="strong">:</emphasis>25–28.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0280" role="bibliographyEntry">
            <para>280.<emphasis role="strong">Desakorn V, Simpson AJH, Wuthiekanun V, Sahassananda D, Rajanuwong A, Pitisuttithum P, Howe PA, Smith MD, White NJ.</emphasis> 2002. Development and evaluation of rapid urinary antigen detection tests for diagnosis of penicilliosis marneffei. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">40:</emphasis>3179–3183.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0281" role="bibliographyEntry">
            <para>281.<emphasis role="strong">Vega PT, Erramilli S, Lee E.</emphasis> 2019. <citetitle><emphasis>Talaromcyes marneffei</emphasis></citetitle> laboratory cross reactivity with <citetitle><emphasis>Histoplasma</emphasis></citetitle> and <citetitle><emphasis>Blastomcyes</emphasis></citetitle> urinary antigen. <citetitle><emphasis>Int J Infect Dis</emphasis></citetitle> <emphasis role="strong">86:</emphasis>15–17.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0282" role="bibliographyEntry">
            <para>282.<emphasis role="strong">Chaiyaroj SC, Chawengkirttikul R, Sirisinha S, Watkins P, Srinoulprasert Y.</emphasis> 2003. Antigen detection assay for identification of <citetitle><emphasis>Penicillium marneffei</emphasis></citetitle> infection. <citetitle><emphasis>J Clin Microbiol</emphasis></citetitle> <emphasis role="strong">41:</emphasis>432–434.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0283" role="bibliographyEntry">
            <para>283.<emphasis role="strong">Pruksaphon K, Intaramat A, Ratanabanangkoon K, Nosanchuk JD, Vanittanakom N, Youngchim S.</emphasis> 2018. Development and characterization of an immunochromatographic test for the rapid diagnosis of <citetitle><emphasis>Talaromyces (Penicillium) marneffei. PLoS One</emphasis></citetitle> <emphasis role="strong">13:</emphasis>e0195596.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0284" role="bibliographyEntry">
            <para>284.<emphasis role="strong">Lau SK, Lo GC, Lam CS, Chow WN, Ngan AH, Wu AK, Tsang DN, Tse CW, Que TL, Tang BS, Woo PC.</emphasis> 2017. In vitro activity of posaconazole against <citetitle><emphasis>Talaromyces marneffei</emphasis></citetitle> by broth microdilution and Etest methods and comparison to itraconazole, voriconazole, and anidulafungin. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">61:</emphasis>e01480–16.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0285" role="bibliographyEntry">
            <para>285.<emphasis role="strong">Odabasi Z, Paetznick VL, Rodriguez JR, Chen E, Ostrosky-Zeichner L.</emphasis> 2004. In vitro activity of anidulafungin against selected clinically important mold isolates. <citetitle><emphasis>Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">48:</emphasis>1912–1915.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0286" role="bibliographyEntry">
            <para>286.<emphasis role="strong">Liu D, Liang L, Chen J.</emphasis> 2013. In vitro antifungal drug susceptibilities of <citetitle><emphasis>Penicillium marneffei</emphasis></citetitle> from China. <citetitle><emphasis>J Infect Chemother</emphasis></citetitle> <emphasis role="strong">19:</emphasis>776–778.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0287" role="bibliographyEntry">
            <para>287.<emphasis role="strong">Zhang J, Liu H, Xi L, Chang YC, Kwon-Chung KJ, Seyedmousavi S.</emphasis> 2021. Antifungal susceptibility profiles of olorofim (formerly F901318) and currently available systemic antifungals against mold and yeast phases of <citetitle><emphasis>Talaromyces marneffei. Antimicrob Agents Chemother</emphasis></citetitle> <emphasis role="strong">65:</emphasis>e00256–e21.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0288" role="bibliographyEntry">
            <para>288.<emphasis role="strong">Ouyang Y, Cai S, Liang H, Cao C.</emphasis> 2017. Administration of voriconazole in disseminated <citetitle><emphasis>Talaromyces (Penicillium) marneffei</emphasis></citetitle> infection: a retrospective study. <citetitle><emphasis>Mycopathologia</emphasis></citetitle> <emphasis role="strong">182:</emphasis>569–575.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0289" role="bibliographyEntry">
            <para>289.<emphasis role="strong">Guo LN, Yu SY, Wang Y, Liu YL, Yuan Y, Duan SM, Yang WH, Jia XM, Zhao Y, Xiao M, Xie XL, Dou HT, Hsueh PR, Xu YC.</emphasis> 2021. Species distribution and antifungal susceptibilities of clinical isolates of <citetitle><emphasis>Penicillium</emphasis></citetitle> and <citetitle><emphasis>Talaromyces</emphasis></citetitle> species in China. <citetitle><emphasis>Int J Antimicrob Agents</emphasis></citetitle> <emphasis role="strong">58:</emphasis>106349.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0290" role="bibliographyEntry">
            <para>290.<emphasis role="strong">Cao C, Liu W, Li R, Wan Z, Qiao J.</emphasis> 2009. In vitro interactions of micafungin with amphotericin B, itraconazole or fluconazole against the pathogenic phase of <citetitle><emphasis>Penicillium marneffei. J Antimicrob Chemother</emphasis></citetitle> <emphasis role="strong">63:</emphasis>340–342.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0291" role="bibliographyEntry">
            <para>291.<emphasis role="strong">Horner WE, Helbling A, Salvaggio JE, Lehrer SB.</emphasis> 1995. Fungal allergens. <citetitle><emphasis>Clin Microbiol Rev</emphasis></citetitle> <emphasis role="strong">8:</emphasis>161–179.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0292" role="bibliographyEntry">
            <para>292.<emphasis role="strong">Santos PE, Piontelli E, Shea YR, Galluzzo ML, Holland SM, Zelazko ME, Rosenzweig SD.</emphasis> 2006. <citetitle><emphasis>Penicillium piceum</emphasis></citetitle> infection: diagnosis and successful treatment in chronic granulomatous disease. <citetitle><emphasis>Med Mycol</emphasis></citetitle> <emphasis role="strong">44:</emphasis>749–753.</para>
          </listitem>
          <listitem id="ch0144s0025s0001li0293" role="bibliographyEntry">
            <para>293.<emphasis role="strong">Kumar S, Stecher G, Tamura K.</emphasis> 2016. MEGA7: molecular evolutionary genetics analysis version 7.0 for bigger datasets. <citetitle><emphasis>Mol Biol Evol</emphasis></citetitle> <emphasis role="strong">33:</emphasis>1870–1874.</para>
          </listitem>
        </itemizedlist>
      </sect2>
    </sect1>
  </chapter>
